Neurogenetics
Unravelling hidden diseases.
THE WAY WE SEE IT, EVEN GREY MATTERS.

LET'S GIVE IT MEANING. TOGETHER.

Driving Excellence in Neurology.
Be part of one of humankind's most ambitious projects to help uncover the workings of the nervous system. EAN connects 45,000 specialists in neurology in 47 countries across Europe. Promoting excellence, cutting-edge science and innovative therapies for a better life for more than 430 million patients in Europe alone. Read more on ean.org

Great Minds.
General Information

Welcome Message ......................................................... 03
About EAN ................................................................. 04
Board and Committees .................................................. 05
EAN Membership Information ......................................... 06
Educational grants Information ......................................... 07
Resident and Research Fellow Section (EAN-RRFS) ............ 09
Congress Grants .......................................................... 10
Appreciation and thanks ............................................... 12
Continuing Medical Education, Accreditation ................... 13
Instructions for Speakers and Presenters ......................... 14
Information from A-Z ................................................... 14
Floor plans ................................................................. 24
EAN Business meeting overview .................................... 28
ePoster and ePresentation Overview .............................. 31
Networking Programme and Other Activities ...................... 36
Timetable/Session Overview .......................................... 42

Scientific Programme

Saturday, 16 June 2018

Educational Sessions ............................................. .50, 56, 58, 61, 62
Focused Workshops .............................................. 51, 52
Special Sessions ................................................... 52, 58, 61
Symposia ............................................................... 53, 54
Teaching Courses .................................................. 59, 60, 61
Oral Sessions .......................................................... 64

Sunday, 17 June 2018

Educational Sessions ............................................. 70, 71, 76, 79
Focused Workshops .............................................. 71, 72
Presidential Symposium .......................................... 75
Special Sessions ................................................... 73, 76, 77
Teaching Courses .................................................. 77
Oral Sessions .......................................................... 80

Monday, 18 June 2018

Educational Sessions ............................................. 86, 91, 92, 94
Focused Workshops .............................................. 87, 88
Special Sessions ................................................... 89
Symposia ............................................................... 90
Teaching Courses .................................................. 92
Oral Sessions .......................................................... 96

Tuesday, 19 June 2018

Educational Sessions ............................................. 106, 107, 108, 109
Highlight + Breaking News ....................................... 108
Special Sessions ................................................... 107
Symposia ............................................................... 106
Teaching Courses .................................................. 109
Oral Sessions .......................................................... 112

Industry Sponsored Programme

Acknowledgements ...................................................... 119
Exhibitors and Exhibition Floor Plan ............................. 120
Satellite Symposia Programmes .................................... 126
3-Days Satellite Sessions .......................................... 153
Forum Talk Programmes ........................................... 157
Index ........................................................................... 161
OUR UNIVERSE IS MADE UP OF 86 BILLION NEURONS.

LET’S EXPLORE IT TOGETHER.

Driving Excellence in Neurology.

Be part of one of humankind’s most ambitious projects to help uncover the workings of the nervous system. EAN connects 45,000 specialists in neurology in 47 countries across Europe. Promoting excellence, cutting-edge science and innovative therapies for a better life for more than 430 million patients in Europe alone. Read more on ean.org

Great Minds.
Welcome

On behalf of the European Academy of Neurology and the Portuguese Society of Neurology, we are pleased to you to the 4th Congress of the European Academy of Neurology (EAN) taking place in Lisbon, Portugal from June 16-19, 2018.

The overarching theme for the Lisbon congress is ‘Neurogenetics – Unravelling hidden diseases’. Diagnosis and treatment are increasingly using genetic methods and one purpose of the congress is to highlight clinically useful aspects of genetic medicine in Neurology. But as always, progress in all fields of neurology will be presented and participants will be updated about recent developments and news in clinical neurology. The selection of the educational programme is meanwhile organised within a newly adapted 5-year EAN educational curriculum. This curriculum is covering all important aspects a neurologist should learn and update in this period.

Lisbon is a modern town, easily accessible from almost everywhere, where you can enjoy the hospitality of its people, walking around town exploring culture, arts and food. The charming capital of Portugal is located by the wide estuary of Tagus River where you will find scenic views from almost every corner. Here, you can absorb the unique scent of the near Mediterranean, mild and pleasant climate of early summer and the peculiar luminosity of a blue sky reflected on its white ancient houses in historic areas. Lisbon is dominated by its castle, more than one thousand years old, with a unique view. This is a city full of history where you may feel the ambiance of the old Arab neighborhood of Alfama and Mouraria, where Fado, the national sentimental song, was born. Needless to say, that it was from Lisbon, that the navigators left to discover the world and you can meet history at several museums and monuments.

EAN and the Portuguese Society of Neurology cordially welcome the European neurological community to celebrate the strength and beauty of our field and to get inspired by meeting with colleagues and friends.

Paul Boon
Chair
Programme Committee
of the European Academy of Neurology

Günther Deuschl
President
European Academy of Neurology

Joaquim Ferreira
Chair
Local Organising Committee
The European Academy of Neurology (EAN) has been founded in 2014 on the initiative of the European Neurological Society (ENS) and the European Federation of Neurological Societies (EFNS), who both considered it essential to have one joint professional and scientific Neurology organisation in Europe. EAN shall provide the essential infrastructure together with the organisational framework for the support and development of neurological education and research in Europe.

The Aim of EAN is Excellence in Neurology in Europe

About EAN

The European Academy of Neurology (EAN) has been founded in 2014 on the initiative of the European Neurological Society (ENS) and the European Federation of Neurological Societies (EFNS), who both considered it essential to have one joint professional and scientific Neurology organisation in Europe. EAN shall provide the essential infrastructure together with the organisational framework for the support and development of neurological education and research in Europe.

The Aim of EAN is Excellence in Neurology in Europe

EAN is a non-profit organisation and identifies itself with the following five values:

• Professionalism. EAN will strive to reach the highest scientific standards and to deliver unbiased information in its research and educational activities.
• High ethical standards. EAN will apply high ethical standards in all its activities within science, education, communication, and administration, complying with applicable regulations and codes of ethics.
• Involvement. EAN will strive to involve its members and collaborators in the organisation of research, education and liaison activities.
• Independence. EAN will operate as a professional and scientific organisation, independent from the political or commercial interests of external companies or organisations.
• Transparency. EAN will provide transparency in the organisation of all its scientific and administrative activities.

EAN is an organisation of:

• 47 European national neurological societies
• 900 individual members
• 10 corresponding member societies

EAN consists of:

• an Assembly of Delegates of institutional and individual delegates
• elected officers
• 4 committees (+ 3 sub-committees)
• 31 Scientific Panels
Committees

EAN Board

Günther Deuschl, Germany
President
Franz Fazekas, Austria
President elect
Didier Leys, France
Secretary General
Marianne de Visser, The Netherlands
Treasurer
Antonio Federico, Italy
Chair Scientific Committee
David B. Vodušek, Slovenia
Chair Communication Committee

Programme Committee

Paul A.J.M. Boon, Belgium, (Chair)
Joaquim Ferreira, Portugal, (Co-Chair)
Valeria Caso, Italy
Hannah Cock, UK (Chair Education Committee)
Marianne Dieterich, Germany
Antonio Federico, Italy (Chair Scientific Committee)
Ivan Rektor, Czech Republic
Philip Scheltens, The Netherlands
Aksel Siva, Turkey
Riccardo Soffietti, Italy
Claudia Sommer, Germany (Chair Teaching Course sub-Committee)
Guido Stoll, Germany
Pille Taba, Estonia (MDS-ES representative)

Local Organising Committee

Joaquim Ferreira, (Chair)
Mamede de Carvalho, Manuel Correia, Rui Costa, José Ferro,
Victor Oliveira, Ana Amélia Nogueira Pinto, Isabel Pavão Martins

Teaching Course sub-Committee

Claudia Sommer, Germany, (Chair)
Anish Bahra, United Kingdom
Theodor Landis, Switzerland
Elena R. Lebedeva, Russian Federation
Milija Mijajlovic, Serbia
Viktoria Papp, Denmark (RRFS Representative)
Erich Schmutzhard, Austria
Pille Taba, Estonia (MDS-ES representative)
EAN Membership Information

Become an EAN individual member and benefit from the following:

- reduced membership fee at the annual congresses
- active and passive voting rights at the Assembly of Delegates of the EAN
- possibility to participate in EAN Committees and Scientific Panels
- free online access to the online learning platform eBrain
- free online access to the European Journal of Neurology
- free online access to the guidelines
- access to educational grants (if applicable)
- right to purchase the European Journal of Neurology (EJN) at a reduced rate
- a membership certificate
- monthly mailshots of the EAN electronic newsletter
- one free Teaching Course at EAN annual congresses
- free access to VIP area at EAN annual congresses
- free professional photo taken at Congress
- free access to selected congress webcasts on the website after the congress
- AAN shared Membership:

If you are an AAN Member, you are eligible of a 10% discount off your EAN Individual Membership fee. In reverse, EAN Individual members receive a 10% discount when applying for AAN membership.

Corresponding Individual Member:
- Neurologists who are nationals of and practice in countries other than EAN member countries
- Health Professionals and/or Scientists of other specialities or professions related to Neurology

Undergraduate Student:
Undergraduate medical students can become individual members. They need to explain their special interest in neurology and the purpose why they request membership.

Fellow of EAN (FEAN)

The title ‘Fellow of the EAN’ acknowledges a limited number of neurologists who are full individual members and who deserve a special recognition of the EAN because of:

- a scientific achievement that places them within the European leaders in their field, or
- significant and continuing service in a leadership position for of a European or World society for neurology or neurological subspecialty society, or
- a service for neurological patients that is considered exceptional

Fellow of the EAN is a title honouring special service to neurology and the Society.

Please apply by sending your application form and CV (in English) to the EAN Head Office: membership@ean.org
Forms can be downloaded online or be sent to upon request.

Honorary Members and Service Award 2018

Mark Hallett, Bethesda, USA and Alistar Compston, Cambridge, UK will be awarded the EAN Honorary Membership during the Opening.

Amadou Gallo Diop, Dakar, Senegal and Riad Gouider, Tunis, Tunisia will be receive the EAN Service Award during the EAN Assembly of Delegates
Clinical Fellowship 2019

Application Deadline: October 31, 2018

The purpose of this award is to provide a well-defined observational clinical practice, service structure or technical experience to support training. The grant is to support a visit of six weeks duration.

Each grant is amounting to € 1,500.-/month (plus travel expenses of up to € 300.-)

A list of approved hosting departments (and details for interested hosts of how to apply) is available on www.ean.org

Candidates from all EAN member (and corresponding member) countries are eligible to apply. Applicants must be current residents with a minimum of 2 years training in neurology, or have obtained their board certificate/completed training within the last 3 years at the time of application; be fluent in English or the local language (host department).

Awardees from previous years are no more qualified.

All applicants must be Full member or RRFS member at time of application.

All application documents must be submitted by October 31, 2018 by email to Ms. Magda Dohnalová: dohnalova@ean.org

Application is open between 1 August and 31 October 2018

EAN Research Fellowship 2019

Application deadline: August 31, 2018

The purpose is to support training and experience for European Neurologists in any area of basic or clinical or applied research in neuroscience. The research work must be carried out at a European academic neurological department outside the country of residence. All applications should demonstrate experience/training of clear value to the home department/individual beyond that available in their own countries/institutions.

Successful applicants will be awarded € 2,000.- per month.

Research training fellowship: Expected to be of typically 12 months and no less than 6 months, to lead either to completion of a higher degree, a grant application or peer-reviewed publication.

Research experience fellowship: Expected to be of typically and no more than 6 months duration for individuals who might otherwise not have the opportunity to gain high quality research experience; more experienced clinicians/researchers requiring training in a specific research methodology or technique not currently available in their own country and of clear value to home department will also be considered.

Candidates from EAN member countries and affiliated to a European academic neurological department with a minimum of 2 years neurology training, up to a maximum of 5 years beyond their final degree (PhD, MD, or equivalent) at the time of application are eligible to apply.

All applicants must be Full member or RRFS member at time of application.

All application documents must be submitted by August 31, 2018 by email to Ms. Julia Mayer: fellowship@ean.org

Application Deadline: August 31, 2018

EAN Spring School 2019

May 2019

Application deadline: January 31, 2019

Dedicated to clinical neurologists in training who did not yet complete their residency/clinical speciality training who wish to boost their knowledge and to get the chance to enable personal contacts among participants and faculty members

Preliminary Programme:
1. Stroke
2. Higher cortical functions
3. Neurorehabilitation

Structure: morning plenary sessions and case-based workshops in the afternoons.
All applicants must be neurologists in training (not yet completed residency/clinical speciality training) who will have had at least 2 years of clinical experience by the time of the course, and who are able to attend the full course. Participants nominated for attendance by their national neurological societies will be prioritised, but individual applications are also welcome up to the full capacity. Awardees from previous years are no more qualified. All applicants must be Full member or RRFS member at time of application.

Accommodation, tuition, board and programme are sponsored by the EAN. Participants pay for their travel only.

All application documents must be submitted by January 31, 2019 by email to Ms. Magda Dohnalová: dohnalova@ean.org

Application open between 1 October 2018 and 31 January 2019

EAN Autumn School 2018
November 8-11, 2018

Increase your knowledge of clinical neurology! Experienced neurologists and sub-specialists will illustrate how they approach specific clinical presentations, including an update on relevant diagnostic and treatment approaches for key conditions in the relevant areas.

Preliminary Programme:
1. Episodic Loss of consciousness
2. Gait Disorders
3. Tremor (jointly organised with MDS-ES)

Structure: morning plenary sessions and hands-on/case-based clinical workshops (video and patient presentations) for 20 persons each in the afternoons.

Location: Loutraki, Greece (1,5h from Athens airport)

All applicants must be neurologists in training (not yet completed residency/clinical speciality training) who will have had at least 2 years of clinical experience by the time of the course, and who are able to attend the full course.

Accommodation, tuition, board and programme are sponsored by the EAN. Participants pay for their travel only.

All application documents must be submitted by July 31, 2018 by email to Ms. Magda Dohnalová: dohnalova@ean.org

Application open between 1 June and 31 July 2018

EAN Regional Teaching Courses (RTC) and EAN-Day

EAN-RTCs are specially designed for the purpose to bring neurological standards directly to the countries in the East or Sub-Saharan Africa to avoid that our colleagues in training have to travel to distant congresses. RTCs provide basic teaching in neurology and thus also establish friendly relations with all colleagues. These courses are held in English language and have a duration of 3 days.

4 plenary session will be held each morning and will deal with each of the three main topics of the RTC, i.e. focus on one main topic per day. Small tuitional groups in the afternoon are set up to enhance the hand-on learning (case-based videoclips, Hands-on course, Workshops). Organisers are either National Neurological Societies or Neurological University departments.

The next EAN RTC will be in Struga, Macedonia, September 14-16, 2018

The EAN-Day aims at bringing excellent teaching and special recognition by EAN to our National Neurological Member Societies (and Corresponding Member Societies). This day takes place directly prior or after a National Neurological Society meeting.

Three plenary sessions will take place in the morning addressing 3 different topics. After a lunch break, there will be rotating workshops on the same 3 topics, case-based video clips or hands-on courses for participants to work and learn in smaller groups. The language is English.

All Guidance documents and application forms can be found online: www.ean.org- LEARN- Educational events
**CME Articles**

Each month a CME article is published in the *European Journal of Neurology* and on the EAN website. Answer 5 article-related questions correctly and receive a certificate recommending one hour of CME.

Please log-in on the EAN website for free-of-charge access to all e-learning features and the online version of the European Journal of Neurology.

**eBrain**

ebrain represents the world’s largest, most comprehensive web-based training resource in clinical neuroscience designed to support training and continuous professional development for clinical neuroscience trainees, consultants and non-specialists. It is free-of-charge for EAN members. Please log-in on www.ean.org to have direct access. If you need help, please come to the EAN booth/LEARN, or contact education@ean.org

The multimedia-rich, engaging materials are designed to enhance traditional learning, support existing teaching methods and provide a valuable reference point that is accessible anytime, anywhere.

The online training content comprises approximately 20 modules of e-learning, with each of the 550+ individual lessons taking around 20 minutes to complete.

**Guideline papers**

Included in the EJoN, the Handbook as well as FREE OF CHARGE for EAN members via the Guideline Reference Center on the EAN website.

---

**Resident and Research Fellow Section**

RRFS represents the junior generation of neurologists within EAN. Our members are physicians currently working as a resident in Neurology, research fellow, PhD student or neurologist with not more than 3 years of practice after completion of the residence training. Application for membership can be done directly at the EAN booth or be sent to rrf@ean.org, further information is provided on the EAN homepage.

The aims of RRFS are to support neurology trainees in their clinical training or research, to promote network between European junior neurologists and different generations of neurologists.

**Activities of the Resident and Research Fellow Section during the Congress**

**Join us at the RRFS booth**

During the congress, RRFS members are available at the LEARN and HOME area of the EAN booth in order to provide up-to-date information about membership, education and travel/EBN grants and other congress activities.

**RRFS special session**

Sunday, June 17, 8.00 - 9.30h, room Oslo

Resident and Research Fellow Section Round Table Discussion

This is the ideal opportunity to
- Learn about academic career and research opportunities around Europe
- Get expert advices on laboratory and clinical research
- Meet experts from different parts of Europe and improve the professional European network
- Get to know opinion leaders’ careers and how they got there

Participants will meet worldwide renowned professors around Europe covering different field of interests as well as basic and clinical neuroscience.

**Table 1** - José M Ferro, Lisbon, Portugal
(Main interest: stroke)

**Table 2** - Klaus Viktor Toyka, Würzburg, Germany
(Main interest: Disease models of neuro-immuno logical and degenerative disorders of the nervous system)

**Table 3** - Hannah Cock, London, United Kingdom
(Main interest: epilepsy)

**Table 4** - Eva Kubala Havrdová, Prague, Czech Republic
(Main interest: multiple sclerosis)
Following the successful session last year, the special session of RRFS is held as a round table discussion. As participants found it most helpful and interesting to have direct discussions with the speaker, participants and speakers will directly sit down at four round tables with each Professor from different parts of Europe and with different fields of interest and the participants will then circulate between the round tables.

RRFS General Assembly
Monday, June 18, 14.15 - 15.15h, room 0.01
All RRFS members are invited to join the RRFS General Assembly.

RRFS annual hospital visit
Monday, June 18, 18:15h
This year, the traditional hospital visit is organised on Monday, June 18. Participants will be introduced to the local neurology education while visiting the Neurology Department of the Centro Hospitalar Lisboa Norte - Hospital de Santa Maria (Santa Maria University Hospital/North Lisbon Hospitalary Center). Afterwards, transfer will be organised to the EAN “Meet your neurology network” event that will take place in the Museu Nacional de Arte Antiga (reduced entrance fee for all hospital visit participants). Registration is necessary due to limited places. If you would like to join us, send an email to rrfs@ean.org.

Congress Grants

Bursaries
The 4th EAN Congress offered 240 bursaries consisting of free registration and up to four nights of hotel accommodation.

Eligible were PhD (neurology) students, residents of neurology or certified clinical neurologists (with no more than 3 years practice since completing training) who are working in Europe and whose abstract had been accepted.

It was also possible for colleagues in training from Algeria, Egypt, Jordan, Lebanon, Libya, Mauretania, Morocco, Palestine, Syria and Tunisia as well as from sub-Saharan countries belonging to the HINARI Group A list of countries as established by WHO (www.who.int/hinari/eligibility/en/) to apply for bursaries.

Applications were accompanied by a letter from the chairperson of the applicant’s department confirming that they are in training. Only one bursary per abstract was awarded.

Bursary recipients were selected by the Programme Committee based on abstract evaluation.

Bursaries will be available for EAN RRFS and full members only.
The bursaries were co-sponsored by an educational grant from MDS-ES.

Applications for the 5th EAN congress Oslo 2019 can be submitted by the time of the abstract submission deadline: 23 January 2019.

Investigator Award
All free presentations (oral presentations, posters) selected for presentation at the 4th EAN Congress 2018 will automatically take part in the selection of an Investigator Award. The award for the 20 best presentations will be a registration to the 5th EAN Congress in Oslo, Norway, a diploma and the winners will be announced in EAN Pages. The award will be given to the first author who needs to be the person to present the work at the congress. The EAN Scientific Panels together with the Scientific Committee and the Programme Committee will be responsible for the evaluation process before as well as during the congress.
Tournament for Neurologists in Training

A tournament for neurologists in training will take place. The tournament will be carried out in two groups. One on basic neurological science, Sunday, June 17, 2018 (see page 80) and one on clinical related research on Monday, June 18, 2018 (see page 96).

Eligible were PhD (neurology) students, residents of neurology or certified clinical neurologists (with no more than 3 years practice since completing training) working in Europe and whose abstract has been accepted.

Selection of candidates: The EAN Programme Committee has selected 6 candidates for each tournament group based on the contents of the abstracts submitted. The clinical subjects had to be received from authors who work in Europe and thus carry out their projects in Europe. For the basic science session, clinical relevance was weighted.

Financial support: Candidates selected for the tournament have received a bursary consisting of free registration to the Congress, up to four nights hotel accommodation, and a travel grant.

Presentation: Each selected candidate is allotted 10 minutes for presentation of his/her paper plus five minutes for discussion with the jury.

Jury: Members of the Programme, the Scientific and the Teaching Course Committees.

Evaluation: Candidates will be judged not only on the scientific value of the work presented, but also on the quality of the oral presentation and the way the candidate responds to the questions of the jury.

Prize: The winner of each group will receive a prize consisting of: Free registration at the 5th EAN Congress in Oslo 2019, up to four nights hotel accommodation as well as a travel grant. The prize is not transferable and will not be paid off in cash.

Two runner-up prizes in each, the clinical and basic tournament will be awarded. They will consist of a certificate and a free registration to the 5th EAN Congress in Oslo 2019.
We would like to thank the reviewers of the submitted abstracts for their invaluable help and assistance:

A
Federica Agosta, Italy
Diana Aguiar de Sousa, Portugal
Yuri Alekseenko, Belarus
Pasquale Annunziata, Italy
Fabio Antonaci, Italy
Angelo Antonini, Italy
Zohar Argov, Israel
Nadine Attal, France

B
Shakya Bhattacharjee, UK
Paul Boon, Belgium
Thomas Brandt, Germany
Geir Brathen, Norway
Filipe Brogueira Rodrigues, UK
Wallace Brownlee, UK
Jean Marc Burgunder, Switzerland

C
Pasquale Calabrese, Switzerland
Stefano Cappa, Italy
Valeria Caso, Italy
Declan Chard, UK
Hannah Cock, UK
Carlo Colosimo, Italy
Giancarlo Comi, Italy
Pamela Correia, Switzerland
Ana Cristina Duque Santos, Portugal
Laszlo Csiba, Hungary
Anna Czlonkowska, Poland

D
Maxwell Damian, UK
Marianne de Visser, The Netherlands
Vida Demarin, Hungary
Günter Deuschl, Germany
Giovanni Di Liberto, Switzerland
Marianne Dieterich, Germany
Karim Diserens, Switzerland
João Luís Oliveira Durães, Portugal
Raffaele Dubbioso, Italy
Andrei Dubenko, Ukraine
Francois Ducray, France

E
Edvard Ehler, Czech Republic
Stefan Evers, Germany

F
Franz Fazekas, Austria
Antonio Federico, Italy
Luigi Ferlini-Strambi, Italy
José Ferro, Portugal
Massimo Filippi, Italy
Alessandro Filla, Italy

G
Thomas Gattringer, Austria
Raquel Gil-Gouveia, Portugal
Raquel Gutiérrez Zúñiga, Spain

H
Mario Habek, Hungary
Hans-Peter Hartung, Germany
Wolfgang Heide, Germany
Raimund Helbok, Austria
Max J. Hilz, Germany

K
Ulf Kallweit, Germany
Reeta Kälviäinen, Finland
Vincent Keereman, Belgium
Michael Khalil, Austria
Nina Khizanishvili, Germany
Thomas Klopotock, Germany
Christian Kranup, Denmark
Jera Kruja, Albania
Jan Kukuň, The Netherlands

L
Lieven Lagae, Belgium
Maurizio Leone, Italy
Vitalie Lisnic, Moldova

M
Monica Margoni, Italy
Hugh Markus, UK
Geert Mayer, Germany
Patrik Michel, Switzerland

O
Stefan Oberndorfer, Austria
Oana Maria Obrisca, Romania
David Oliver, UK
Irina Orban, Romania
Serefür Öztürk, Turkey

P
Eleftherios Papathanasiou, Cyprus
Viktoria Papp, Denmark
Simon Podnar, Slovenia
Werner Poewe, Austria
Maura Pugliatti, Italy

R
Olivier Rascol, France
Radu Razvan, Romania
Heinz Reichmann, Germany
Ivan Rektor, Czech Republic
Roberta Rudá, Italy
Marina Ruiz Piñero, Spain

S
Maria José Sá, Portugal
Simona Sacco, Italy
Anna Sauerbier, UK
Philip Scheltens, The Netherlands
Erich Schmutzhard, Austria
Stefan Schwab, Germany
Alessandro Simonati, Italy
Aksel Siva, Turkey
Riccardo Soffietti, Italy
Aleksandra Sokolowska, Poland
Claudia Sommer, Germany
Israel Steiner, Israel
Guido Stoll, Germany
Walter Struhal, Austria

T
Pille Taba, Estonia
Miguel Tábuas-Pereira, Portugal
Radu Tanasescu, Romania
Maarten Titulaer, The Netherlands
Antonio Toscano, Italy
Klaus Toyka, Germany
Marie Trad, France

U
Iris Unterberger, Austria

V
José Valdueza, Germany
Josep Valls-Solé, Spain
Domizia Vecchio, Italy
David B. Vodušek, Slovenia
Tim von Oertzen, Austria
Pieter Vos, The Netherlands
Continuing Medical Education

Purpose

The purpose of the 4th EAN Congress is to offer a forum for clinical and basic discussion on a variety of neurological topics including presentations of current research and available treatments.

Learning Objectives

Through Plenary Symposia, Symposia, Focused Workshops, Teaching Courses, Case-based workshops, Hands-on Courses, controversy sessions, Career development Sessions, Interactive sessions and special sessions, participants will be better able to:
1. Describe the pathophysiology and neurobiology of neurological diseases
2. Discuss the diagnostic approaches and tools available for neurological diseases
3. Discuss the pharmacological and non-pharmacological treatment options available for neurological diseases

Target Audience

The target audience includes clinicians, researchers, post-doc fellows, medical residents, students and other healthcare professionals with an interest in the current research and diagnosis and treatment of neurological diseases. Kindly note that in the description of some courses the target audience is separately disclosed.

Financial disclosure information

It is the policy of the European Academy of Neurology to ensure objectivity, independence and balance in all congress activities. All participants are required to disclose any real or apparent conflict(s) of interest that can have a direct bearing on the subject matter of the activity. Financial disclosure information will be provided on the presentations and/or abstracts.

EACCME Accreditation statement

EACCME EVENT CODE: LEE17-00902

The 4th Congress of the European Academy of Neurology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS): http://www.uems.net.

The Congress of the European Academy of Neurology (Saturday, Sunday, Monday, Tuesday) is designated for a maximum of 24 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. These points are accepted by several national societies, and thus they be claimed in these countries. Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Ethical MedTech has endorsed the congress

CME Certificates and Attendance Tracking Report

If you need a report of your attendance in sessions, please use the EAN website and app and evaluate all sessions that you have attended. From Thursday, 21 June, onwards you will receive a certificate including a report of all sessions you have attended and evaluated.

CME Certificates will only be provided to participants who have evaluated the sessions attended during the congress. Evaluation is possible until Wednesday, 20 June 2018, 23.59 CET.

Please see page 18, “Evaluation” for further information.
Instructions for Speakers and Presenters

Speakers’ Service Centre

All speakers are requested to hand in their presentations (PowerPoint only) via a USB compatible memory stick at the Speakers’ Service Centre (SSC) at least three hours before the beginning of the session. The SSC is located on the press gallery next to the entrance of Auditorium II and the EAN Members’ Lounge on the first floor (Foyer D).

Speakers will have the opportunity to check their presentations on PCs available in the SSC.

The speakers’ service centre (SSC) is supported by ePresentations and ePosters.

All posters will be presented electronically only. Within the ePoster area (located in Hall 4 and Hall 5) there are 22 poster screens (and 25 computer stations next to Hall 4) available throughout the whole congress, where presenters and audience are invited to interact with each other. You will be able to contact all presenters and meet with them at any time at one of the poster screens to discuss his/her work. In addition, there will be scheduled sessions, taking place Saturday to Monday from 12.30 - 13.15 and 13.30 - 14.15.

All ePoster and ePresentation sessions will be discussed with a chairperson. The chairperson will be present and discuss each presentation with the presenter and the audience. In ePoster sessions (45 minutes) up to 15 presentations are scheduled at the dedicated poster screens. Each presenter will have 2 minutes of presentation time and approximately 1 minute of discussion. ePresentation sessions will be 45 minutes long as well and accommodate up to 10 presentations. Each presenter will have 3 minutes of presentation time and 2 minutes of discussion.

Please make sure that you are present at your screen at the beginning of your session. Please see page 31 or the Interactive Programme Planner (IPP) for details and exact session times. For better audio quality, please pick up a receiver and earphones from the ePoster desk before the session. Different sessions will have different channels, indicated next to each poster screen.

Poster Desk

Technicians and hosts will be available throughout the congress in the ePoster area (Hall 4).

Information from A to Z

Abstracts

All accepted abstracts will be published as a supplement to the European Journal of Neurology. There will be no printed book available, but a USB drive can be picked up in the Exhibition Area at the Sanofi Genzyme booth. You will receive a voucher together with your bag. You can create your personal abstract book by using the Interactive Programme Planner (IPP). The abstracts can also be found online on www.ean.org/Lisbon2018 www.europeanjournalofneurology.com.

App

The congress app “EAN Congress” is available for download free of charge on Google Play and iTunes.

It includes the interactive programme planner (IPP), all session evaluations as well as the voting system for the Interactive sessions. Please download the app and login with your EAN user information. You can then go ahead and create your personal congress programme. You will also be able to access the favourites you made on the EAN Congress website.

Seize all benefits of the EAN Congress app to connect and meet with colleagues, prepare your meeting schedule, be able to actively participate in the Interactive Sessions and have additional and up-to-date information on the congress.

The congress app is supported by Celgene.

ATM/Cash Machine

An ATM/cash machine is located in the registration area.

Attendance tracking report

See page 13

Badges

Access to all scientific and networking events will only be possible with your personal badge. All participants are requested to wear their name badge throughout the congress. If you forget your badge, we can reprint it for a deposit of
Information from A to Z

30€. The deposit will be returned once you show that you still have both badges, of which we will keep one. If you lost your badge or do not show both badges anymore, 30€ will be charged.

Scanning of badges
Participants are not obliged to allow exhibitors to scan their badge in the exhibition area or when entering an industry symposium. Participants must show their badge for proof of access rights, but do not need to let someone scan it. With allowing a company to scan, you acknowledge that your registration details will be forwarded to the exhibitor.

Caring for the environment
Bag recycling – You can leave your congress bag at the registration desk when leaving the congress.

Green print – The print materials of this congress have been printed on paper that is PEFC approved. PEFC is an organisation that certifies paper manufacturers who keep to sustainable forest management criteria.

Reducing print – The printed programme is available only for participants who order it in advance at registration. The complete programme can also be found online in the Interactive Programme Planner (IPP) and on our congress app and you can create your individual schedule & abstract book.

Recycling – As part of our efforts we try to produce less waste, and recycle plastic, glass, cans and paper.

Offset your Carbon Footprint – You can contribute to our ecological efforts by offsetting the Carbon Footprint of your travels to Lisbon. A Carbon Offset represents a reduction in emissions somewhere else. You can learn more and offset your carbon footprint at: www.carbonfund.org.

We are doing our best and there is still much to learn. We will be happy to hear your ideas; please do not hesitate to write to us at headoffice@ean.org.

Certificates including CME Accreditation:

If you wish to receive individual reports of your attendance in sessions, please use the EAN website and congress app and evaluate all sessions that you have attended. You can also find a designated “evaluation station” in the congress entrance area in Foyer B.

Evaluation is possible until Wednesday, 20 June 2018, 23:59 CET. From Thursday, 21 June, onwards, you can download your CME certificate including a report of all sessions you have attended and evaluated. The certificate lists all sessions that were evaluated and includes all CME points.

The 4th Congress of the European Academy of Neurology (EAN) has been accredited by EACCME and is designated for a maximum of, or up to 24 European CME credits (ECMEC). Please find a list of countries that accept EACCME accreditation on the UEMS Website. The UEMS-EACCME® has mutual recognition agreements with the American Medical Association (AMA) and with the Royal College of Physicians and Surgeons of Canada for live Events.

Children at EAN Congress 2018

There is no childcare facility available at the congress. Accompanying children over the age of 1 year are not allowed to access the exhibition area due to the pharma codex. Thank you for your understanding.

Cloakroom

A cloakroom is located in front of the CCL in a separate tent and is open during the secretariat opening hours. The cloakroom service is free of charge.

Congress secretariat and registration helpdesk

The registration helpdesk, located in the entrance area of the congress venue is open during the following hours:

- Friday, 15.06.2018: 16.00 – 19.00 h (badge/congress bag pick-up for pre-registered delegates only)
- Saturday, 16.06.2018: 7.30 – 20.00 h
- Sunday, 17.06.2018: 7.30 – 19.00 h
- Monday, 18.06.2018: 7.30 – 19.00 h
- Tuesday, 19.06.2018: 7.30 – 16.45 h

All documents included in the registration package (congress bag, personal name badge) will be handed over to the registered participants. Onsite registration will be accepted, but receipt of all congress documents cannot be guaranteed.

The registration helpdesk can be reached at +351 96 2799370

CME Certificates will only be provided to participants who have evaluated the sessions attended during the congress.
CONGRESS VENUE

Lisbon Congress Centre CCL
Praça das Indústrias
1300-307 Lisbon
Portugal
www.lisboacc.pt

The 4th Congress of the European Academy of Neurology takes place at the Lisbon Congress Centre (CCL) which is located only a few minutes away from the city centre and only 20 minutes away from the airport.

Best way to go from the airport to the congress centre is by taxi - the average cost is around 10 to 15 €. By public transportation, you need to take the bus: the fast way is take bus nº 783 and then change at Campo Pequeno to bus nº 756 (no direct connection).

- For bus & tram, please check: http://carris.transporteslisboa.pt/en/home/
- For train connection, please check: https://www.cp.pt/passageiros/en
- Local cab-companies: AUTOCOOP Tel. (+351) 217 932 756; RETALIS Tel. (+351) 218 119 000; TELETAXIS Tel. (+351) 218 111 100

Currency

The official currency of the 4th EAN Congress in Lisbon is Euro (€). The easiest way to get Euros is to withdraw cash from a Multibanco ATM (“Caixa automático”), which are everywhere in Lisbon. Most ATMs work with credit cards of the Visa and MasterCard type, and debit cards that use the Maestro or Cirrus systems.

Most banks and post offices are open from Monday to Friday between 8.30h and 15.00h. Exchange bureaus are usually open from 9.00-13.00h and from 14.00-19.00h.

EAN Booth – Your Home of neurology

“700.000.000 brains - 45.000 members - 47 countries - one community!”
Location: first floor, between Auditorium I and II.

Opening hours:
Saturday, 16.06.2018: 08.00 – 18.00 h
Sunday, 17.06.2018: 07.30 – 18.00 h
Monday, 18.06.2018: 07.30 – 18.00 h
Tuesday, 19.06.2018: 07.30 – 15.00 h

Visit the EAN Booth and its different areas (HOME, MEET, LEARN and RESEARCH) and find out more about the European Academy of Neurology, your home of neurology, and its aims and missions:

HOME & MEET area

Visit this area already in the morning for a cup of coffee and a chat among colleagues from all over Europe and the world and seize the opportunity for quick casual business meetings. Relax on our sofas and feel at HOME. Learn everything about EAN and the benefits of being a valuable part of Europe’s largest community of neurologists. Get all information on our different membership programmes, meet the people behind EAN, the EAN Board as well as the EAN Head Office.

Get information on MyEAN and our activities in social networks.

Latest information on the 2019 EAN Congress in Oslo will also be made available.

EAN Congress Postcards can be mailed – just drop them in the EAN mailbox, EAN will provide the stamp and mail it for you!

Join us and become a member of our community!

LEARN

When visiting the LEARN area, you can find all educational aspects that underpin the EAN vision to promote excellence in Neurology in Europe. From study programmes outside the EAN congress or grants to support projects in other European Neurological Departments or online learning possibilities.

During coffee and lunch breaks, challenge yourself with the tricky EAN “hot wire” game – special prizes will be offered for the lucky winners.

Need one-of-a-kind memorabilia? Come by and purchase one of the unique EAN bags – strictly limited to only 150 pieces maximum per congress year, made of the poster background tarps of the 2015, 2016 and 2017 EAN congresses in Berlin, Copenhagen and Amsterdam. EAN decided to re-use nearly all printed tarps and cloths of the poster booths and design its very own limited collector item. Be sure to get your one-of-a-kind limited bag for only €20 (discount possibilities: 2 for €35 and 3 for €45 only)
The EAN bags are produced locally in Vienna, Austria by WienWork, an organisation that enables people with disabilities, chronic illnesses or long-term unemployed people to participate in economic and social life. With every purchase of a bag you support this project.

The EAN Photo-wall is also be located here... come by and have your photo taken – while waiting for your turn, just solve one of the funny brain puzzles.

RESEARCH

Get all the information on Scientific Panels - not only on panel membership but also what these panels do. Grab your copy of the European Journal of Neurology and make yourself familiar with other great publications. Learn more about EAN Guideline Production, related crossword puzzles are available. Come by and pick a paper printout of your #ean2018 picture posted on social media.

SCIENTIFIC THEATRE

In Lisbon, the scientific theatre is an extension of the EAN booth, where EAN committees, working-groups and task forces as well as partner organisations and related sub-specialties societies can use short timeslots to talk about their work, inform about their missions and encourage people to have a seat and listen-in. The Programme overview can be found on page 20.

During lunch and coffee breaks, the scientific theater is made available for forum talks by our industry partners. The detailed programme can be found on page 157. Capacity is for 40 people, please bring your earphones (available at the Poster help desk).
Evaluation/Quality control

In order to guarantee the quality of the upcoming congresses, we are carrying out congress evaluations.

General Evaluation

The general evaluation of the congress will be sent to all congress participants after the congress.

Session Evaluation/CME Certificate

If you wish to receive individual reports of your attendance in sessions, please use the EAN website and congress app and evaluate all sessions that you have attended. You can also find a designated “evaluation station” in the congress entrance area in Foyer B. Evaluation is possible until Wednesday, 20 June 2018, 23:59 CET.

CME Certificates will only be provided to participants who have evaluated the sessions attended during the congress.

From Thursday, 21 June, onwards you can download your CME certificate including a report of all sessions you have attended and evaluated. The certificate lists all sessions that were evaluated and includes all CME points.

Please take time to complete the electronic evaluation forms provided for each session you attend. Your input is essential for planning future EAN congresses and for receiving your certificate.

Exhibition

An extensive exhibition will be held concurrently with the congress.

Exhibition opening hours are:
Saturday, 16 June 2018: 09.30 – 17.00h
Sunday, 17 June 2018: 09.30 – 17.00h
Monday, 18 June 2018: 09.30 – 17.00h
Tuesday, 19 June 2018: 09.30 – 13.30h

Accompanying children over the age of 1 year are not allowed to access the exhibition area due to the Pharma Codex. Thank you for your understanding.

The exhibition floor plan can be found on page 121.

Film and photos

Please be advised that photographs and video recordings may be taken at the 4th EAN Congress. By participating in the congress, you consent to the publication, release, exhibition and/or reproduction of such photos to be used for the EAN website, EAN newsblog “EAN pages”, and on social media.

Hotel and travel

Official Housing Agency
Congrex Switzerland Ltd.,
Email: hotel.ean@congrex.com
Congrex Switzerland is present at the Congress registration help desk. Staff can assist you with your hotel bookings.

Insurance & Liability

The Congress organisers and PCO cannot accept liability for personal accidents or loss of or damage to private property of participants, either during or indirectly arising from the 4th Congress of the European Academy of Neurology.

You can choose your individual cancellation and travel insurance package when registering to the congress at extra costs. It is recommended that all participants take advantage of this.

Internet Corner

An Internet Corner is located in the exhibition area (Hall 3) and is available to all congress participants during the opening hours of the exhibition.

Wi-Fi information on page 22.

Interactive Programme Planner (IPP)

Please use the IPP in order to create your personal programme and abstract book.

All invited lectures, oral sessions and poster presentations will be available in the IPP. By logging in with your EAN user information, you will be able to save and edit your personal programme. It is available for desktop, laptop and in our congress app.

Contents are sorted by topic and can be searched through standard web search functions. Once you have created your personal programme, you can export it to different calendar formats, or download it as a book of abstracts.

The IPP will be available before and during the congress.
Information from A to Z

Language

The official language of the congress is English. No simultaneous translation will be provided.

Lost & Found

Please apply to the congress registration helpdesk.

Lunch and Coffee breaks

Light lunch and coffee is included in the registration fee and will be served in the exhibition area as per the times indicated in the timetable. Coffee will be served in Halls 1, 2 and 3. Lunch will only be served in Hall 2.

Mail/Messages

ePoster and ePresentation presenters can be contacted via the online poster system. If you wish to leave a message for somebody, please apply to the information desk.

Media Contact

B&K
Dr Birgit Kofler
Phone: +43-1-319 43 78
Mobile: +43-676-63 68 930
E-Mail: kofler@bkkommunikation.com
Skype: bkk_Birgit.Kofler
PRESS OFFICE

Medical assistance

Please apply to the congress registration helpdesk.

Members’ lounge

EAN Full and Corresponding individual members, FEANs and Faculty Members have the possibility to network and enjoy their lunch in a separated Members’ Lounge. The Members’ Lounge is located next to the EAN Booth area and is open during the exhibition opening hours. A separate “Members working Lounge” can be found above the staircase to Hall 4 (ePoster area).

A photographer, to take a portrait picture of you for your EAN profile, is located in Foyer E during on-site announced hours.

Mini-Programme

The mini-programme gives you an overview of the scientific programme at a glance.

Mobile charging stations

Mobile charging stations will be placed all over the venue available to all congress participants. The mobile charging stations are supported by

![Biogen](#) ![Roche](#)

Mobile phones

Please note that mobile phones must be switched off during all sessions.

Networking

Opening and Welcome Reception (See page 37)
Challenges for women in neurology (see page 38)
Musical Recital (see page 39)
History of Neuroscience visit (see page 40)
Networking event “Meet your Neurology Network” (see page 40)
Resident and Research Fellow Section Activities (see page 9)
Members’ Lounge (see page 19)
EAN booth (see page 16)

Poster Sessions /Poster Overview

Please see page 14 and 31

Press room

A media room with wireless internet access is available to registered journalists. The Press Room is located in Foyer A on the ground floor.
Information from A to Z

Scientific Replay lounge

The Scientific Replay Lounge is located in the exhibition area (Hall 3) and will be available for the comfort of participants, providing a place to see webcasts of selected previous sessions, relax and meet with colleagues.

Scientific Theatre

Located on the ground floor, in Exhibition Hall 2, the Scientific Theatre is a forum for EAN committees, working groups, task forces and other EAN partner organisations to inform the audience in short about their latest achievements and future ambitions.

Set-up for 40 participants with their own ear phones.

Scientific Theatre Programme

Saturday, June 16

10:00-10:30
Forum talks by industry (page 157)

10:30-11:00
How political action can improve the lives of neuropathic pain patients? An introduction to the Societal Impact of Pain campaign
Marc Marlion – EFIC

11:30-12:00
EAN grants and other possibilities
G. di Liberto, L. Klingelhoefer, V. Papp

12:30-13:00
Presentation: eBook on neurological examination
Klaus V. Tokya

14:00-14:30
EAN Guideline Production
Maurizio Leone – EAN

15:30-16:00
How to prepare a scientific paper for publication
Pertti Saloheimo - European Journal of Neurology

Sunday, June 17

9:30-10:00
Forum talks by industry (page 157)

10:00-10:30
News from European Union of Medical Specialists – European Board of Neurology
Patrick Cras – UEMS – SN

10:30-11:00
European Board Exam for Neurology
Jan Kuks – UEMS

11:30-12:00
IFCN European Chapter – Training and education in Europe in Clinical Neurophysiology
Johnathan Cole – IFCN

12:00-12:30
Mind the Treatment Gap!
Wolfgang Oertel – EAN
Joke Jaarsma – EFNA

12:30-13:00
How to build a successful health policy campaign?
Lesson learnt from the Societal Impact of Pain campaign
Sam Kynman – EFIC

14:00-14:30
EBC – VoT Project – Improved patient journey in neurology
Joke Jaarsma – EFNA
Maura Pugliatti – EAN

15:00-15:30
EAN Guideline task force – Palliative Care in MS
Allesandra Solari

16:15-16:45
Forum talks by industry (page 157)

Monday, June 18

9:30-10:00
Forum talks by industry (page 157)

10:00-10:30
Palliative Care and Neurology
David Oliver – EAPC

10:30-11:00
News from the International Neuro-Urology Society
Jalesh Panicker – INUS
Information from A to Z

11:30-12:00  
**EAN grants and other possibilities**  
*G. di Liberto, L. Klingelhoefer, V. Papp*

12:30-13:00  
**EAN Scientific Panels – how to get involved**  
*Celia Oreja-Guevara – EAN*

13:30-14:00  
**Health, wealth and workability: young people with MS**  
*Helen Chandler – EMSP*

14:00-14:30  
Presentation: eBook on neurological examination  
*Klaus V. Tokya*

15:30-16:00  
**Action Plan for Stroke in Europe in Cooperation with SAFE – Stroke Alliance for Europe**  
*Valeria Caso – ESO*

**Tuesday, June 19**

12:00-12:30  
**EAN grants and other possibilities**  
*G. di Liberto, L. Klingelhoefer, V. Papp*

---

**Session descriptions and Buttons**

Please make sure to be in session halls on time as all sessions will begin as per schedule.

If you wish to receive individual reports of your attendance in sessions, please use the EAN website and congress app and evaluate all sessions that you have attended. You can also find a designated “evaluation station” in the congress entrance area in Foyer B.

---

**CME Certificates will only be provided to participants who have evaluated the sessions attended during the congress.**

---

**Scientific Sessions:**

**Symposia:**
Symposia are scheduled on each congress day and will last 2 hours each. Lecturers will give general information on the main topics of the congress.

**Focused Workshops:**
Focused workshops (FWs) will be held in the morning and last for 1.5 hours. They cover narrow topics and aim to promote discussion around new ideas, evidence or theories. Ample time for discussion will be provided.

---

**Special Sessions:**
Special Sessions (SPS) cover topics of special interest.

---

**Educational Sessions:**

**Teaching Courses:**
If you wish to participate, tickets can still be purchased at the Registration for a fee of €50/€30, availability permitting.

TCs are held on each congress day in the afternoon and last for 3 hours (plus 1/2 hour coffee break). They are interactive with ample opportunity for participants to ask questions. All TCs are aimed primarily at a post-graduate audience.

There are 3 levels of TCs:
Level 1 (Introductory): Aimed primarily at neurologists in training, or those wishing to refresh/update their basic knowledge in the field. Level 1 can also be suitable for undergraduates or general trainees with a particular interest.

Level 2 (standard): Assumes familiarity with basic clinical knowledge and practice, aimed at specialist trainees or practitioners wishing to update and further develop their knowledge in the field.

Level 3 (advanced): Aimed at specialist trainees or practitioners with a particular interest in that field, covering the latest advances of particular interest to a specialist audience.

Participation is not included in the registration fee. Participants will receive a manuscript of the lectures.

---

**Hands-on Courses:**
If you wish to participate, tickets can still be purchased at the Registration for a fee of €50/€30, availability permitting.

These Hands-on Courses (HoC) are for a small number of participants only, with some built-in work in smaller groups who attend parallel by rotating to each presenter of the course. Live demonstrations with screening machines are the core of these courses.

Participation is not included in the registration fee. For a limited number of participants only (first come-first-served basis). Participants will receive a manuscript of the presentations.

---

**Case-based Workshops:**
If you wish to participate, tickets can still be purchased at the Secretariat for a fee of €50/€30, availability permitting.

The case-based workshops are to support knowledge and practice in clinical diagnosis and management in a format, which requires the attendees to actively participate, with opportunities for direct discussion/contact with leading experts to discuss pre-prepared cases.
Participation is not included in the registration fee. For a limited number of participants only (first come-first-served basis).

Interactive Sessions:
These sessions are open for all participants. Through an interactive voting system via the congress app, the opinions of colleagues will be collected. Please download the congress app to actively participate in the Q&A.

Controversy Sessions:
Allow to give a critical overview of the current and most recent advances on key topics, share knowledge, stimulate debate and forge opinions on controversial issues of clinical care, research, educational practice and therapy.

Career development Sessions:
This format shall allow to share and improve knowledge on: “how to best write an academic paper”; “how to plan and organize a clinical or scientific study”; “how to apply for a grant”, “how to get a paper accepted” etc...
These sessions are open for all participants and primarily aim at a post-graduate audience.

Smoking policy
Smoking is prohibited at all times in the meeting halls, exhibit halls and restrooms. Your compliance is appreciated.

Speakers’ Service Centre (SSC)
See page 14.

Wi-Fi
Wi-Fi will be available free of charge in the registration and exhibition area as well as in the session rooms.

Network name: EAN-2018_supportedbyRoche
Username: ROCHEatEAN
Password: StartNOW

The Wi-Fi is supported by Roche.

Information from A to Z

The Overarching Theme for the 2018 Congress is “Neurogenetics”. Sessions with this button are dedicated to the Overarching theme and were created by the Programme committee together with Local Organising committee.

EFNA (European Federation of Neurological Associations), the federation uniting European Patients’ Associations, has selected these sessions as high priority.

These are the highlights of the congress and/or innovative sessions.

These sessions were selected by the EAN Rare Neurological Disease Task Force.
WELCOME TO OSLO

Norway has about one certified neurologist per 10,000 inhabitants, distributed among 18 Neurological departments. With more than 700 members, the Norwegian Neurological Association is looking forward to celebrate its 100th anniversary in 2020. Neurologists have been highly active in the development of the health care system in Norway, leading up to Norway being the first country in Europe to launch a National Brain Strategy Plan in 2018. We consider public education to be important, and during the annual Brain Awareness Week, Neurologists offer free lectures and other activities to the public.

The Norwegian Neurological Association and all our members are looking forward to seeing you in Oslo for the 5th EAN Congress 29 June – 2 July 2019!
Second Floor

ePoster Area

Hall 4
ePoster Area

Hall 5
ePoster Area

Meeting Rooms
Toilets
Lift
EAN Info Area
ePoster Area

screens A
screens B
screens C
CONGRESS OF NEUROLOGY

14-17TH NOVEMBER 2018
PORTO PALÁCIO HOTEL CONGRESS CENTER | PORTO | PORTUGAL

MAIN THEME:
NEUROLOGY, ARTIFICIAL INTELLIGENCE, TECHNOLOGICAL INNOVATION

Pre-congress courses:
Neuro-Otology
Neurosonology

Pre-congress Nurses Meeting

The Portuguese Society of Neurology (Sociedade Portuguesa de Neurologia - SPN) was founded in 1982.

The Society gathers all healthcare professionals working in the care of neurological patients including Doctors, Nurses, Psychologists, and Physiotherapists, as well as researchers working in the field of translational and clinical neuroscience.

Join us in Porto in November 2018!

sec.spn@gmail.com
## Overview of business meetings

(in chronological order, as per date of printing)
Additional meetings reserved after the date of printing will be announced on the Message screen in the registration area and can be found in the IPP (App).

<table>
<thead>
<tr>
<th>Group/Committee</th>
<th>Day</th>
<th>Time</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>European Affairs sub-Committee</td>
<td>Saturday, 16 June</td>
<td>08:30 – 10:00</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>EBN/UEMS Board Meeting</td>
<td>Saturday, 16 June</td>
<td>09:00 – 17:00</td>
<td>Room 1.08</td>
</tr>
<tr>
<td>Assembly of Delegates</td>
<td>Saturday, 16 June</td>
<td>13:00 – 15:00</td>
<td>Auditorium II</td>
</tr>
<tr>
<td>RRFS National representatives</td>
<td>Saturday, 16 June</td>
<td>14:15 – 15:15</td>
<td>Room 1.17</td>
</tr>
<tr>
<td>Quality Assurance sub-Committee</td>
<td>Sunday, 17 June</td>
<td>08:30 – 10:00</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>TF Neurology – SSA + Corresponding Societies</td>
<td>Sunday, 17 June</td>
<td>10:00 – 12:00</td>
<td>Room 1.17</td>
</tr>
<tr>
<td>European Journal of Neurology Editorial Board</td>
<td>Sunday, 17 June</td>
<td>13:30 – 14:30</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>EAN / Wiley Meeting</td>
<td>Sunday, 17 June</td>
<td>15:00 – 16:00</td>
<td>Room 1.17</td>
</tr>
<tr>
<td>eCommunication Board</td>
<td>Sunday, 17 June</td>
<td>16:00 – 17:30</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>Teaching Course sub-Committee</td>
<td>Monday, 18 June</td>
<td>08:00 – 09:30</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>Scientific Panel Chairs Meeting</td>
<td>Monday, 18 June</td>
<td>12:00 – 14:00</td>
<td>Auditorium III</td>
</tr>
<tr>
<td>Communication Committee</td>
<td>Monday, 18 June</td>
<td>12:30 – 14:00</td>
<td>Room 1.17</td>
</tr>
<tr>
<td>Local Organising Committee Oslo</td>
<td>Monday, 18 June</td>
<td>12:30 – 14:00</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>RRFS General Assembly</td>
<td>Monday, 18 June</td>
<td>14:15 – 15:15</td>
<td>Room 0.01</td>
</tr>
<tr>
<td>Scientific Committee</td>
<td>Monday, 18 June</td>
<td>14:30 – 16:30</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>Industrial Relations Board (IRB)</td>
<td>Monday, 18 June</td>
<td>15:00 – 16:30</td>
<td>Auditorium III</td>
</tr>
<tr>
<td>Guideline Production Group</td>
<td>Monday, 18 June</td>
<td>17:00 – 18:30</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>Education Committee</td>
<td>Tuesday, 19 June</td>
<td>08:30 – 10:00</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>Programme Committee</td>
<td>Tuesday, 19 June</td>
<td>14:00 – 15:30</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>Board debriefing</td>
<td>Tuesday, 19 June</td>
<td>16:00 – 17:00</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>Rare disease Taskforce</td>
<td>please see IPP (App)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eCommunication Board and Scientific Panel Website representatives</td>
<td>please see IPP (App)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Overview of business meetings of Scientific Panels, Task Forces

(in chronological order, as per date of printing)

Additional meetings reserved after the date of printing will be announced on the Message screen in the registration area and can be found in the IPP (App).

<table>
<thead>
<tr>
<th>Group/Committee</th>
<th>Day</th>
<th>Time</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Panel Autonomic nervous system disorders</td>
<td>Saturday, 16 June</td>
<td>13:00 – 14:30</td>
<td>Room 1.16</td>
</tr>
<tr>
<td>Scientific Panel Neuroepidemiology</td>
<td>Saturday, 16 June</td>
<td>14:30 – 16:00</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>Scientific Panel Translational neurology</td>
<td>Saturday, 16 June</td>
<td>15:00 – 16:00</td>
<td>Room 1.11</td>
</tr>
<tr>
<td>Scientific Panel Multiple sclerosis</td>
<td>Saturday, 16 June</td>
<td>15:15 – 16:15</td>
<td>Room 1.13</td>
</tr>
<tr>
<td>Scientific Panel Neuroimaging</td>
<td>Saturday, 16 June</td>
<td>17:00 – 18:00</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>Scientific Panel Muscle &amp; NMJ disorders</td>
<td>Sunday, 17 June</td>
<td>09:00 – 10:30</td>
<td>Room 1.11</td>
</tr>
<tr>
<td>Scientific Panel Higher cortical functions</td>
<td>Sunday, 17 June</td>
<td>10:00 – 11:00</td>
<td>Room 1.13</td>
</tr>
<tr>
<td>Scientific Panel Neurorehabilitation</td>
<td>Sunday, 17 June</td>
<td>11:00 – 12:00</td>
<td>Room 1.12</td>
</tr>
<tr>
<td>Scientific Panel Neuro-oncology</td>
<td>Sunday, 17 June</td>
<td>12:00 – 13:00</td>
<td>Room 1.12</td>
</tr>
<tr>
<td>Scientific Panel Clinical neurophysiology</td>
<td>Sunday, 17 June</td>
<td>12:30 – 14:00</td>
<td>Room 1.16</td>
</tr>
<tr>
<td>Scientific Panel Neurotraumatology</td>
<td>Sunday, 17 June</td>
<td>13:00 – 14:00</td>
<td>Room 1.13</td>
</tr>
<tr>
<td>Task Force &quot;Coma and chronic disorders of consciousness&quot; Guideline</td>
<td>Sunday, 17 June</td>
<td>13:00 – 15:00</td>
<td>Room 1.11</td>
</tr>
<tr>
<td>Scientific Panel Pain</td>
<td>Sunday, 17 June</td>
<td>14:00 – 15:00</td>
<td>Room 1.12</td>
</tr>
<tr>
<td>Scientific Panel Neurosonology</td>
<td>Sunday, 17 June</td>
<td>14:00 – 15:00</td>
<td>Room 1.16</td>
</tr>
<tr>
<td>Scientific Panel Neurocritical care</td>
<td>Sunday, 17 June</td>
<td>15:00 – 16:30</td>
<td>Room 1.16</td>
</tr>
<tr>
<td>Scientific Panel Sleep-wake disorders</td>
<td>Sunday, 17 June</td>
<td>16:00 – 17:00</td>
<td>Room 1.13</td>
</tr>
<tr>
<td>Scientific Panel Palliative care</td>
<td>Sunday, 17 June</td>
<td>16:00 – 17:00</td>
<td>Room 1.12</td>
</tr>
<tr>
<td>Task Force &quot;Narcolepsy&quot; Guideline</td>
<td>Sunday, 17 June</td>
<td>17:00 – 18:30</td>
<td>Room 1.13</td>
</tr>
<tr>
<td>Scientific Panel Neuro-ophthalmology and -otology</td>
<td>Sunday, 17 June</td>
<td>16:45 – 18:00</td>
<td>Room 1.17</td>
</tr>
<tr>
<td>Task Force &quot;Palliative care in MS&quot; Guideline</td>
<td>Sunday, 17 June</td>
<td>17:00 – 19:00</td>
<td>Room 1.12</td>
</tr>
<tr>
<td>Task Force &quot;Parkinson’s diseases&quot; Guideline</td>
<td>Sunday, 17 June</td>
<td>17:00 – 18:00</td>
<td>Room 1.16</td>
</tr>
</tbody>
</table>
Overview of business meetings of Scientific Panels, Task Forces

(in chronological order, as per date of printing)
Additional meetings reserved after the date of printing will be announced on the Message screen in the registration area and can be found in the IPP (App).

<table>
<thead>
<tr>
<th>Group/Committee</th>
<th>Day</th>
<th>Time</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Panel Epilepsy</td>
<td>Monday, 18 June</td>
<td>09:00 – 11:00</td>
<td>Room 1.16</td>
</tr>
<tr>
<td>Scientific Panel Headache</td>
<td>Monday, 18 June</td>
<td>09:30 – 10:30</td>
<td>Room 1.13</td>
</tr>
<tr>
<td>Scientific Panel Dementia and cognitive disorders</td>
<td>Monday, 18 June</td>
<td>10:00 – 11:00</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>Scientific Panel Stroke</td>
<td>Monday, 18 June</td>
<td>11:00 – 12:00</td>
<td>Room 1.15</td>
</tr>
<tr>
<td>Scientific Panel Neuropathies</td>
<td>Monday, 18 June</td>
<td>14:15 – 15:45</td>
<td>Room 1.17</td>
</tr>
<tr>
<td>Scientific Panel Neurogenetics</td>
<td>Monday, 18 June</td>
<td>15:00 – 16:00</td>
<td>Room 1.16</td>
</tr>
<tr>
<td>Scientific Panel Infectious diseases</td>
<td>Monday, 18 June</td>
<td>17:00 – 18:00</td>
<td>Room 1.11</td>
</tr>
<tr>
<td>Scientific Panel Child neurology</td>
<td>Tuesday, 19 June</td>
<td>10:00 – 11:00</td>
<td>Room 1.12</td>
</tr>
<tr>
<td>Scientific Panel Coma and chronic disease of</td>
<td>Tuesday, 19 June</td>
<td>10:00 – 12:00</td>
<td>Room 1.13</td>
</tr>
<tr>
<td>consciousness</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ePoster overview

ePoster presenters are requested to be at their poster screen at the beginning of the session. Pick up your audio equipment at the poster desk!

Saturday, 16 June 2018
12:30–13:15

<table>
<thead>
<tr>
<th>Topic</th>
<th>Screen Nr</th>
<th>Poster Numbers</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ageing and dementia</td>
<td>Screen A1</td>
<td>EPO1001 – EPO1011</td>
<td>Miguel Tábuas-Pereira, Portugal</td>
</tr>
<tr>
<td>Cerebrovascular diseases 1</td>
<td>Screen A3</td>
<td>EPO1012 – EPO1022</td>
<td>Diana Aguiar de Sousa, Portugal</td>
</tr>
<tr>
<td>Cognitive neurology/neuropsychology</td>
<td>Screen A6</td>
<td>EPO1023 – EPO1033</td>
<td>Alexandre Mendonça, Portugal</td>
</tr>
<tr>
<td>Epilepsy 1</td>
<td>Screen B1</td>
<td>EPO1034 – EPO1043</td>
<td>Ettore Beghi, Italy</td>
</tr>
<tr>
<td>Headache and pain 1</td>
<td>Screen B3</td>
<td>EPO1044 – EPO1052</td>
<td>Isabel Pavão, Portugal</td>
</tr>
<tr>
<td>Miscellaneous 1</td>
<td>Screen B9</td>
<td>EPO1053 – EPO1064</td>
<td>Bartosz Karaszewski, Poland</td>
</tr>
<tr>
<td>Movement disorders 1</td>
<td>Screen B6</td>
<td>EPO1065 – EPO1075</td>
<td>Aleksandra Herrera-Sokołowska, Poland</td>
</tr>
<tr>
<td>MS and related disorders 1</td>
<td>Screen B11</td>
<td>EPO1076 – EPO1089</td>
<td>Giovanni Di Liberto, Switzerland</td>
</tr>
<tr>
<td>MS and related disorders 2</td>
<td>Screen B7</td>
<td>EPO1090 – EPO1095</td>
<td>João Sá, Portugal</td>
</tr>
<tr>
<td>Muscle and neuromuscular junction disease 1</td>
<td>Screen C1</td>
<td>EPO1096 – EPO1105</td>
<td>Mamede de Carvalho, Portugal</td>
</tr>
<tr>
<td>Neurological manifestations of systemic diseases</td>
<td>Screen C4</td>
<td>EPO1106 – EPO1115</td>
<td>Irina Alexandra Orban, Romania</td>
</tr>
</tbody>
</table>

Sunday, 17 June 2018
12:30–13:15

<table>
<thead>
<tr>
<th>Topic</th>
<th>Screen Nr</th>
<th>Poster Numbers</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebrovascular diseases 2</td>
<td>Screen A3</td>
<td>EPO2001 – EPO2012</td>
<td>Natan Bornstein, Israel</td>
</tr>
<tr>
<td>Child neurology/developmental neurology</td>
<td>Screen A6</td>
<td>EPO2013 – EPO2020</td>
<td>Teresa Temudo, Portugal</td>
</tr>
<tr>
<td>Clinical neurophysiology</td>
<td>Screen B3</td>
<td>EPO2021 – EPO2027</td>
<td>Simon Podnar, Slovenia</td>
</tr>
<tr>
<td>Epilepsy 2</td>
<td>Screen B1</td>
<td>EPO2029 – EPO2037</td>
<td>Andrei Dubenko, Ukraine</td>
</tr>
<tr>
<td>Infectious diseases; Sleep disorders</td>
<td>Screen B9</td>
<td>EPO2038 – EPO2048</td>
<td>Stefan Golaszewski, Austria</td>
</tr>
<tr>
<td>Movement disorders 2</td>
<td>Screen B6</td>
<td>EPO2049 – EPO2059</td>
<td>Angelo Antonini, Italy</td>
</tr>
<tr>
<td>Movement disorders 3</td>
<td>Screen B11</td>
<td>EPO2060 – EPO2070</td>
<td>Panagiotis Zis, United Kingdom</td>
</tr>
<tr>
<td>MS and related disorders 3</td>
<td>Screen B7</td>
<td>EPO2071 – EPO2080</td>
<td>Patrick Vermersch, France</td>
</tr>
<tr>
<td>Neurogenetics 1</td>
<td>Screen C1</td>
<td>EPO2081 – EPO2091</td>
<td>Isabelle Le Ber, France</td>
</tr>
<tr>
<td>Neuro-oncology</td>
<td>Screen C4</td>
<td>EPO2092 – EPO2100</td>
<td>Francois Ducray, France</td>
</tr>
<tr>
<td>Neurorehabilitation</td>
<td>Screen C2</td>
<td>EPO2101 – EPO2111</td>
<td>Fior Dafin Muresanu, Romania</td>
</tr>
<tr>
<td>Peripheral nerve disorders</td>
<td>Screen A1</td>
<td>EPO2112 – EPO2124</td>
<td>Vitalie Lismic, Moldova</td>
</tr>
</tbody>
</table>

All posters will be available throughout the congress on the poster screens and computer stations in the exhibition area. You can contact ePoster and ePresentation presenters via the poster system. For this, please use one of the poster screens in the ePoster area and navigate to the poster you would like to contact the author of. You can find a contact link on the bottom of that page. You can do the same via the link on the congress website.
ePoster presenters are requested to be at their poster screen at the beginning of the session.
Pick up your audio equipment at the poster desk!

Monday, 18 June 2018
12:30–13:15

<table>
<thead>
<tr>
<th>Topic</th>
<th>Screen Nr</th>
<th>Poster Numbers</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebrovascular diseases 3</td>
<td>Screen A3</td>
<td>EPO3001 – EPO3012</td>
<td>Kristaps Jurjans, Latvia</td>
</tr>
<tr>
<td>Epilepsy 3</td>
<td>Screen B1</td>
<td>EPO3013 – EPO3022</td>
<td>Jera Kruja, Albania</td>
</tr>
<tr>
<td>Headache and pain 2</td>
<td>Screen B3</td>
<td>EPO3023 – EPO3031</td>
<td>Raquel Gil-Gouveia, Portugal</td>
</tr>
<tr>
<td>Miscellaneous 2</td>
<td>Screen A1</td>
<td>EPO3032 – EPO3043</td>
<td>Vida Demarin, Croatia</td>
</tr>
<tr>
<td>Motor neurone diseases; Cognitive neurology/</td>
<td>Screen A6</td>
<td>EPO3044 – EPO3055</td>
<td>Riadh Gouider, Tunisia</td>
</tr>
<tr>
<td>neuropsychology</td>
<td>Screen B6</td>
<td>EPO3056 – EPO3066</td>
<td>K Ray Chaudhuri, United Kingdom</td>
</tr>
<tr>
<td>Movement disorders 4</td>
<td>Screen B6</td>
<td>EPO3067 – EPO3076</td>
<td>Celia Oreja-Guevara, Spain</td>
</tr>
<tr>
<td>MS and related disorders 4</td>
<td>Screen B11</td>
<td>EPO3077 – EPO3086</td>
<td>Josef Finsterer, Austria</td>
</tr>
<tr>
<td>Muscle and neuromuscular junction disease 2</td>
<td>Screen C1</td>
<td>EPO3087 – EPO3097</td>
<td>Jean Marc Burgunder, Switzerland</td>
</tr>
<tr>
<td>Neurogenetics 2</td>
<td>Screen C4</td>
<td>EPO3098 – EPO3105</td>
<td>Neşe Celebisoy, Turkey</td>
</tr>
<tr>
<td>Neuro-ophthalmology/ neuro-otology</td>
<td>Screen C2</td>
<td>EPO3106 – EPO3116</td>
<td>Teresa Paiva, Portugal</td>
</tr>
<tr>
<td>Sleep disorders</td>
<td>Screen B7</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All posters will be available throughout the congress on the poster screens and computer stations in the exhibition area.
You can contact ePoster and ePresentation presenters via the poster system. For this, please use one of the poster screens in the ePoster area and navigate to the poster you would like to contact the author of. You can find a contact link on the bottom of that page. You can do the same via the link on the congress website.
ePresentation overview

ePresentation presenters are requested to be at their poster screen at the beginning of the session. Pick up your audio equipment at the poster desk!

Saturday, 16 June 2018
13:30–14:15

<table>
<thead>
<tr>
<th>Topic</th>
<th>Screen Nr</th>
<th>Presentation Numbers</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ageing and dementia 1</td>
<td>Screen A1</td>
<td>EPR1001 – EPR1008</td>
<td>Federica Agosta, Italy</td>
</tr>
<tr>
<td>Cerebrovascular diseases 1</td>
<td>Screen A3</td>
<td>EPR1009 – EPR1017</td>
<td>Hugh Markus, United Kingdom</td>
</tr>
<tr>
<td>Cerebrovascular diseases 2</td>
<td>Screen A2</td>
<td>EPR1018 – EPR1026</td>
<td>Serefür Öztürk, Turkey</td>
</tr>
<tr>
<td>Cognitive neurology/neuropsychology 1</td>
<td>Screen A6</td>
<td>EPR1027 – EPR1032</td>
<td>Elisa Canu, Italy</td>
</tr>
<tr>
<td>Epilepsy 1</td>
<td>Screen B1</td>
<td>EPR1033 – EPR1040</td>
<td>Kristl Vonck, Belgium</td>
</tr>
<tr>
<td>Headache and pain 1</td>
<td>Screen B3</td>
<td>EPR1041 – EPR1049</td>
<td>Radu Razvan, Romania</td>
</tr>
<tr>
<td>Motor neurone diseases 1</td>
<td>Screen A4</td>
<td>EPR1050 – EPR1057</td>
<td>Thomas M. Jenkins, United Kingdom</td>
</tr>
<tr>
<td>Movement disorders 1</td>
<td>Screen B6</td>
<td>EPR1058 – EPR1065</td>
<td>Miguel Coelho, Portugal</td>
</tr>
<tr>
<td>Movement disorders 2</td>
<td>Screen B8</td>
<td>EPR1066 – EPR1073</td>
<td>Jean-Philippe Azulay, France</td>
</tr>
<tr>
<td>Movement disorders 3</td>
<td>Screen B10</td>
<td>EPR1074 – EPR1081</td>
<td>Anna Członkowska, Poland</td>
</tr>
<tr>
<td>MS and related disorders 1</td>
<td>Screen B11</td>
<td>EPR1082 – EPR1090</td>
<td>Declan Chard, United Kingdom</td>
</tr>
<tr>
<td>MS and related disorders 2</td>
<td>Screen B7</td>
<td>EPR1091 – EPR1098</td>
<td>Maria José Sá, Portugal</td>
</tr>
<tr>
<td>MS and related disorders 3</td>
<td>Screen B5</td>
<td>EPR1099 – EPR1106</td>
<td>Gavin Giovanni, United Kingdom</td>
</tr>
<tr>
<td>Muscle and neuromuscular junction disease 1</td>
<td>Screen C1</td>
<td>EPR1107 – EPR1114</td>
<td>Zohar Argov, Israel</td>
</tr>
<tr>
<td>Neurogenetics 1</td>
<td>Screen C3</td>
<td>EPR1115 – EPR1121</td>
<td>Corrado Angelini, Italy</td>
</tr>
<tr>
<td>Neuroimaging 1</td>
<td>Screen A5</td>
<td>EPR1122 – EPR1128</td>
<td>Sofia Reimão, Portugal</td>
</tr>
<tr>
<td>Neuroimmunology 1</td>
<td>Screen B9</td>
<td>EPR1129 – EPR1136</td>
<td>Alvaro Cobo-Calvo, France</td>
</tr>
<tr>
<td>Neurological manifestations of systemic diseases</td>
<td>Screen C4</td>
<td>EPR1137 – EPR1143</td>
<td>Markus Weber, Switzerland</td>
</tr>
<tr>
<td>Neuro-ophthalmology/neuro-otology; Spinal cord and root disorders</td>
<td>Screen B2</td>
<td>EPR1144 – EPR1151</td>
<td>Eleftherios Paphianasiou, Cyprus</td>
</tr>
<tr>
<td>Neurorehabilitation 1</td>
<td>Screen C2</td>
<td>EPR1152 – EPR1159</td>
<td>Anabela Pinto, Portugal</td>
</tr>
<tr>
<td>Peripheral nerve disorders 1</td>
<td>Screen B4</td>
<td>EPR1160 – EPR1168</td>
<td>Geir Julius Braathen, Norway</td>
</tr>
<tr>
<td>Peripheral nerve disorders 2</td>
<td>Screen B12</td>
<td>EPR1170 – EPR1177</td>
<td>Teresa Paiva, Portugal</td>
</tr>
</tbody>
</table>

All posters will be available throughout the congress on the poster screens and computer stations in the exhibition area. You can contact ePoster and ePresentation presenters via the poster system. For this, please use one of the poster screens in the ePoster area and navigate to the poster you would like to contact the author of. You can find a contact link on the bottom of that page. You can do the same via the link on the congress website.
ePresentation overview

ePresentation presenters are requested to be at their poster screen at the beginning of the session. Pick up your audio equipment at the poster desk!

Sunday, 17 June 2018
13:30–14:15

<table>
<thead>
<tr>
<th>Topic</th>
<th>Screen Nr</th>
<th>Presentation Numbers</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ageing and dementia 2</td>
<td>Screen A1</td>
<td>EPR2001 – EPR2008</td>
<td>Alla Guekht, Russia</td>
</tr>
<tr>
<td>Autonomic nervous system; Sleep disorders</td>
<td>Screen C4</td>
<td>EPR2009 – EPR2017</td>
<td>Mario Habek, Croatia</td>
</tr>
<tr>
<td>Cerebrovascular diseases 3</td>
<td>Screen A3</td>
<td>EPR2018 – EPR2024</td>
<td>Patrik Michel, Switzerland</td>
</tr>
<tr>
<td>Cerebrovascular diseases 4</td>
<td>Screen A2</td>
<td>EPR2025 – EPR2033</td>
<td>Raquel Gutiérrez Zúñiga, Portugal</td>
</tr>
<tr>
<td>Child neurology/developmental neurology</td>
<td>Screen A6</td>
<td>EPR2034 – EPR2040</td>
<td>Urs Fisch, Switzerland</td>
</tr>
<tr>
<td>Clinical neurophysiology</td>
<td>Screen B3</td>
<td>EPR2041 – EPR2049</td>
<td>Letizia Leocani, Italy</td>
</tr>
<tr>
<td>Epilepsy 2</td>
<td>Screen B1</td>
<td>EPR2050 – EPR2057</td>
<td>Mar Carreño, Spain</td>
</tr>
<tr>
<td>Headache and pain 2</td>
<td>Screen B2</td>
<td>EPR2058 – EPR2065</td>
<td>Delphine Magis, Belgium</td>
</tr>
<tr>
<td>Infectious diseases</td>
<td>Screen B9</td>
<td>EPR2066 – EPR2072</td>
<td>Erich Schmutzhard, Austria</td>
</tr>
<tr>
<td>Movement disorders 4</td>
<td>Screen B6</td>
<td>EPR2073 – EPR2080</td>
<td>Carlo Colosimo, Italy</td>
</tr>
<tr>
<td>Movement disorders 5</td>
<td>Screen B11</td>
<td>EPR2081 – EPR2088</td>
<td>Philippe Damier, France</td>
</tr>
<tr>
<td>Movement disorders 6</td>
<td>Screen B8</td>
<td>EPR2089 – EPR2096</td>
<td>Olivier Rascol, France</td>
</tr>
<tr>
<td>MS and related disorders 4</td>
<td>Screen B7</td>
<td>EPR2097 – EPR2104</td>
<td>Ludwig Kappos, Switzerland</td>
</tr>
<tr>
<td>MS and related disorders 5</td>
<td>Screen B10</td>
<td>EPR2105 – EPR2112</td>
<td>Michael Khalil, Austria</td>
</tr>
<tr>
<td>MS and related disorders 6</td>
<td>Screen B5</td>
<td>EPR2113 – EPR2120</td>
<td>Abhijit Chaudhuri, United Kingdom</td>
</tr>
<tr>
<td>Neurogenetics 2</td>
<td>Screen C3</td>
<td>EPR2121 – EPR2127</td>
<td>Max Hilz, Germany</td>
</tr>
<tr>
<td>Neurogenetics 3</td>
<td>Screen C1</td>
<td>EPR2128 – EPR2133</td>
<td>Christine Van Broeckhoven, Belgium</td>
</tr>
<tr>
<td>Neuroimaging 2</td>
<td>Screen A5</td>
<td>EPR2134 – EPR2140</td>
<td>Laszlo Csiba, Hungary</td>
</tr>
<tr>
<td>Neurological manifestations of systemic diseases; Neuro-oncology</td>
<td>Screen B12</td>
<td>EPR2141 – EPR2146</td>
<td>Riccardo Soffietti, Italy</td>
</tr>
<tr>
<td>Neurorehabilitation 2</td>
<td>Screen C2</td>
<td>EPR2147 – EPR2154</td>
<td>Andreas Bender, Germany</td>
</tr>
<tr>
<td>Peripheral nerve disorders 3</td>
<td>Screen B4</td>
<td>EPR2155 – EPR2163</td>
<td>Ingemar SJ Merkies, The Netherlands</td>
</tr>
<tr>
<td>Peripheral nerve disorders; Muscle and neuromuscular junction diseases</td>
<td>Screen A4</td>
<td>EPR2164 – EPR2171</td>
<td>Yuri Alekseenko, Belarus</td>
</tr>
</tbody>
</table>

All posters will be available throughout the congress on the poster screens and computer stations in the exhibition area. You can contact ePoster and ePresentation presenters via the poster system. For this, please use one of the poster screens in the ePoster area and navigate to the poster you would like to contact the author of. You can find a contact link on the bottom of that page. You can do the same via the link on the congress website.
**ePresentation overview**

ePresentation presenters are requested to be at their poster screen at the beginning of the session. Pick up your audio equipment at the poster desk!

**Monday, 18 June 2018**  
13:30–14:15

<table>
<thead>
<tr>
<th>Topic</th>
<th>Screen Nr</th>
<th>Presentation Numbers</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ageing and dementia 3</td>
<td>Screen A1</td>
<td>EPR3001 – EPR3007</td>
<td>Pasquale Calabrese, Switzerland</td>
</tr>
<tr>
<td>Autonomic nervous system</td>
<td>Screen B2</td>
<td>EPR3008 – EPR3015</td>
<td>Walter Struhal, Austria</td>
</tr>
<tr>
<td>Cerebrovascular diseases 5</td>
<td>Screen A3</td>
<td>EPR3016 – EPR3023</td>
<td>Stefan Schwab, Germany</td>
</tr>
<tr>
<td>Cognitive neurology/neuropsychology 2</td>
<td>Screen A6</td>
<td>EPR3024 – EPR3030</td>
<td>Maria Assunta Rocca, Italy</td>
</tr>
<tr>
<td>Epilepsy 3</td>
<td>Screen B1</td>
<td>EPR3031 – EPR3039</td>
<td>Reetta Kälviäinen, Finland</td>
</tr>
<tr>
<td>Headache and pain 3</td>
<td>Screen B3</td>
<td>EPR3040 – EPR3048</td>
<td>Simona Sacco, Italy</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Screen B9</td>
<td>EPR3049 – EPR3055</td>
<td>Patrick Cras, Belgium</td>
</tr>
<tr>
<td>Motor neurone diseases 2</td>
<td>Screen A4</td>
<td>EPR3056 – EPR3062</td>
<td>Christian Krarup, Denmark</td>
</tr>
<tr>
<td>Movement disorders 7</td>
<td>Screen B6</td>
<td>EPR3063 – EPR3070</td>
<td>Mário M. Rosa, Portugal</td>
</tr>
<tr>
<td>Movement disorders 8</td>
<td>Screen B8</td>
<td>EPR3071 – EPR3078</td>
<td>Leonor Correia Guedes, Portugal</td>
</tr>
<tr>
<td>Movement disorders 9</td>
<td>Screen A2</td>
<td>EPR3079 – EPR3086</td>
<td>Andreas Zwergal, Germany</td>
</tr>
<tr>
<td>MS and related disorders 7</td>
<td>Screen B11</td>
<td>EPR3087 – EPR3094</td>
<td>Per Soelberg Sörensen, Denmark</td>
</tr>
<tr>
<td>MS and related disorders 8</td>
<td>Screen B10</td>
<td>EPR3095 – EPR3102</td>
<td>Heinz Wiendl, Germany</td>
</tr>
<tr>
<td>MS and related disorders 9</td>
<td>Screen B5</td>
<td>EPR3103 – EPR3110</td>
<td>Tjalf Ziemssen, Germany</td>
</tr>
<tr>
<td>Muscle and neuromuscular junction disease 2</td>
<td>Screen C1</td>
<td>EPR3111 – EPR3117</td>
<td>Antonio Toscano, Italy</td>
</tr>
<tr>
<td>Neuroepidemiology</td>
<td>Screen B12</td>
<td>EPR3118 – EPR3126</td>
<td>Maura Pugliatti, Italy</td>
</tr>
<tr>
<td>Neurogenetics 4</td>
<td>Screen C4</td>
<td>EPR3127 – EPR3133</td>
<td>Michelangelo Mancuso, Italy</td>
</tr>
<tr>
<td>Neuroimmunology 2</td>
<td>Screen A5</td>
<td>EPR3134 – EPR3141</td>
<td>Luca Massacesi, Italy</td>
</tr>
<tr>
<td>Neuro-ophthalmology/ neuro-otology</td>
<td>Screen C2</td>
<td>EPR3142 – EPR3150</td>
<td>Michael Leo Strupp, Germany</td>
</tr>
<tr>
<td>Neurorehabilitation 3</td>
<td>Screen C3</td>
<td>EPR3151 – EPR3157</td>
<td>Volker Dietz, Germany</td>
</tr>
<tr>
<td>Peripheral nerve disorders 5</td>
<td>Screen B4</td>
<td>EPR3158 – EPR3164</td>
<td>Jean Marc Leger, France</td>
</tr>
<tr>
<td>Sleep disorders</td>
<td>Screen B7</td>
<td>EPR3165 – EPR3173</td>
<td>Luigi Ferini-Strambi, Italy</td>
</tr>
</tbody>
</table>

All posters will be available throughout the congress on the poster screens and computer stations in the exhibition area. You can contact ePoster and ePresentation presenters via the poster system. For this, please use one of the poster screens in the ePoster area and navigate to the poster you would like to contact the author of. You can find a contact link on the bottom of that page. You can do the same via the link on the congress website.
12:00 – 15:00h
Room 0.01 CCL - Lisbon Congress Centre

„Huntington’s Disease - Scientific Updates for the HD Community (EHA and APDH)“

12:00h
Opening Words

12:10h
EHDN past, present and future
Jean-Marc Burgunder (Bern, Switzerland)

“The European Huntington’s Disease Network has been created in 2004 with the aim to advance research, conduct clinical trials and improve clinical care for patients with the disease and their family. EHDN started as a small group with a core study, Registry, and constantly grew thanks to the strong involvement of members and the support by CHDI. After the globalisation of the observational study, now called Enroll-HD, EHDN has reshaped its activities still working on the same aims. EHDN tasks are still at hand and the network will continue its activities in close collaboration with the patients’ organisations.”

Jean-Marc Burgunder has graduated in Medicine at the Faculty of Medicine in Bern, Switzerland, and trained in internal medicine, neurology and neuroscience in Switzerland and in Bethesda, USA. He is a Professor of Experimental Neurology at the University in Bern. He is now, Chair of the EHDN Executive Committee, Co-Chair of the Scientific Panel on Neurogenetics of EAN, Chair of the European Reference Network on Rare Neurological disorders Advisory board. He is also director of the NeuroZentrum Siloah in Gümligen (Bern).

12:50h
EHDN and Registry/Enroll-HD studies in Portugal
Leonor Correia Guedes (Lisbon, Portugal)

“How Portuguese patients and families collaborate in global HD research and how the European Huntington’s disease network collaborates in clinical care and research in HD in Portugal.”

Portuguese Coordinator of the European Huntington’s disease Network; Member of the EHDN Scientific and Bioethical advisory board; Neurologist at Hospital de Santa Maria, Lisbon, Portugal; Professor of Neurology, Medical School of the University of Lisbon, Portugal.

13:20h–13:40h
Coffee-Break

13:40h
Clinical Trials in Huntington’s Disease
G. Bernhard Landwehrmeyer (Ulm, Germany)

G. Bernhard Landwehrmeyer, MD, FRCP is Professor of Neurology at Ulm University Hospital, Dept. of Neurology where the Central Coordination of the European Huntington’s Disease Network (EHDN) is situated. In 2004 he was instrumental in founding EHDN and served as chairman of the Executive Committee until 2014. EHDN serves as a platform for professionals, people affected by Huntington’s disease (HD), and their relatives to facilitate working together throughout Europe and conducts large prospective natural history studies in HD. He received his Doctoral Degree from the Albert-Ludwigs-University, Freiburg. He was trained at the Royal Victoria Hospital, Queen’s University, Belfast, at the Kantonsspital, Basel and worked as post-Doc at MGH, Harvard Medical School, Boston.

14:20h
20 Years’ Experience with Genetic Testing and Counselling for Huntington Disease in Portugal
Jorge Sequeiros (Porto, Portugal)

“Genetic testing for HD began to be provided in 1998, at IBMC, following the IHA/WFN Guidelines and a genetic counselling protocol already in use for Machado-Joseph disease. As a reference lab for HD, we acquired some data on the number of patients/families in Portugal, as well as on population frequency of intermediate and low-penetrance alleles. The genetic counselling experience with HD helped building our research on psychosocial genetics, improving our protocol and clinical practice, as well as contributing to the revised international guidelines proposed by the EHDN. In the meantime, having begun as a research effort, our lab became fully licensed and accredited (ISO 15189).”

Jorge Sequeiros obtained his MD from the Fac. Medicine, Univ. Porto (1975) and a PhD in Genetics from ICBAS, Univ. Porto (1990). He was post-doctoral Fellow in Medical Genetics (1982-1985) at Johns Hopkins Hosp., Baltimore. He is Director of the MSc on Genetic Counselling, ICBAS, Univ. Porto and research group leader of UnIGENe and Director of the Centre for Predictive and Preventive Genetics (www.cgppe.eu) for clinical and laboratory genetic services at IBMC. He has held numerous positions including founder and first-President (1999-2009) of the College of Medical Genetics, at the Portuguese Medical Association. He has been a member of EHDN (then Euro-HD) since its beginning in 2003, and organised the 1st meeting of Portuguese-speaking study sites (Porto, 2004). He has been part of the EHDN working groups since their first meetings.

14:50h
Closing Words
Official Networking Programme & other activities  

Saturday 16 June

CCL Auditorium I
18:30h

Opening & Welcome Reception

Welcoming addresses by
Joaquim Ferreira, Local Chairperson
Günther Deuschl, EAN President

Honorary Membership Awards
Mark Hallett, Bethesda, USA
Alistair Compston, Cambridge, UK

Announcement:
Paul Boon, Chair EAN Programme Committee

Opening Lecture:
“Should we concern about ethical limits in neurogenetics?”
Alexandre Quintanilha, Porto, Portugal

Musical performance:
Original Fado Guitar Performance by Marta Pereira da Costa

All participants and exhibitors are invited to the Opening and the Welcome reception afterwards. This year the reception will be outside on the plaza in front of the CCL. We are happy to serve food and cold drinks. Please wear your badge.
Challenges for Women in Neurology

Chairperson:
Elena Moro (Grenoble, France)

The aim of the event is to help identify and overcome the challenges that women can find during their academic and hospital career development in neurology. This event is mainly directed to female neurology residents and female neurologists at the beginning of their career.

You are invited to bring your lunch to this session.

Catherine Lubetzki, Paris, France

Catherine Lubetzki is Professor of Neurology at Pierre and Marie Curie University and head of the department of neurology in Salpêtrière Hospital, Paris, France. She is and/or has been involved in several committees and funding boards, including ECTRIMS executive committee and the scientific committee of ARSEP (French multiple sclerosis association for research). Her clinical activity is mainly dedicated to the management of multiple sclerosis patients through the Salpêtrière multiple sclerosis clinic and clinical research center. She leads a research group in the Brain and Spinal cord Institute (ICM), located within the Salpêtrière campus. The research topic is focused on the cellular and molecular mechanisms involved in central nervous system myelination and remyelination, using different in vitro models as well as in vivo approaches and post-mortem analysis. The general aim of the research projects is to understand why some multiple sclerosis lesions remyelinate whereas others do not. This with the perspective of developing, through activation of promoting cues, or suppression of inhibitory pathways, strategies aimed at stimulating endogenous remyelination, hence preventing axonal damage and limiting disability progression in Multiple Sclerosis patients.

Jera Kruja, Tirana, Albania

Dr Jera Kruja, Professor of Neurology, is head of the University Service of Neurology, Faculty of Medicine, University of Medicine and UHC Mother Teresa in Tirana, Albania. She has been president of the Albanian Society of Neurology and for more than 20 years the delegate of this chapter and an active member of scientific panels of the European Federation of Neurological Societies (EFNS) and afterward to the European Academy of Neurology. Prof. Kruja was also a member of the Scientific Committee of EAN. Since 2014 she is a member of Teaching Course Committee of the World Federation of Neurology (WFN). She is a Lancet Commissioner for LMIC. Furthermore, she was a trainer of European Academy of Epilepsy. From 2010-2013 she was the National Health Contact Point, European Commission, CORDIS Fp7 programme and she was the first Rector of the University of Medicine of Tirana, Albania. Prof. Kruja is a member of numerous national and international editing boards and speaker in many international meetings.

Claudia Trenkwalder, Kassel, Germany

Claudia Trenkwalder, MD, started her clinical education in neurology and movement disorders at the University Hospital of the Ludwig-Maximilian-University in Munich in 1988 and was head of the “Movement Disorders and Sleep” research group at the Max- Planck Institute of Psychiatry in Munich from 1993-2000, before moving to the Department of Clinical Neurophysiology at the University of Goettingen as Associate Professor. She is Medical Director of the Elena Klinik, in Kassel, the largest neurological hospital for Parkinson and Movement Disorders in Germany, since 2003. In 2012, she became Full Professor of Neurology as a Foundation Chair at University Medical Center in Goettingen. Her research interests are early symptoms and therapy in Parkinson disease, movement disorders in sleep such as Rem Sleep Behavior Disorder and Restless Legs Syndrome. She has published more than 365 peer reviewed papers and supports female careers in many ways including mentoring programs at the university site. She has been active in the International Parkinson and Movement Disorder Society (IPMDS) for many years and is currently President-Elect of IPMDS, but was also Founding Member of the World Association of Sleep Medicine (WASM), and President of WASM from 2011-13 and active member of many national and international scientific societies.
20.15h

Music Recital at CCL, Auditorium II


This chamber music recital is the third one organised and scheduled at the time of an EAN congress by the neurologists Klaus V. Toyka, Würzburg, and Hannah Cock, London, and pianist Beate Toyka, co-organised by the Faculty Neurology Department of the Lisbon University Hospital.

Participants of the congress are cordially invited to spend an hour of relaxed listening.

The tickets are € 15 (€ 10 reduced fee).
13:00h

**History of Neuroscience Visit to the Egas Moniz Museum**

The participants of the History of Neuroscience Visit will be picked up by bus at 13.00 on Monday, June 18. All participants will arrive at the museum between 13.15 and 13.20. Between 14.45 and 15.00 the bus will take the participants back to the CCL.

The Museum Egas Moniz is located at the Department of Neurology - Hospital Santa Maria (6th floor) in Lisbon. The Hospital Santa Maria is the largest hospital in Portugal, inaugurated in 1953, it received the heritage of the Department of Neurology of the old School Hospital of Santa Marta where Egas Moniz developed his activity as investigator, Head of Department and Chair of Neurology until his retirement in 1945.

As a tribute to the founder of the first department of Neurology and Neurosurgery in Portugal and his pioneer work in angiography and psychosurgery, an area of the department was dedicated to preserve and display the original instruments created by him to perform the first angiograms and surgical interventions in psychiatric patients, together with a photo collection, books written by him, and diplomas from numerous international scientific societies.

A very important part of the exhibition is a sequence of x rays performed during the process to obtain the first angiograms in humans and another sequence displaying the use of angiography in various pathologies from different types of tumors to several vascular abnormalities.

The original furniture of his office was brought from the old hospital and is also displayed reconstructing its Spartan ambiance.

The visit is divided in two groups:
- A visit to the library of the Department (coffee will be served)
- A slide presentation about the life and work of Egas Moniz
- A visit to the Museum

20.00-22.30h

**“Meet your Neurology Network” Museu Nacional de Arte Antiga, Lisbon**

The meet and greet event will take place in the Museu Nacional de Arte Antiga. Created in 1884 and housed in the Palácio Alvor for almost 130 years, the MNAA-Museu Nacional de Arte Antiga has had its current title for more than a century. It is the home to the most important Portuguese public collection of art, ranging from paintings to sculpture, and gold and silverware, as well as decorative arts from Europe, Africa and the Far East.

Since its foundation, it has been housed at the palace built in the late 17th century at the behest of the first Count of Alvor, after his return from India, where he had served as Viceroy. The palace remained in the hands of the family until the mid-18th century, when it became the property of a brother of the Marquis of Pombal, Paulo de Carvalho, before becoming the residence of a rich diamond trader, Dutch consul in Portugal, Daniel Gildemeester, who sponsored major improvement work to the building’s interior spaces.

Being a typical example of the Portuguese civil architecture of that period, the palace has a long façade running parallel to the street. The building has a highly simple design with the only decoration being its ornamental baroque doorways.

The entrance fee is € 25 (reduced fee € 20) and includes free snacks and drinks, the entrance to the museum and free guiding through selected areas.

Between 20.00-21.00h, 6 guided tours will be made available.

It is easy to reach from the Congress center by trams number 714 or 727 (station Rua da Junqueira next to the CCL to Rua Presidente Arriaga) or within a 25-minute walk along the river.

Location: R. das Janelas Verdes, 1249-017 Lisboa, Portugal

14th Meeting of European Neuro-Ophthalmological Society

**EUNOS**

**PORTO**

16-19 JUNE 2019

Alfândega Congress Centre
Porto, Portugal

Scientific Sessions, Hot Topics, Interactive Clinical Challenges & Educational Sessions.

**Main Topics:**
- Imaging in Neuro-ophthalmology - OCT and Functional MRI
- Optic neuropathies (auto-immune, ischaemic and hereditary)
- Ocular myasthenia gravis

Secretariat - Skyros Congressos
eunos2019@skyros-congressos.com
www.eunos2019.org
<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Location</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYMP1</td>
<td>10:00-12:30</td>
<td>Auditorium</td>
<td>EAN / MDS-ES</td>
</tr>
<tr>
<td>SYMP2</td>
<td>12:30-14:30</td>
<td>Room</td>
<td>Diagnosing genetic epilepsies</td>
</tr>
<tr>
<td>SYMP3</td>
<td>14:45-16:15</td>
<td>Auditorium</td>
<td>EAN / MDS-ES</td>
</tr>
</tbody>
</table>

10:45-11:00 Celgene: New ILAE classification of the epilepsies
11:00-11:15 The importance of brain network re-organisation in old age and for successful rehabilitation after stroke
11:15-11:30 Biomedical: a catalyst for a new approach to management
11:30-11:45 Ability to drive in neurological disorders
11:45-12:00 Ability to drive in neurological disorders
12:00-12:15 Ability to drive in neurological disorders

12:00-12:30 Lunch break @ exhibition Hall 2 and Foyer A (lunch served from 12:00-13:30)
12:30-13:15 ePoster sessions
13:15-14:15 ePresentation Sessions

14:45-16:15 Motor Unit Number Index (MUNIX) and phenotypic nerve conduction studies - Level 3
14:45-16:15 Cases of dropleaf, myasthenia and axial weakness and related treatment

16:15-16:45 Coffee break @ exhibition Halls 1, 2, 3 and Foyer A
16:30-16:45 Forum Talks | ALNYLAM PHARMACEUTICALS - Acute Hepatic Porphyrias | Scientific Theatre (Exhibition Hall 1)
### Schedule Overview

#### Saturday, June 16

**Morning Sessions**

- **8:00-9:30**
  - **EAN / MDS-ES:** Novel genetic techniques in neurological practice – time for responsible clinical and research implementation
  - **EAN / MDS-ES:** Impact of technology in neuro-rehabilitation
  - **EAN / MDS-ES:** Impact of technology in neuro-rehabilitation
  - **EAN / MDS-ES:** Impact of technology in neuro-rehabilitation
  - **EAN / MDS-ES:** Impact of technology in neuro-rehabilitation

- **9:30-10:00**
  - **Novartis:** Current treatment of myasthenia gravis
  - **Biogen:** How to diagnose acute vertigo and acute double vision
  - **Biogen:** How to diagnose acute vertigo and acute double vision
  - **Biogen:** How to diagnose acute vertigo and acute double vision
  - **Biogen:** How to diagnose acute vertigo and acute double vision

**Lunch Break**

**12:00-15:00**

**Afternoon Sessions**

- **13:00-14:30**
  - **Novartis:** Management of Parkinson’s disease: Why, when, and how
  - **Merck:** Management of Parkinson’s disease: Why, when, and how
  - **Merck:** Management of Parkinson’s disease: Why, when, and how
  - **Merck:** Management of Parkinson’s disease: Why, when, and how
  - **Merck:** Management of Parkinson’s disease: Why, when, and how

**Continuing Education**

- **13:45-14:15**
  - **Bial:** Management of Parkinson’s disease: Why, when, and how
  - **Bial:** Management of Parkinson’s disease: Why, when, and how
  - **Bial:** Management of Parkinson’s disease: Why, when, and how
  - **Bial:** Management of Parkinson’s disease: Why, when, and how
  - **Bial:** Management of Parkinson’s disease: Why, when, and how

**Networking**

#### Sunday, June 17

**Morning Sessions**

- **8:00-9:30**
  - **Merck:** Current treatment of myasthenia gravis
  - **Merck:** Current treatment of myasthenia gravis
  - **Merck:** Current treatment of myasthenia gravis
  - **Merck:** Current treatment of myasthenia gravis
  - **Merck:** Current treatment of myasthenia gravis

**Lunch Break**

**12:00-15:00**

**Afternoon Sessions**

- **13:00-14:30**
  - **Novartis:** Novel genetic techniques in neurological practice – time for responsible clinical and research implementation
  - **Novartis:** Impact of technology in neuro-rehabilitation
  - **Novartis:** Impact of technology in neuro-rehabilitation
  - **Novartis:** Impact of technology in neuro-rehabilitation
  - **Novartis:** Impact of technology in neuro-rehabilitation

**Networking**

**3-Day Satellite Session**

- **09:30-10:00**
  - **EAN / MDS-ES:** Current treatment of myasthenia gravis
  - **EAN / MDS-ES:** Current treatment of myasthenia gravis
  - **EAN / MDS-ES:** Current treatment of myasthenia gravis
  - **EAN / MDS-ES:** Current treatment of myasthenia gravis
  - **EAN / MDS-ES:** Current treatment of myasthenia gravis

**Hand-on Course**

- **09:30-09:45**
  - **Alnylam Pharmaceuticals:** Acute Hepatic Porphyrias
  - **Alnylam Pharmaceuticals:** Acute Hepatic Porphyrias
  - **Alnylam Pharmaceuticals:** Acute Hepatic Porphyrias
  - **Alnylam Pharmaceuticals:** Acute Hepatic Porphyrias
  - **Alnylam Pharmaceuticals:** Acute Hepatic Porphyrias

**Coffee Break**

- **10:00-11:00**
  - **Merck:** Multiple Sclerosis patients
  - **Merck:** Multiple Sclerosis patients
  - **Merck:** Multiple Sclerosis patients
  - **Merck:** Multiple Sclerosis patients
  - **Merck:** Multiple Sclerosis patients

**EAN Correlative Symposium**

- **10:00-12:00**
  - **Novartis:** Novel genetic techniques in neurological practice – time for responsible clinical and research implementation
  - **Novartis:** Impact of technology in neuro-rehabilitation
  - **Novartis:** Impact of technology in neuro-rehabilitation
  - **Novartis:** Impact of technology in neuro-rehabilitation
  - **Novartis:** Impact of technology in neuro-rehabilitation

**Presidential Symposium**

- **12:15-13:15**
  - **Lilly:** Management of Parkinson’s disease: Why, when, and how
  - **Lilly:** Management of Parkinson’s disease: Why, when, and how
  - **Lilly:** Management of Parkinson’s disease: Why, when, and how
  - **Lilly:** Management of Parkinson’s disease: Why, when, and how
  - **Lilly:** Management of Parkinson’s disease: Why, when, and how

**Networking**

**13:00-14:30**

- **Novartis:** Novel genetic techniques in neurological practice – time for responsible clinical and research implementation
  - **Novartis:** Impact of technology in neuro-rehabilitation
  - **Novartis:** Impact of technology in neuro-rehabilitation
  - **Novartis:** Impact of technology in neuro-rehabilitation
  - **Novartis:** Impact of technology in neuro-rehabilitation

**Networking**

**13:30-14:15**

- **Bial:** Management of Parkinson’s disease: Why, when, and how
  - **Bial:** Management of Parkinson’s disease: Why, when, and how
  - **Bial:** Management of Parkinson’s disease: Why, when, and how
  - **Bial:** Management of Parkinson’s disease: Why, when, and how
  - **Bial:** Management of Parkinson’s disease: Why, when, and how

**Networking**

**14:30-16:00**

- **Novartis:** Novel genetic techniques in neurological practice – time for responsible clinical and research implementation
  - **Novartis:** Impact of technology in neuro-rehabilitation
  - **Novartis:** Impact of technology in neuro-rehabilitation
  - **Novartis:** Impact of technology in neuro-rehabilitation
  - **Novartis:** Impact of technology in neuro-rehabilitation

**Networking**

**16:15-18:00**

- **Bial:** Management of Parkinson’s disease: Why, when, and how
  - **Bial:** Management of Parkinson’s disease: Why, when, and how
  - **Bial:** Management of Parkinson’s disease: Why, when, and how
  - **Bial:** Management of Parkinson’s disease: Why, when, and how
  - **Bial:** Management of Parkinson’s disease: Why, when, and how

**Networking**

**18:30-20:00**

- **Novartis:** Management of Parkinson’s disease: Why, when, and how
  - **Novartis:** Management of Parkinson’s disease: Why, when, and how
  - **Novartis:** Management of Parkinson’s disease: Why, when, and how
  - **Novartis:** Management of Parkinson’s disease: Why, when, and how
  - **Novartis:** Management of Parkinson’s disease: Why, when, and how

**Networking**

**Sunday, June 17**

- **09:30-17:00** Exhibition opening hours

- **09:30-10:00** Coffee break @ exhibition Halls 1, 2, 3 and Foyer A

- **09:30-09:45** Forum Talks | **ALNYLAM PHARMACEUTICALS:** Acute Hepatic Porphyrias | Scientific Theatre (Exhibition Hall 1)

- **09:45-10:00** Forum Talks | **MERCK:** Multiple Sclerosis | Scientific Theatre (Exhibition Hall 1)

**Satin Special Satellite Symposium**

- **09:30-09:45** Forum Talks | **Biogen:** Progressive supranuclear palsy | Scientific Theatre (Exhibition Hall 1)

**Hands-on Course**

- **10:00-12:00** Hands-on Course

**Networking**

- **12:30-13:15** Poster Sessions & Presentation Sessions

- **16:15-16:30** Forum Talks | **BIOGEN:** Progressive supranuclear palsy | Scientific Theatre (Exhibition Hall 1)

**Networking**

- **18:00-20:00** Coffee break @ exhibition Halls 1, 2, 3 and Foyer A

**Hands-on Course**

- **18:30-20:00** Hands-on Course

**Networking**

- **20:30-22:00** Networking
**Session Overview**

**Monday 18 June**

**General Information**

**Auditorium**

- **I**
- **II**
- **V**
- **VI**
- **VII**
- **VIII**
- **IX**
- **X**
- **XI**
- **XII**
- **XIII**
- **XIV**
- **XV**
- **XVI**
- **XVII**
- **XVIII**
- **XIX**
- **XX**
- **XXI**
- **XXII**
- **XXIII**
- **XXIV**
- **XXV**
- **XXVI**
- **XXVII**
- **XXVIII**
- **XXIX**
- **XXX**

**Room**

- **Berlin**
- **Amsterdam**
- **Lisbon**
- **Oslo**
- **Copenhagen**
- **HoC**
- **Cbw**
- **0.01**

**08:00 - 09:30**

- **Session 1**
  - **Precision**
  - **Neurogenetic**
  - **Diagnostic pitfalls**
  - **EAN / MDS-ES:**
  - **CGRP inhibition**
  - **Autoimmune**
  - **Guillain-Barré**
  - **Interpreting MRI**
  - **Antibodies**
  - **History of encephalitis in Neurology – medicine in avenues and in neuromuscular disease**
  - **Evidence-based medicine in practice – hype or hope?**

**09:30-17:00**

- **Exhibition opening hours**
  - **Coffee break @ exhibition Halls 1, 2, 3 and Foyer A**

**12:00 - 13:00**

- **Lunch break @ exhibition Hall 2 and Foyer A (lunch served from)**

**13:00 - 14:30**

- **Symposium 5**
  - **Symp 6**
  - **TC 11**
  - **TC 12**
  - **TC 13**
  - **Controversy**
  - **TC 14**

**14:30 - 15:00**

- **Coffee break @ exhibition Halls 1, 2, 3 and Foyer A**

**15:00 - 17:00**

- **Symposium 6**
  - **Symp 7**
  - **TC 11**
  - **TC 12**
  - **TC 13**

**15:00 - 18:00**

- **PS Overflow**

**18:00 - 20:00**

- **Networking Event**

---

**3-Day Satellite Session**

**09:30 - 10:00**

- **Celgene: Drug sequencing**
  - **Forum Talks | BIOGEN – Alzheimer’s disease | Scientific Theatre (Exhibition Hall 1)**

**09:45 - 10:00**

- **Forum Talks | MERCK – Multiple Sclerosis | Scientific Theatre (Exhibition Hall 1)**

**10:00 - 12:00**

- **Molecular and genetic therapies for neurogenetic disorders**

**12:15 - 13:15**

- **Akcea: Amyloid transthyretin (ATTR) amyloidosis: One disease, many symptoms**

**13:00 - 14:30**

- **Biogen: The new EAN / ECTRIMS (ATTR)**
  - **Multiple Sclerosis amyloidosis: guidelines.**
  - **One disease, many symptoms**

**13:30 - 14:15**

- **Celgene: Latest tales of migraine: the unexpected:**
  - **Sanofi Genzyme: Latest tales of stroke patients – recovery**

**13:45 - 14:15**

- **Celgene:**
  - **Everpharma:**
  - **The ideal real world in Multiple Sclerosis care – a permanent clinical trial?**

**14:30 - 15:15**

- **EAN / ILAE-EEG and avoid over-reading in a seizure in the neurological ICU**

**15:00 - 18:15**

- **EAN / MDS-ES:**
  - **Tournament for neurologists in training - clinical trial?**

**15:30 - 16:15**

- **Teva: The role of CGRP in migraine: the unexpected:**
  - **Illuminating the evidence and its implications in the new era of biologics**

**16:15 - 16:45**

- **Coffee break @ exhibition Halls 1, 2, 3 and Foyer A**

**16:45 - 17:15**

- **Teva: The role of CGRP in migraine: the unexpected:**
  - **Illuminating the evidence and its implications in the new era of biologics**

**17:15 - 18:00**

- **Everpharma:**
  - **The ideal real world in Multiple Sclerosis care – a permanent clinical trial?**

---

**Networking Event**

**20:30 - 22:30**
<table>
<thead>
<tr>
<th>Auditorium I</th>
<th>Auditorium VI</th>
<th>Room Berlin</th>
<th>Auditorium II</th>
<th>Auditorium VIII</th>
<th>Room Amsterdam</th>
<th>Room Lisbon</th>
<th>Room Oslo</th>
<th>Auditorium III</th>
<th>Room Copenhagen</th>
<th>Room CbW</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYMP 7</td>
<td>SYMP 8</td>
<td>loS 8</td>
<td></td>
<td></td>
<td>CDS 3</td>
<td>OS</td>
<td>SpS 11</td>
<td>OS</td>
<td>OS</td>
<td>OS</td>
</tr>
<tr>
<td>08:00-10:00 A new look in neuropathogenesis of multiple sclerosis</td>
<td>08:00-10:00 Advances in molecular characterisation and personalised therapies in brain tumours</td>
<td>08:30-10:00 Drug development and clinical trials in neurology</td>
<td>08:30-10:00 Headache and pain</td>
<td>08:30-10:00 Population, migration and neurological disorders</td>
<td>08:30-09:45 Miscellaneous 2</td>
<td>08:30-10:00 Muscle and neuromuscular junction diseases</td>
<td>08:30-10:00 Movement disorders 2</td>
<td>08:30-10:00 Imaging selection of stroke patients for specific treatment interventions</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

09:30-13:30 Exhibition opening hours

10:00-10:30 Coffee break @ exhibition Halls 1, 2, 3 and Foyer A

<table>
<thead>
<tr>
<th>Overview</th>
<th>Overview</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-12:30 Highlights and Breaking News</td>
<td>10:30-12:30 Highlights</td>
</tr>
</tbody>
</table>

12:30-13:30 Lunch break @ exhibition Hall 2 and Foyer A (lunch served from 12:30-13:30)

<table>
<thead>
<tr>
<th>TC 15</th>
<th>TC 15</th>
<th>TC 15</th>
<th>TC 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-16:30 EAN / MDS-ES: Mixed movement disorders: what do we see and how do we approach?</td>
<td>13:00-16:30 The ‘difficult to treat’ headache patient – Level 3</td>
<td>13:00-16:30 Amit unpluck &amp; less</td>
<td>13:00-16:30 Controversial 2</td>
</tr>
</tbody>
</table>

13:00-14:30 Controversies in the diagnosis of Alzheimer’s disease & in the treatment of Multiple Sclerosis

<table>
<thead>
<tr>
<th>TC 16</th>
<th>TC 16</th>
<th>TC 16</th>
<th>TC 16</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-16:30 Advanced neurosonology – Level 3</td>
<td>13:00-16:30 Basic of sleep medicine – Level 1</td>
<td>13:00-16:30 Challenging cases of infections in the nervous system</td>
<td>13:00-14:30 Advanced neurosonology – Level 3</td>
</tr>
</tbody>
</table>

13:00-16:30 Advanced neurosonology – Level 3

14:30-15:00 Coffee break near Auditorium VI + ePoster Area

Separate registration fees apply for:
- Teaching Courses = 50€ / 30€ reduced fee
- Hands-on Courses = 50€ / 30€ reduced fee
- Case-based Workshops = 50€ / 30€ reduced fee
Neurogenetics
Unravelling hidden diseases
Scientific Programme

4th Congress of the European Academy of Neurology

June 16 – 19
Saturday
16 June 2018
Case-based Workshop 1: EAN/EAPC: End-of-life care for neurological patients

Chairperson: David Oliver (Canterbury, UK)

- Ventilation and gastrostomy in ALS at the end of life
  Idris Baker (Swansea, UK)

- Coping with patient/family/team distress at the end of life
  Peter Zepper (Salzburg, Austria)

- Difficult discussions at the end of life
  Orla Hardiman (Dublin, Ireland)

Educational content:
As a patient with progressive neurological disease deteriorates and comes to the end of life, there are increasing issues to be discussed:

- Awareness of the issues regarding the decisions as to continue or withdraw treatment, such as ventilation or gastrostomy feeding
- Awareness of the need for discussions with patient and family about the disease deterioration and helping them to plan ahead
- Awareness that the discussion within teams can be difficult, as members cope with the issues differently, potentially leading to conflict
- Awareness and ideas as to the possible ways of lead discussions about end of life, including the discussion of what to expect at the end of life, the fears that patients and families may have, preparations for the care at the end of life, consideration of hastened death

All these areas will be considered with opportunities for discussion of these difficult issues – practically and ethically.

Limited to 60 participants. Please register separately – additional fees will apply.

Career development Session 1: Etiological investigation of disease: case-control studies

Chairperson: Maura Pugliatti (Ferrara, Italy)

- Problems with the investigation of disease etiology
  Pierre-Marie Preux (Limoges, France)

- Structure and pitfalls of the case-control studies
  Maura Pugliatti (Ferrara, Italy)

- Statistical methods in case-control studies
  Derrick Bennett (Oxford, UK)

Educational content: Case-control studies represent the commonest study design for the investigation of the etiology of a disease. Although case-control studies can be easily run and are the only way to investigate rare diseases, they are affected by a number of confounders that must be controlled at the planning and analysis stage. The participation to this course will consent the participants to learn the indications, basic structure and pitfalls of this study design. Some basic statistical principles will be offered for the conduction and interpretation of case-control studies.

Limited to 60 participants. Please register separately – additional fees will apply.

Interactive Session 1: EAN/ILAE-CEA: Classification of the epilepsies: old wine in new skins?

Chairperson: Tim J von Oertzen (Linz, Austria)

- Classifications of seizure types
  Tim J von Oertzen (Linz, Austria)

- Terminology of seizure types
  Philippe Ryvlin (Lausanne, Switzerland)

- Classification of epilepsies
  Eugen Trinka (Salzburg, Austria)

Educational content: A new concept of classification of epilepsies, seizure types and terminology were recently published by the ILAE. This session will discuss the transition of the new classification into clinical practice. The talks will summarise the main idea and structure of the new classification, the discussion will focus on the clinical applicability and its challenges.

Please download the app “EAN Congress” to actively participate in this Session and vote.
**Focused Workshop 1: Brain health in Multiple Sclerosis: a catalyst for a new approach to management**

**Chairperson:**
Gavin Giovannoni (London, UK)

- Treating-2-target: the case for maximising brain health in MS
  Gavin Giovannoni (London, UK)

- The economic cost of MS in Europe
  Gisela Kobelt (Mulhouse, France)

- Translating recommendations for improving MS care into improved outcomes
  Jeremy Hobart (Plymouth, UK)

**Scientific content:**
Treating to target is an approach that has been successfully adopted in several therapeutic areas; owing to recent advances in treatment, this is now also a realistic goal for the clinical management of Multiple Sclerosis (MS). Early diagnosis and treatment of MS could improve outcomes for patients. MS Brain Health is thus promoting a strategy to maximise lifelong brain health by minimising delays in the care pathway. The focus of MS management is indeed shifting towards early diagnosis and intervention; this has been associated with changes in the drivers of the costs of care. We present the results of a large European study, which assesses differences in the burden of illness between countries. Understanding these between-country differences is crucial in order to evaluate the potential economic impact of future changes in MS care. To change existing practice, however, it is necessary to define measures relating to ‘early’ diagnosis and treatment, so as to provide a benchmark that MS service providers can use for comparison. A modified Delphi process that involved experts from over 20 countries was conducted to define standards for the timing of key steps in the MS care pathway. The results of the process and these new consensus standards will be presented at the workshop. Participants in the workshop will be invited to put forward and discuss suggestions for implementing and measuring these standards in clinical practice.

**Focused Workshop 2: Biomarkers of neuromuscular disorders**

**Chairperson:**
Corrado Angelini (Venice, Italy)

- Micro-RNA in muscular dystrophies
  Corrado Angelini (Venice, Italy)

- Inflammatory neuropathies and antibodies
  Luis A Querol Gatizzrez (Barcelona, Spain)

- Mitochondrial disorders and biomarkers
  Rita Horváth (Newcastle, UK)

**Scientific content:**
The scientific content of the focused workshop is intended to highlight the biomarkers in neuromuscular disorders, neuropathies and mitochondrial diseases, since the follow-up of these disorders could be better performed by clinicians if they follow not only by clinical examination but also by specific molecular biomarkers in future clinical trials to treat these disorders.

**Focused Workshop 3: The importance of brain network reorganisation in old age and for successful rehabilitation after stroke**

**Chairperson:**
Paolo Maria Rossini (Rome, Italy)

- Methods of directly interacting with brain function
  Walter Paulus (Göttingen, Germany)

- The importance of shifting our models of the effects of NIBS from producing pure excitation or inhibition of target structures to considering the wider network effects
  John C. Rothwell (London, UK)

- Connectivity disturbances in stroke as revealed by integrated multimodal neuroimaging by fMRI, EEG and TMS-EEG
  Paolo Maria Rossini (Rome, Italy)

**Scientific content:**
Non-invasive brain stimulation (NIBS) is available to many neurology and psychiatry departments nowadays but its use for interaction with brain circuitry in many neurological and psychiatric conditions is not much more than empirical. The course will focus on discussing the effects of brain stimulation and especially viewing these effects on a wide network, not just focusing on a single effect on a certain brain site or function. This will be specially focused on stroke and the information obtained by using electrophysiological and neuroimaging techniques together.
Focused Workshop 4: Ability to drive in neurological disorders

**Chairperson:**
*Johannes Mathis (Bern, Switzerland)*

- **Fitness to drive in sleepy patients**
  *Johannes Mathis (Bern, Switzerland)*

- **Fitness to drive after the first epileptic seizure**
  *Tony Marson (Liverpool, UK)*

- **Fitness to drive after stroke**
  *Catarina Lundberg (Stockholm, Sweden)*

**Scientific content:**
Permission to drive is of great importance in all patients, but because of accident risk due to disease this stands in conflict with public safety. Physicians will be more and more responsible, not only to diagnose and treat patients, but also to achieve driving rehabilitation, to consult patients on their individual driving risks including the legal situation and to decide if fitness to drive cannot be attested.

Focused Workshop 5: Familial amyloid polyneuropathy: phenotype, genetics, treatment

**Chairperson:**
*Teresa Coelho (Porto, Portugal)*

- **60 years of transthyretin familial amyloid polyneuropathy in Europe: epidemiology, clinical presentation and genetic basics**
  *Teresa Coelho (Porto, Portugal)*

- **The course and prognostic factors**
  *Laura Obici (Pavia, Italy)*

- **Recent advances in therapy**
  *Isabel Conçeicão (Lisbon, Portugal)*

**Scientific Content:**
Familial Amyloid Polyneuropathy first described in Portugal by Andrade in 1952, is no longer just a rare neuropathy. Nowadays ATTR amyloidosis is recognised as a complex systemic disease, distributed worldwide. It can be related to the presence of TTR mutations or simply to the aging process. A large genotype and phenotype variability is increasingly recognised but it’s always a severe, progressive and ultimately fatal disease. Misdiagnosis is a major problem. Several disease-modifying therapies are presently available, and others are under development. They have changed significantly the quality of life and survival of many patients.

The presenters of this focused workshop work in three European Reference Centres for ATTR amyloidosis and will present data on genetic aspects, epidemiology, clinical presentation, progression, prognostic factors and recent advances in therapy.

Special Session 12: 25 Years of European Journal of Neurology – History, future and how to prepare your paper for publication

**Chairperson:**
*Anthony Schapira (London, UK)*

- **History: the Editor-in-Chief’s view**
  *Anthony Schapira (London, UK)*

- **Future: the publisher’s view**
  *Silvana Losito*

- **“How to prepare a scientific paper for publication”**
  *Pertti Saloheimo (Espoo, Finland)*

**Scientific Content:**
In this session, special attention to 25 years of the European Journal of Neurology (EJN) will be given. The editor-in-chief will give an insight into how we review and handle papers, the publisher will outline how things have changed over 25 years and what the future of journal publishing holds. Particular knowledge on how to prepare your scientific paper for publication will be shared by one of the EJN’s associate-editors.
10:30 – 12:30  
Auditorium I

Symposium 1: EAN/MDS–ES: Tauopathies: pathophysiology, clinical features and experimental therapies

Chairpersons:  
Carlo Colosimo (Terni, Italy)  
Isabelle Le Ber (Paris, France)

- Tau protein in normal and pathological brain  
Tiago F. Outeiro (Gottingen, Germany)

- The spectrum of frontotemporal dementias  
Isabelle Le Ber (Paris, France)

- Progressive supranuclear palsy and corticobasal degeneration: one disease or two  
Carlo Colosimo (Terni, Italy)

- Emerging disease-modifying treatments for tauopathies  
Guenter U. Hoeglinger (Munich, Germany)

Scientific content:  
Clinical features and diagnosis strategy would be presented in the first part of each lecture (didactic) and potential therapeutic new strategies could be presented (including treatments that have been proposed and have no effects) in the second part.

10:30 – 12:30  
Auditorium VI

Symposium 2: Diagnosing genetic epilepsies

Chairpersons:  
Reetta K. Kälviäinen (Kuopio, Finland)  
Hannah Cock (London, UK)

- Is epilepsy a genetic disease?  
Simon D. Shorvon (London, UK)

- Molecular diagnosis in genetic epilepsies: why we need to test  
Sarah Weekhuysen (Antwerpen, Belgium)

- New therapeutic strategies in development for the genetic epilepsies  
José M. Serratosa (Madrid, Spain)

- Whole exome sequencing (WES)  
Reetta K. Kälviäinen (Kuopio, Finland)

Scientific content:  
Epilepsy is a common neurological disease, and there might be a genetic basis in almost half of the people with epilepsy. The diagnosis of genetic epilepsies makes the patient assured of the reasons of his/her seizures and avoids unnecessary, expensive, and invasive investigations. Last decade has shown tremendous growth in gene sequencing technologies, which have made genetic tests available at the bedside. Whole exome sequencing is now being routinely used in the clinical setting for making a genetic diagnosis. Genetic testing not only makes the diagnosis but also has an effect on the management of the patients, for example, the role of aggravating sodium channels blockers in SCN1A-Dravet syndrome patients and usefulness of ketogenic diet therapy in SLC2A1-generalised epilepsy patients. The purpose of this symposium is to give an overview in this direction and encourage the clinicians to start considering genetic testing as an important investigation along with EEG and magnetic resonance imaging for better understanding and management of epilepsy in their patients. However, we will also discuss the important potential social implications of the genetic findings, which should not be forgotten.

10:30 – 12:30  
Auditorium V

Symposium 3: EAN/ESO: Cerebral small vessel disease – recent advances and clinical implications

Chairpersons:  
José Ferro (Lisbon, Portugal)  
Hugh Markus (London, UK)

- “Occult” SVD on an MRI scan: what does it mean and what should I do?  
Stéphanie Debette (Paris, France)

- New insights into what causes SVD- and treatment implications  
Hugh Markus (London, UK)

- Cognitive impairment in SVD- mechanisms and management  
Frank-Erik de Leeuw (Nijmegen, The Netherlands)

Scientific content:  
Cerebral Small Vessel Disease (SVD) causes a quarter of all strokes, being directly responsible for lacunar stroke and also contributing to intracerebral haemorrhage. It is also the most common cause of vascular cognitive impairment, and increasing evidence suggests it may increase the risk that someone with Alzheimer’s pathology presents with clinical dementia during life. Despite its importance there is much we do not understand about it clinically and there are limited treatment options. This symposium will update attendees on a number of important advances in the field. It will start with new data on what incidental findings of SVD e.g. white matter hyperintensities and microbleeds, which are often found incidentally on MRI scans mean in terms of patient risk. This is followed by new insights into what causes SVD and what implications these may have for treatment. The symposium concludes with an update on what causes cognitive decline in this patient group.
Symposium 9: EAN/ECTRIMS: Therapeutic challenges in progressive Multiple Sclerosis

Chairpersons:
Per Soelberg Sørensen (Copenhagen, Denmark)
David Miller (London, UK)

- Pathological concepts of progressive MS
  Christine Stadelmann (Göttingen, Germany)

- Understanding progression: the contribution of clinical trials and natural history studies
  Jaume Sastre-Garriga (Barcelona, Spain)

- Present and future treatment options in progressive MS
  Tobias Derfuss (Basel, Switzerland)

- Who and how to treat progressive MS
  Giancarlo Comi (Milan, Italy)

Scientific content:
The pathological features of progressive MS and insight into the factors that drive progression of disability based on pathophysiological concepts (mitochondrial failure, ectopic expression of ion channels, virtual hypoxia, compartmentalized inflammation, microglial activation) will be summarised in the first talk. In the second talk, the clinical definition of progressive MS, epidemiology of progressive MS, time course and quality of disability development in progressive MS, contributing factors for progression (small vessel disease, neurodegeneration, environmental factors, e.g., smoking, infections) will be described. Then clinical trials on progressive MS, concept of immunomodulation versus neuroprotection/remyelination will be presented. In the last talk, the practical aspects of treatment of progressive MS will be highlighted: which patients might profit most, how to monitor treatment, when to stop treatment.

Symposium 4: EAN/EAPC: Palliative care and neurology

Chairpersons:
Phil Larkin (Dublin, Ireland)
Paul Boon (Ghent, Belgium)

- Palliative care from a neurologist’s perspective: the evidence
  David Oliver (Canterbury, UK)

- Guidelines in progress across Europe
  Raymond Voltz (Cologne, Germany)

- What can a neurologist learn from palliative care specialists?
  Simone Veronese (Turin, Italy)

Scientific content:
Results of recent research on the effectiveness of palliative care in neurology/new evidence-based guidelines developed.

CME Topical Symposium: Digital outcome assessment

Chairpersons:
Ludwig Kappos (Basel, Switzerland)
Jochen Klucken (Erlangen, Germany)

- Digital outcome assessment in Multiple Sclerosis
  Ludwig Kappos (Basel, Switzerland)

- Digital outcome assessment in epilepsy
  Sandor Beniczky (Dianalund, Denmark)

- Digital outcome assessment in Parkinson’s disease
  Jochen Klucken (Erlangen, Germany)

Scientific content:
Besides patient-reported outcomes objective outcome measures reflective of new diagnostic and therapeutic techniques are becoming increasingly important in neurological conditions. In this session digital outcome measures in MS, epilepsy and Parkinson’s disease will be discussed in detail. This is particularly relevant to innovation driven clinical practice.

This symposium is supported by an educational grant from Roche.
14:15 – 16:15
Room HoC

Hands-on Course 1: Motor Unit Number Index (MUNIX) and phrenic nerve conduction studies - Level 3

Chairperson:
Markus Weber (St. Gallen, Switzerland)

- Introduction: MUNIX – a progression marker of motor neuron loss
  Markus Weber (St. Gallen, Switzerland)

- Introduction: Phrenic nerve conduction studies
  Mamede Alves de Carvalho (Lisbon, Portugal)

- Device 1 – MUNIX – UL muscles – 20 minutes
  Markus Weber (St. Gallen, Switzerland)

- Device 2 – MUNIX – Biceps – 20 minutes
  Christoph Neuwirth (St. Gallen, Switzerland)

- Device 3 – MUNIX – LL muscles – 20 minutes
  Sanjeev Nandedkar (Hopewell Junction, USA)

- Device 4 – Phrenic nerve conduction – 20 minutes
  Mamede Alves de Carvalho (Lisbon, Portugal)

Educational content:
Objective markers of disease progression in ALS clinical trials are urgently needed. Weakness in ALS is mostly dependent on lower motor neuron loss. Force evaluation depends on patient cooperation and fatigue. This is also true for respiratory tests; in addition, bulbar patients do not perform well due to weak facial muscles. Quantification of motor unit loss by means of MUNIX has the great advantage that this measure directly reflects the underlying pathology. Likewise, phrenic nerve conduction studies will not only objectively reveal diaphragmatic function but also provides prognostic information. Both methods have gained a lot of scientific attention over the past few years and are at the forefront of ALS research. Their potential application in future clinical trials fuel the interest about these techniques. This course will focus on practical issues. Participants will understand the applicability and limitations of these methods. Participants will apply the methods at each other. MUNIX will be performed on APB, ADM, FDI, Biceps, TA, EDB. After the course attendees will be able to make high quality and reliable MUNIX measurements and CMAP recordings of the diaphragm. Participants will be ready to apply these techniques in their centres, in particular in future clinical trials in ALS.

This course is supported by NATUS Medical Inc.

14:45 – 16:15
Room CbW

Case-based Workshop 2: Cases of drophead, camptocormia and axial weakness and related treatment

Chairperson:
John Vissing (Copenhagen, Denmark)

- Drophead syndrome
  Roberto Massa (Rome, Italy)

- Camptocormia
  Heinz Reichmann (Dresden, Germany)

- Axial weakness
  John Vissing (Copenhagen, Denmark)

Educational content:
The workshop is directed towards the diagnostic utility of recognising different causes and mechanisms of “drop head”, camptocormia and axial weakness related to a differential diagnosis in neuromuscular disorders and other neurological conditions. Treatment or management should be part of the presentation.

Limited to 60 participants. Please register separately – additional fees will apply.
Interactive Session 2: Update in chronic headache disorders

Chairperson:
Anish Bahra (London, UK)

- Chronic migraine
  Julio Pascual (Santander, Spain)

- Medication overuse headache
  Rigmor Jensen (Glostrup, Denmark)

- Chronic daily headache
  Anish Bahra (London, UK)

Educational content:
Participants will learn how to diagnose chronic headache disorders according to the IHS classification and how to apply eventual further investigations and treatment strategies. Although chronic migraine is a common disorder that severely impacts patient functioning and quality of life, it is usually underdiagnosed, and treatment responses often remain poor even after diagnosis. In addition, effective treatment options are limited due to the rarity of randomised controlled trials involving such patients. In the present course pharmacological, non-pharmacological, treatment options for chronic migraine will be discussed.

Medication overuse headache is a common and disabling headache disorder. It has a prevalence of about 1-2 % in the general population. The International Classification of Headache Disorders 3rd edition (beta version) has defined MOH as a chronic headache disorder with clearcut diagnostic criteria. Chronic daily headache is a challenging condition to treat and it is often accompanied by significant comorbidities, such as chronic fatigue, depression, anxiety and insomnia, which further complicate treatment. Unrealistic expectations of treatment goals can lead to patient frustration and, as a result, decrease treatment adherence. Patients often desire headache-free status, but this outcome is not realistic for many patients. By contrast, an effective treatment goal starts with establishing the correct diagnosis and creating a multimodal treatment plan to improve function and well-being. With proper comprehensive treatment, the condition improves in most patients.

The aim of the course is familiarising neurologists in training how to recognize chronic headache disorders one from another and to develop strategies to approach the problem.

Please download the app “EAN Congress” to actively participate in this Session and vote.

Special Session 3: EAN/EFAS: Autonomic dysfunction as early markers in rare and neurodegenerative diseases

Chairperson:
Gregor Wenning (Innsbruck, Austria)

- Preclinical target discovery in MSA: pitfalls and how can we avoid them
  Gregor Wenning (Innsbruck, Austria)

- Biomarkers in MSA, a prerequisite for disease modification
  Alessandra Fanciulli (Innsbruck, Austria)

- Can autonomic dysfunction differentiate early neurodegenerative diseases including dementia, Parkinson and MSA?
  Walter Struhal (Tulln, Austria)

- Autonomic dysfunction in hereditary sensory and autonomic neuropathies and Fabry’s disease
  Max Hilz (Erlangen, Germany)

Session Content:
Central and peripheral autonomic structures are compromised early in a number of neurodegenerative diseases. Autonomic dysfunction is of considerable interest to be employed as early biomarkers. Knowledge on the evaluation of autonomic nervous system however is not widely taught due to a lack of autonomic experts in Europe. This SPS discusses available early autonomic biomarkers on three manageable entities: dementia patients, Fabry’s disease and synucleinopathies. Multiple system atrophy (MSA) is an adult-onset, fatal neurodegenerative disease presenting with progressive autonomic failure, parkinsonian, cerebellar and pyramidal features in various combinations. Up to date only symptomatic therapy is available. Several considerations may account for the therapeutic failure of many current trials: currently available MSA preclinical testbeds may not reflect the complexity of human MSA pathology; preclinical interventional
protocols may be substantially different from human ones; a putative neuroprotective compound might be effective in early, or pre-clinical, disease stages only.

In the present session, the speakers will focus on the role of oligodendroglial dysfunction, synuclein aggregation and mitochondrial failure in the pathogenesis of MSA and their role in testbed modelling, as well as pre-clinical target discovery. Early clinical, autonomic, imaging and wet MSA-biomarkers and predictors of progression. Pitfalls of concluded RCTs and solutions how to overcome them in ongoing RCTs. The audience will learn on evaluation and interpretation of autonomic results and fitting those data into diagnosis and management of early neurodegenerative disease.

14:45 – 18:15
Auditorium I

Teaching Course 1: EAN/MDS-ES: Dystonia - how to recognise and treat - Level 1

Chairperson:
Marie Vidailhet (Paris, France)

- Inherited familial forms of dystonia
  Christine Klein (Lübeck, Germany)
- Generalised dystonia
  Marie Vidailhet (Paris, France)
- Focal dystoniae
  Alberto Albanese (Milan, Italy)
- Functional dystonias and fixed dystonias
  Kailash Bhatia (London, UK)

Educational content:
The phenomenology and classification of dystonia will be presented. For each sub-type of dystonia, clinical features, diagnosis strategy and illustrative cases will be detailed. The value of genetic testing and the nomenclature of genetic forms will be discussed. A general overview of treatments, then a case-based discussion on each particular treatment and indication (limits and adverse effects) will be done (including special focus on specific forms such as the Dopa-responsive dystonia group). Differential diagnosis and look-alike will be discussed. Current concepts on pathophysiology will be briefly exposed. The sub-group of functional dystonias and fixed dystonia, diagnosis criteria, care and perspective will be specifically discussed.

14:45 – 18:15
Auditorium III

Teaching Course 2: How to proceed with a suspected myopathy? - Level 2

Chairperson:
Antonio Toscano (Messina, Italy)

- How to proceed with elevation of serum CK
  Juan J Vilchez (Valencia, Spain)
- Bioenergetic failure in muscle disorders
  Antonio Toscano (Messina, Italy)
- Clinical relevance of autoantibodies in MDs clinical practice
  Benedikt Schoser (Munich, Germany)
- How to deal with myotonic disorders
  Guillaume Bassez (Paris, France)

Educational content:
Myopathies are a heterogeneous group of rare disorders where skeletal muscle is primarily compromised. These disorders are relatively rare and may show a wide range of symptoms at infancy, childhood or adulthood. More recently, increased awareness, detailed characterisation of the clinical spectrum and improved diagnostic workup have made it easier to recognize these clinical entities although this is still challenging either in infantile or in adult cases. Innovative diagnostic techniques such as use of new released autoantibodies, biochemical approaches or molecular genetic methods as NGS (Next Generation Sequencing) or whole exome/genome sequencing have been considered to better evaluate either known or emerging clinical myopathic entities. This teaching course is aimed to update the evaluation of these disorders, taking into consideration the main pathogenic mechanisms of muscle dysfunction determined by genetic, bioenergetic and dis-immune causes, also to reach an early diagnosis, mainly in cases where a specific therapy is available.
Teaching Course 3: The diagnoses of ALS – old and new approaches - Level 2

Chairperson: Philip Van Damme (Leuven, Belgium)

- How to diagnose ALS? Clinical aspects and staging of disease
  Philip Van Damme (Leuven, Belgium)

- Neurophysiological measurements of ALS diagnosis and progression
  Susanne Petri (Hannover, Germany)

- Neuroimaging biomarkers
  Martin R. Turner (Oxford, UK)

- Blood and CSF biomarkers
  Vincenzo Silani (Milan, Italy)

Educational content:
In this teaching course, an overview of the clinical presentation and diagnosis of ALS will be given. The classification of ALS, which is based on clinical features and genetics will be explained, as well as the contribution of novel neurophysiological measurements to ALS diagnosis and progression. In addition, recent advances in neuroimaging and fluid biomarkers - reflecting various aspects of the disease - will be discussed.

a) The diagnosis of ALS largely remains a clinical diagnosis, relying on correct clinical judgement of the presenting symptoms and signs of the patients. The diagnostic algorithm of ALS will be discussed. ALS is a heterogeneous disorder and several clinical subtypes of ALS exist, which have different rates of progression. The first staging systems of ALS are emerging and will be discussed.

b) Neurophysiological measurements remain the most important test in the diagnostic algorithm of ALS, as they can confirm the presence of lower motor neuron involvement and allows for precise assessment of the extent of lower motor neuron degeneration. In addition, several novel neurophysiological techniques can evaluate upper motor neuron involvement as well as disease progression. Their value in the diagnosis and follow-up of patients will be explored.

c) In clinical routine, neuroimaging is mostly used to exclude other pathologies that could mimic specific symptoms and signs of patients with ALS. However, a growing body of evidence suggests that neuroimaging techniques can also contribute to the diagnosis of ALS by revealing specific and progressive changes in the brain and spinal cord. In addition, some imaging techniques can shed light on the underlying disease mechanisms, which may become important to track the effect of treatment interventions. A review of the value and prospects of neuroimaging biomarkers will be given.

d) A simple laboratory test for ALS is lacking, but over the last years a lot of progress has been made to identify and validate diagnostic biomarkers for ALS in blood and CSF. Such markers can not only aid in diagnosis, but may also contain prognostic information. Moreover, some of them reflect underlying disease mechanisms, important to follow in early phase clinical trials. An update on the current state of blood and CSF biomarkers for ALS will be given.

Teaching Course 4: Neuroimaging and early detection of neurological diseases - Level 2

Chairperson: Federica Agosta (Milan, Italy)

- Radiologically isolated syndromes
  Nicola de Stefano (Siena, Italy)

- Genetic motor neuron diseases
  Peter Bede (Dublin, Ireland)

- Preclinical Alzheimer’s disease and frontotemporal dementia
  Federica Agosta (Milan, Italy)

- Preclinical stages of Parkinson’s disease
  Klaus Seppi (Innsbruck, Austria)

Educational content:
Advanced neuroimaging techniques are of special interest for their potential to characterise the signature of demyelinating and neurodegenerative conditions and aid both the diagnostic process and the monitoring of disease progression. This TC will overview recent research on the study of the preclinical stages of demyelinating/neurodegenerative diseases as well as genotype-specific changes in asymptomatic gene mutation carriers. Characterising brain structural and functional abnormalities in these subjects using neuroimaging may help anticipating the diagnosis and perhaps prevent the devastating impact of these conditions. This aspect will become crucial when disease-modifying (personalised) therapies will be established.
Teaching Course 5: Acute emergencies in neuromuscular disease - Level 2

Chairperson:
Maxwell Damian (Cambridge, UK)

- Evaluation and differential diagnosis of acute neuromuscular weakness
Zohar Argov (Jerusalem, Israel)

- Vasculitis of the peripheral nervous system
Alexander Vrancken (Utrecht, The Netherlands)

- Emergencies in myasthenia, botulism and myasthenic syndromes
Maxwell Damian (Cambridge, UK)

- Emergencies in advanced genetic muscle disease
Marianne de Visser (Amsterdam, The Netherlands)

Educational content:
The diagnosis and management of neuromuscular emergencies is difficult, and requires very significant specialist expertise. This session provides teaching from leading experts in the different facets of neuromuscular disorders that may present as emergencies, emphasising the rarer conditions that are often initially misdiagnosed.

Scientific content:
The session will be focused on the presentation of the European Reference Networks (ERNs) on Rare Diseases, a recent organization by the European Union, that created 24 ERNs dedicated to the rare diseases related to different specific rare disorders. The ERNs, networking centres at least from 8 EU countries, will improve the care and the research for rare disorders. After 1 year of activity, we will discuss the activities of the ERNs related to the main neurologic rare diseases: Epilepsy, Rare Neurologic Diseases, and Neuromuscular disorders. We will also present the EAN activities in this field.

Special Session 4: EAN and European involvement in Rare Neurologic Diseases (European Reference Networks and other activities)

Chairperson:
Antonio Federico

- Introduction: EAN’s activity on Rare Neurologic Diseases
Antonio Federico (Siena, Italy)

- Epicare: the European Reference Network for Rare Epilepsies
Reetta Kälviäinen (Kuopio, Finland)

- NMD-ERN: the European Reference Network for Neuromuscular Diseases
Teresinha Evangelista (Newcastle, UK)

- RND-ERN: the European Reference Network for Rare Neurologic Diseases
Holm Graessner (Tuebingen, Germany)

- General discussion

Interactive Session 9: EAN BrainChallenge – Quiz Show

Moderators:
Angelo Antonini (Padua, Italy)
Marie Vidailhet (Paris, France)

- Local Team

- International Team

The aim of the session is to promote a meaningful and interactive learning experience based on clinical study cases designed for both senior and junior neurologists from all over the world. The cases will not only show how prompt and accurate diagnosis can be achieved despite the complexity of neurology, but will also draw attention to rarely recognised conditions.

A team of local neurologists is competing with a team of international neurologists - each team consists of 4 senior and 2 junior neurologists.

Please download the app “EAN Congress” to actively participate in this Session and vote.
Hands-on Course 2: Nerve conduction studies and nerve echography - Level 1

**Chairperson:**
Simon Podnar (Ljubljana, Slovenia)

- Nerve conduction studies
  Simon Podnar (Ljubljana, Slovenia)
- Nerve and muscle echography
  Luca Padua (Rome, Italy)

**Educational content:**
Nerve conduction studies are possibly the first and easiest approach of the neurologist intending to practice neurophysiology. In some countries, nerve conduction studies are performed by technicians. However, a few techniques require good technical skills and interpretation abilities according to the clinical context. This course is intended to revise all motor and sensory nerve conduction techniques utilised in human clinical neurophysiology, in order to avoid mistakes and errors in the interpretation of signals. Long latency responses such as the F-wave will also be part of this course.

Nerve and muscle echography is an important complement of the diagnosis of peripheral nerve lesions. It is becoming increasingly used in many centers to assess nerve compression and entrapment syndromes. Where nerve conduction studies may fall short, echography can reach further and the other way around. The speaker will present the basis of testing, the ways to recognise the structures under the ultrasound probe and the methods of analysis, as well as clinical cases illustrating the increasing importance of ultrasound in the assessment of peripheral nerve lesions.

Limited to 60 participants. Please register separately – additional fees will apply.

This course is supported by NATUS Medical Inc.
EUROPEAN PAIN FEDERATION EFIC

As an organisation, the European Pain Federation EFIC® has been growing steadily over the last 25 years in its core domains of education, research, and advocacy. We have developed into Europe’s most important multi-disciplinary and multi-professional organization in the field of pain medicine, representing 37 constituent national pain societies with over 20,000 scientists, physicians, nurses, psychologists, physiotherapists and other healthcare professionals.

OUR 11TH CONGRESS BRINGING THE FUTURE TO THE PRESENT

The 11th Congress of the European Pain Federation EFIC® will be held in Valencia, Spain from 4th to 7th September 2019. The congress will offer numerous lectures, workshops, refresher courses and networking initiatives on several aspects of pain. Along with the newest developments in basic science, we will discuss all aspects of multimodal interdisciplinary care for patients suffering from pain. This emphasis on the future of pain medicine leads up to the theme of our 2019 meeting: “BRINGING THE FUTURE TO THE PRESENT”. A comprehensive Industrial Exhibition, and sponsored Satellite Symposia, will complement the scientific content.

OUR ACTIVITIES IN THE FIELD OF EDUCATION, RESEARCH AND ADVOCACY

With regards to education, the European Pain Federation organises ‘Pain Schools’, bringing together leading educators to provide study programs across Europe. We have developed curricula for medical schools, and on pain medicine and pain physiotherapy, as well as accompanying examinations and qualifications. The Examination for the European Diploma in Pain Medicine (EDPM) was launched in 2017. The Examination for the European Diploma in Pain Physiotherapy (EDPP) has been launched for the first time in 2018. Concerning research, the European Pain Federation provides grants and fellowships for researchers and takes part in international research consortia.

On advocacy, we partner within the Societal Impact of Pain platform, along with the pharmaceutical company Grüenthal, the patients’ organisation Pain Alliance Europe, and the citizens’ rights organisation Active Citizenship Network. The European Pain Federation takes part in the Global Year Against Pain campaign, known as the European Year Against Pain in Europe.

Contact Information:
European Pain Federation (EFIC) • Grensstraat 7 4th Floor • B1831 Diegem • BELGIUM
Tel.: +32 2 251 55 10 • Fax: +32 2 251 48 10 • Email: secretary@efic.org

www.efic.org
Neurological manifestations of systemic diseases

Chairpersons:
Theodor Landis (Lausanne, Switzerland)
Viktoria Papp (Aarhus, Denmark)

14.45 | O105
Phase 1/2, randomised, placebo controlled and open-label extension studies of givosiran an investigational RNA interference (RNAi) therapeutic, in patients with acute intermittent porphyria

1 Solna, Sweden, 2 Salt Lake City, USA, 3 Solna, Sweden, 4 New York, USA, 5 London, UK, 6 Birmingham, USA, 7 San Francisco, USA, 8 Winston-Salem, USA, 9 Emilia-Romagna, Italy, 10 Solna, Sweden, 11 Cambridge, USA, 12 Galveston, USA

15.00 | O104
Impact of prior TTR stabilizer use in patients with hereditary transthyretin-mediated amyloidosis in the APOLLO phase-3 study of patisiran

1 Pavia, Italy, 2 Porto, Portugal, 3 Le Kremlin-Bicêtre, France, 4 Mexico D.F., 5 Mexico, 6 Lamesa, USA, 7 Taipei, Taiwan, Chinese Taipei, 8 Kumamoto, Japan, 9 Heidelberg, Germany, 10 Sofia, Bulgaria, 11 Munich, Germany, 12 Boston, USA, 13 Cambridge, USA, 14 Umeå, Sweden

15.15 | O103
Impact of Patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary Transthyretin-Mediated Amyloidosis (TMA)

1 Pavia, Italy, 2 Porto, Portugal, 3 Le Kremlin-Bicêtre, France, 4 Mexico D.F., 5 Mexico, 6 Lamesa, USA, 7 Taipei, Taiwan, Chinese Taipei, 8 Kumamoto, Japan, 9 Heidelberg, Germany, 10 Sofia, Bulgaria, 11 Munich, Germany, 12 Boston, USA, 13 Cambridge, USA, 14 Umeå, Sweden

15.30 | O107
Glucose dysregulation in advanced Parkinson’s disease: too much glucose or not enough insulin?

A. Marques1, F. Dutheil2, E. Durand1, I. Rieu1, A. Mulliez2, M.L. Fantini3, Y. Boirie4, F. Durif5
1 Clermont-Ferrand, France
Temporal evolution of biomarkers in isolated REM sleep behavior disorder and early Parkinson’s disease


1Kassel, 2Göttingen, 3Berlin, 4Marburg, Germany

Multimodal MRI markers modifications in Multiple System Atrophy (MSA): a longitudinal study

P. Péran1, M. Galitzy1, W. Meissner2, O. Rascol1, A. Pavy-Le Traon1

1Toulouse, France, 2Bordeaux, France

Effects of Fingolimod on MRI outcomes in patients with paediatric-onset Multiple Sclerosis: results from the Phase-3 PARADIGMS study

D.L. Arnold1, B. Banwell2, A. Bar-or*, A. Ghezzi3, B. Greenberg1, E. Waubant*, G. Giovanoni1, J. Wolinsky*, J. Gärtnert, K. Rostasay1, L. Krupp*, M. Tardieu1, W. Brück1, T. Stites1, G.L. Pearce*, M. Merschhemke1, T. Chitnis1

1Qubec, Canada, 2Philadelphia, USA, 3Gallarte, Italy, 4Dallas, USA, 5San Francisco, USA, 6London, UK, 7Houston, USA, 8Göttingen, Germany, 9Recklinghausen, Germany, 10New York, USA, 11Paris, France, 12East Hanover, USA, 13Bloomington, USA, 14Basel, Switzerland, 15Boston, USA

Characterising the Slowly Evolving Lesions (SEls) in a cohort of secondary progressive Multiple Sclerosis patients

A. Calvi1, F. Prados2, C. Tur, F. de Angelis1, N. John1, A. Doshi1, J. Stutters1, D. Macmanus1, S. Ourselin1, O. Ciccarelli1, J. Chataway1, F. Barkhof1

1London, UK

Spinal cord area is a stronger predictor of physical disability than brain volume in secondary progressive Multiple Sclerosis

F. de Angelis*, J. Stutters1, A. Eshaghi1, A. García1, F. Prados1, D. Plantone1, A. Doshi1, N.A. John1, A. Calvi1, D. Maclmanus1, S. Ourselin1, S. Pavitt1, G. Giovannoni1, R. Parker1, C.J. Weir3, N. Stallard1, C.P. Hawkins1, B. Sharrack1, P. Connick1, S. Chandran1, C.A. Gandini Wheeler-Kingshott1, F. Barkhof1, J. Chataway1

1London, 2Leeds, 3Edinburgh, 4Coventry, 5Keele, 6Sheffield, UK

Characterising dynamic functional network connectivity in the main clinical phenotypes of Multiple Sclerosis

M. Hidalgo de la Cruz, M.A. Rocca, P. Valsasina, B. Colombo, F. Esposito, G. Comi, M. Filippi

Milan, Italy

Long-term prognosis of disease evolution and evidence for sustained Fingolimod treatment effect by plasma neurofilament light in RRMS patients

J. Kuhle1, J.A. Cohen1, H. Kropshofer*, R. Meinert*, C. Barro*, M. Merschhemke1, D. Häring1, D. Leppert1, D. Tomic1, L. Kappos1

1Basel, Switzerland, 2Cleveland, USA, 3Freiburg, Germany

Alemtuzumab provides durable clinical efficacy in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS I (TOPAZ Study)

B. van Wijmenersh1, P. Vermeersch1, A. Boyko1, J. de Seze1, H.-P. Hartung1, E. Kubala Havrdova1, J. Said Inshasi1, P. McComb1, X. Montalban1, C. Pozzili1, M. Melanson1, N. Daizadeh1, C. Rodriguez1, K. Selma1, O.B.O.T.C-M.I.C. and Topaz Investigators1

1Hasselt, Belgium, 2Lille, France, 3Moscow, Russian Federation, 4Strasbourg, France, 5Düsseldorf, Germany, 6Prague, Czech Republic, 7Dubai, United Arab Emirates, 8Brisbane, Queensland, Australia, 9Barcelona, Spain, 10Rome, Italy, 11Cambridge, USA, 12Lodz, Poland
Oral sessions

16.45 – 18.00 Room Lisbon

Peripheral nerve disorders 1

Chairpersons: Christian Krarup (Copenhagen, Denmark) Peter van den Bergh (Brussels, Belgium)

16.45 | O120
Corneal confocal microscopy and skin biopsy in the evaluation of diabetic small fiber neuropathy
J. Bednarik, A. Rajdova, I. Kovalova, M. Horakova, S. Divisova, J. Raputová, E. Vlkova
Brno, Czech Republic

17.00 | O119
Axonal function predicts response to subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
V. Bril1, N. van Geloven2, H.-P. Hartung3, G. Sobue4, J.-P. Lawo5, O. Mielke5, B.L. Durn6, I.S. Merkies7
1Toronto, Canada, 2Leiden, Netherlands, 3Düsseldorf, Germany, 4Nagoya, Japan, 5Marburg, Germany, 6King of Prussia, USA, 7Maastricht, Netherlands

17.15 | O122
Cryoglobulinaemia-associated peripheral neuropathies: clinical characteristics and prognosis from 20 years experience of neuromuscular clinic
M. Mazzoli, A. Ariatti, M.T. Mascia, F. Valzania, P. Nichelli, G. Galassi
Modena, Italy

17.30 | O121
Charcot-Marie-Tooth disease type 4B with myelin outfoldings (CMT4B): a multicentre retrospective study
D. Pareysen1, T. Stojkovic1, S. Leonard-Louis2, J. Horvath1, G. Ricci3, Y. Parman4, E. Battalogue5, M. Tazir5, M. Bellactache6, N. Bonello-Palot1, S. Sacconi7
1Rome, Italy, 2Paris, France, 3Naples, Italy, 4Catonanzo, Italy, 5Nice, France, 6Lyon, France, 7London, UK

17.45 | O123
Long-term efficacy and safety of Inotersen in patients with hereditary transthyretin (hATTR) amyloidosis treated in the open-label extension of the phase-3 study NEURO-TTR
1Creteil, France, 2New York, USA, 3Orange, USA, 4Porto, Portugal, 5Rio de Janeiro, Brazil, 6Baltimore, USA, 7Rochester, USA, 8Sao Paulo, Brazil, 9Boston, USA, 10Buenos Aires, Argentina, 11Le Kremlin-Bicêtre, France, 12London, UK, 13Milan, Italy, 14Philadelphia, USA, 15Portland, USA, 16Lisbon, Portugal, 17Münster, Germany, 18Messina, Italy, 19Barcelona, Spain, 20Carlsbad, USA, 21Indianapolis, USA

17.00 | O126
Phenotypic and neuroimaging expression of NX6-2 mutations lead to a new distinct disease with spastic ataxia and hypomyelination
V. Chelban1, M. Alsagob2, K. Kloth1, A. Chirita-Enamdi1, J. Vandrocova1, S. Efthymiou1, T. Bierhals3, N. Kaya4, N.W. Wood5, H. Houlden6
1London, UK, 2Riyadh, Saudi Arabia, 3Hamburg, Germany, 4Timisoara, Romania

17.15 | O125
UFM1 founder mutation in the Roma population causes severe variant of Hypomyelination with Atrophy of the Basal ganglia and Cerebellum (H-ABC)
E.M. Hamilton1, E. Bertini2, L. Kalaydjieva3, B. Morar4, D. Dojičkova5, D. Diadato5, N. Wolf6, P. Waisfisz7, T.E. Abbink8, M.S. van der Knaap9
1Amsterdam, Netherlands, 2Rome, Italy, 3Perth, Australia, 4Presov, Slovakia

16.45 – 18.15 Room Oslo

Neurogenetics

Chairpersons: Thomas Klopstock (Munich, Germany) Jean-Mark Burgunder (Bern, Switzerland)

16.45 | O124
Estimated lifetime prevalences of autosomal mitochondrial disorders based on allele frequencies of pathogenic variants in exome databases
Munich, Germany

17.00 | O126
Estimated lifetime prevalences of autosomal mitochondrial disorders based on allele frequencies of pathogenic variants in exome databases
Munich, Germany
16.45 – 18.15
Room Copenhagen

**Neuroimmunology**

**Chairpersons:**
Maarten Titulaer
(Rotterdam, The Netherlands)

**Radu Tanasecu, (Nottingham, UK)**

16.45 | O134
Aquaporin-4 autoantibodies from Neuromyelitis Optica Spectrum Disorder: patients cause complement-independent spinal cord pathologies and motor deficits in mice
K.H. Chan, I.W. Yick
Hong Kong, Hong Kong (SAR of China)

17.00 | O132

17.15 | O135
Thrombotic and non-thrombotic neurological manifestations in Primary Antiphospholipid Syndrome
C. Cunha, J. Serodio, I. Moreira, A. Bettencourt, E. Santos, R. Samões, G. Carvalheiras, S. Cavaco, A. Martins Silva

17.30 | O131
Mimics of Autoimmune Encephalitis
J. de Vries, R. Neuteboom, M.W. Vermeij, R. Verdijk, P.A. Sillevis Smitt, M.J. Titulaer
Rotterdam, The Netherlands
PROGRAM 2018

INTERNATIONAL MEETING OF THE SFN IN PARTNERSHIP WITH THE SOFMA
Movement Disorders and Parkinson’s disease
ICM, Paris

SFN PRESIDENT DAY – Pr Bruno Dubois
From gene to behavior: the model of frontotemporal Dementia
ICM, Paris

> 8 & 9
NOVEMBER

> 7
DECEMBER

PROGRAM 2019

3RD MEETING FOR YOUNG NEUROLOGISTS AND CLINICAL RESEARCH “J2N”
In partnership with the College of Teachers in Neurology
Paris

INTERNATIONAL MEETING OF THE SFN
Neurology and Infectious diseases
Paris

> 10 & 11
OCTOBER

SFN PRESIDENT DAY – Pr Christine Tranchant
Cerebellar Ataxia
Strasbourg

> 6
DECEMBER

French Society of Neurology

Contact : Sfneurologie.org@gmail.com
Website : www.sfn.org
Sunday
17 June 2018
Career Development Session 2: Abstract, poster and presentation tips for success at international meetings

Chairperson:
Clauｄia Sommer (Würzburg, Germany)

- How to prepare & submit your abstract
  Marianne Dieterich (Munich, Germany)
- Preparing your poster or slides
  Aksel Siva (Istanbul, Turkey)
- Delivering your poster or oral presentation
  Claudia Sommer (Würzburg, Germany)

Educational content:
Practical advice on every step from abstract preparation to delivering your poster or oral platform presentation will be provided by experts from the Education and Program committees of the EAN, with ample opportunity to ask questions and seek advice.

Target audience:
Neurologists at any level who are relatively inexperienced in submitting work for presentation at international congresses, or experienced in their native country, but may be less competitive/successful on an international stage.

Case-based Workshop 3: The process of MS diagnosis

Chairperson:
Maria José Sá (Porto, Portugal)

- New diagnostic criteria
  Wallace Brownlee (London, UK)
- Most frequent misdiagnosis
  Franz Fazekas (Graz, Austria)
- Patterns of decision making in demyelinating diseases
  Maria José Sá (Porto, Portugal)

Educational content:
Wallace Brownlee will inform on participants the knowledge provided by the international consensus groups of MS experts with a critical analysis of the evolution of MS diagnostic criteria, discussing the main pitfalls in the 2010’s criteria and measures to improve MS diagnostic accuracy.

Franz Fazekas will get the audience acquainted with particular imaging aspects that may be atypical for MS and lead to diagnostic errors (vascular and non-vascular diseases), showing examples of most frequent misdiagnosis prior to MS, and also aspects that may be of help to overcome diagnostic delay in MS.

Maria José Sá will inform how on the need of a structured and disciplined clinical reasoning that must be followed since the suspect of MS, in a step by step way: identify the classical clinical features (typical neurological syndrome, relapsing-remitting pattern of complaints), perform a neurological examination and request complementary exams looking for evidence of MS and exclusion of MS mimickers (MRI, CSF, VEP, OCT, analytic workup) and when to suspect MS misdiagnosis (non-responders to MS therapies, superimposed atypical symptoms, unusual MRI findings).

It will be proposed a step by step approach to overcome MS misdiagnosis: awareness that misdiagnosis do exist also in highly specialised MS Clinics, that patients must be closely monitored and often re-studied and that request for a second opinion may be important.

Limited to 60 participants. This course is sold out.

Hands-on Course 3: Tilt-table testing in neurology and clinical neurophysiology - Level 2

Chairperson:
Gert van Dijk (Leiden, The Netherlands)

- Cardiovascular autonomic nervous system: basic concepts
  Isabel Rocha (Lisbon, Portugal)
- Autonomic function testing in neurogenic orthostatic hypotension
  Alessandra Fanciulli (Innsbruck, Austria)
- Tilt-table patterns in transient loss of consciousness (TLOC): reflex syncope, orthostatic hypotension and psychogenic TLOC
  Gert van Dijk (Leiden, The Netherlands)

Endorsed by European Federation of Autonomic Societies (EFAS)

Educational content:
Syncope is responsible for 3% of hospital admissions; its economic burden of syncope is huge. A considerable part of these high costs is spent on tests that are not indicated. Till now few neurologists have taken an interest in syncope and tilt-table testing (TTT). However, reflex syncope and epilepsy often feature in one another’s differential diagnosis; they require a similar emphasis on history taking and deductive reasoning. A TTT is useful for diagnosis and treatment, not just for reflex syncope but also for various other syndromes including orthostatic hypotension, postural orthostatic tachycardia syndrome and psychogenic pseudo-syncope. Autonomic function testing can provide
additional detail in the differentiation of various autonomic neuropathies. In this course, we will review the basic concepts of cardiovascular physiology.

Limited to 60 participants. Please register separately – additional fees will apply.

08:00 – 09:30
Auditorium VI

Interactive Session 3: EAN/ESO: Treatment decisions in some difficult scenarios of acute ischaemic stroke

Chairperson:
Patrik Michel (Lausanne, Switzerland)

• Ischaemic stroke in a patient with high bleeding risk
Patrik Michel (Lausanne, Switzerland)

• Ischaemic stroke upon awakening
Carla Ferreira (Braga, Portugal)

• Ischaemic stroke in a disabled person
Janika Kõrv (Tartu, Estonia)

Educational content:
In this course participants learn the considerations, options and management steps for using i.v. thrombolysis, mechanical thrombectomy and other treatments in some difficult settings of acute ischaemic stroke.

Please download the app “EAN Congress” to actively participate in this Session and vote.

08:00 – 09:30
Room Berlin

Focused Workshop 6: EAN/MDS-ES: Management of Parkinson’s disease in non-routine circumstances

Chairperson:
Philippe G. Damier (Nantes, France)

• Fasting during Ramadan
Philippe G. Damier (Nantes, France)

• Travelling abroad
Evžen Růžička (Prague, Czech Republic)

• Undergoing a surgical procedure
Heinz Reichmann (Dresden, Germany)

• Can people with PD drive?
Joaquim Ferreira (Lisbon, Portugal)

Scientific content:
Dopamine replacement therapy is highly effective to reduce Parkinson’s disease symptoms and helps many patients to have a fair quality of life. Patients may have to face some non-routine circumstances for which the treatment needs to be adjusted. The workshop aims to provide practical advice to manage such circumstances: Ramadan fasting, travelling abroad, undergoing a surgical procedure or driving. How to adapt a transient treatment reduction or withdrawal, how to change drug administration schedule, how to take into consideration treatment or treatment decrease side effects? What is adjustable? What is not? Clinicians should gain some hints and knowledge helping them in their daily practice.

08:00 – 09:30
Auditorium II

Focused Workshop 7: Epilepsy surgery in 2018: Has anything changed in the last decades?

Chairperson:
Mar Carreño (Barcelona, Spain)

• Update on the concept of drug resistance. When should pediatric and adult patients be referred for epilepsy surgery?
Edouard Hirsch (Strasbourg, France)

• Common and not so common surgically remediable syndromes
Christoph Baumgartner (Vienna, Austria)

• Epilepsy surgery in patients without obvious MRI lesions: are we overusing intracranial electrodes?
José Serratosa (Madrid, Spain)

Scientific content:
To review the current indications to perform epilepsy surgery in children and adults; review the clinical features and clinical outcomes of common and not so common surgically treatable epilepsy syndromes, to review the role of ample resections to treat epilepsy and to review the current approach using invasive electrodes to patients with drug resistant epilepsy and no obvious lesion on the MRI.
Focused Workshop 8: Impact of technology in neuro-rehabilitation

Chairperson:
Volker Dietz (Zurich, Switzerland)

• Rehabilitation of hand function post-stroke: application of research based technology
  Volker Dietz (Zurich, Switzerland)

• Robotic support for cognitive therapy of hand function
  Olivier Lambert (Zurich, Switzerland)

• Robotic technology in the rehabilitation of gait after a stroke and spinal cord injury
  Klaus Jahn (Munich, Germany)

Scientific content:
The FW aims to present the actual advantages and the limitations of technology to improve performance of locomotor and hand function after a stroke or spinal cord injury. A specific goal will be to discuss the devices that are based on research achievements and are shown to be effective in the application in neurorehabilitation centres. Especially aspects of individually adapted rehabilitation of limb function by technology will be presented. Another goal will be to discuss the actual activities to strengthen home training using simple technology with a focus on functional requirements of daily life activities. A special focus will be to discuss the present weaknesses/limitations of robot-supported neurorehabilitation.

Focused Workshop 9: Novel genetic techniques in neurological practice - time for responsible clinical and research implementation

Chairperson:
Thomas Gasser (Tübingen, Germany)

• What should the general neurologist know about Next Generation Sequencing (NGS)?
  Henry Houlden (London, UK)

• Interpretation of NGS test: neurological disease and beyond
  Thomas Gasser (Tübingen, Germany)

• The use of genetic information in the context of clinical trials
  Cristina Sampaio (Lisbon, Portugal)

Scientific Content:
The development of genetic research, made possible mainly by unprecedented technological advances over the past few years, has transformed many areas of neurology. New classification systems based on genetic defects have in many cases replaced the old clinico-pathologic order. Clinical genetic testing has become a routine procedure in clinical neurology, and the first studies are designed that use genetic variants to stratify disease groups.

In this workshop, we will give an overview of existing and emerging technologies and their applications in clinical practice and research.

Focused Workshop 10: Lost in space - clinical and neurobiological aspects of topographagnosia

Chairperson:
Wolfgang Heide (Celle, Germany)

• The map cannot be explored – disorders of spatial exploration in neglect
  (perceptive topographagnosia)
  Masud Husain (Oxford, UK)

• The map is distorted – disorders of the perceptual analysis of space
  (apperceptive topographagnosia)
  Wolfgang Heide (Celle, Germany)

• The map is lost – disorders of spatial memory (associative topographagnosia and topographical amnesia)
  Jan Laczó (Prague, Czech Republic)

Scientific content:
Topographagnosia is a form of agnosia involving an inability to find one’s way around (“lost in space”), read maps, draw plans, or perform similar functions, often associated with damage to the right parietal or temporal lobe. The term stands for different clinical disorders of spatial orientation that according to De Renzi (1982) and Landis (1991) can be divided into 3 groups: 1. disorders of spatial exploration (perceptive topographagnosia), 2. disorders of perceptual analysis of space (apperceptive topographagnosia) and 3. disorders of spatial memory and spatial navigation (associative topographagnosia & topographical amnesia). They are the basis of the 3 lectures of this workshop, where experts in each of these fields will demonstrate the significance of these old clinical terms in the light of recent findings of modern cognitive neurology, neuroimaging and neurorehabilitation in patients with focal or neurodegenerative cortical damage.
Special Session 5: Neurological disorders of famous composers

Chairperson: Tomislav Breitenfeld (Zagreb, Croatia)

- Maurice Ravel’s fatal neurological illness
  Vida Demarin (Zagreb, Croatia)
- Joseph Haydn – a case of subcortical vascular encephalopathy
  Hansjörg Bäzner (Stuttgart, Germany)
- Stroke in famous composers
  Tomislav Breitenfeld (Zagreb, Croatia)
- Breaking barriers in neuro-musicology: Beethoven’s deafness, Schumann’s madness, Porter’s pain, Gershwin’s uncinate seizures
  Phillip L. Pearl (Boston, USA)

Session Content:
This Special session will present a series of biopathographies and short portraits of famous composers describing their biography, talent, creation and medical history. All presented famous composers suffered from different neurological disorders. The presentations will explain influence of those disorders on composer’s creativity and try to interpret historical materials in terms of modern medicine. Audience will be allowed (and animated) to comment and discuss the interaction between neurological disorders and composer’s ability to create art. While trying to explain the complex relationship between neurological disorders and creativity through pathographies of famous composers, organisers intend to present a new, really interesting and "something else from other topics" session.

We believe that it will turn into a memorable gathering of people who share the same passion, genuine love and enthusiasm for both, neurology and music. After all, Lisbon with its glorious cultural, musical and medical history seems to be an ideal site for a special session “Neurological disorders of famous composers”.

Session Content:
Main aims:
- Learn about academic career and research opportunities around Europe
- Get expert advices on laboratory and clinical research
- Meet experts from different parts of Europe and improve the professional European network
- Get to know opinion leaders’ careers and how they got there

The participants will directly sit down with each Professor from different parts of Europe (North, West, Central and East) and with different fields of interest (such as stroke, epilepsy, Multiple Sclerosis). The participants will circulate and have the unique opportunity to discuss questions such as career or research projects in detail. This will offer the opportunity to ask more detailed and individualised questions. We aim to give interested residents an overview of different ways of developing a research or clinical career.
IN OUR WORLD, A STEADY FLOW KEEPS PATIENTS ALIVE.
LET'S TAKE CARE OF IT TOGETHER.

Driving Excellence in Neurology.
Be part of one of humankind's most ambitious projects to help uncover the workings of the nervous system. EAN connects 45,000 specialists in neurology in 47 countries across Europe. Promoting excellence, cutting-edge science and innovative therapies for a better life for more than 430 million patients in Europe alone. Read more on ean.org

Great Minds.

European Academy of Neurology
Plenary Symposium 2: Presidential Symposium: Named Lectures

Chairpersons:
Günther Deuschl (Kiel, Germany)
Manuel Correia (Porto, Portugal)

• Camillo Golgi Lecture –
The Immune Pathogenesis of Multiple Sclerosis: Degeneration, inflammation and gut microbiota – an unholy alliance
Hartmut Wekerle (Munich, Germany)

• Edouard Brown-Séquard Lecture –
The evolution of Alzheimer’s disease and dementia
Philip Scheltens (Amsterdam, The Netherlands)

• Moritz Romberg Lecture –
Migraine mechanisms and new drug targets
Jes Olesen (Glostrup, Denmark)

Prof. Hartmut Wekerle
Hartmut Wekerle was director and member of the Max Planck Institute of Neurobiology. In 2012 he was awarded a Hertie Senior Professorship, and he leads an Extended Emeritus Group. Hartmut Wekerle’s scientific research focuses on the mechanisms initiating and driving Multiple Sclerosis and its experimental models, which imply autoimmune attack against the nervous system. Wekerle’s work led to the identification of brain reactive autoimmune T lymphocytes in the immune system. Most recently, he identified the commensal bacterial gut flora as a factor triggering the pathogenic potential of immune cells. He develops and uses new imaging approaches to detail the mechanisms of autoimmune T-cell migration into the brain. Wekerle has received numerous awards, including the Jung Prize, Zülch Prize, Koetser Prize, Charcot Award (MS International Federation), Grand Prix Louis D. (Institut de France), and a Koselleck Award (DFG), Jacob-Henle-Medal (University Medical Center, Goettingen). He holds an Honorary Professorship of the University of Munich and Honorary Doctorates of the Universities of Hamburg and Wuerzburg. He is a member of the German Academy of Science (Leopoldina), Honorary Member of the Société Française de Neurologie and Honorary Member of the Cuban Neuroscience Society.

Prof. Philip Scheltens
Prof. Dr. Philip Scheltens studied at the VU University Amsterdam, Netherlands, gaining his MD in 1984, and PhD (Magnetic Resonance Imaging in Alzheimer’s disease) in 1993. Since 2000 he is Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center in Amsterdam. His main clinical and research interests are Alzheimer’s disease, vascular dementia, frontotemporal dementia, magnetic resonance imaging, PET imaging and fluid biomarkers. He is active in the field of biomarkers and clinical trials and has been the national PI for many studies, including phase 1-3 multicenter clinical trials. He founded and directs the Alzheimer Center since 2000, from which over 55 PhD theses have appeared since then. In 2013, he co-founded the Dutch national plan against dementia (Deltaplan Dementie) and serves as vice-chair of the board since then. He has authored over 850 peer reviewed publications and his H-factor is currently 103. In 2011, he was elected as member of the Royal Dutch Academy of Arts and Sciences (KNAW) and serves as Secretary General since 2015. In 2016 he was awarded the European Grand Prix for Alzheimer’s Research.

Prof. Jes Olesen
is Professor of Neurology, dr.med. (Copenhagen, Denmark), dr. hon.c. (Rome, Italy), dr. hon.c. (Yekaterinburg, Russia), and fellow of the Royal College of Physicians (FRCP). Born on 9.9.1941 in Hobro, Denmark, Jes Olesen received his MD at the University of Copenhagen 1967. Further specialist education in neurology at major teaching hospitals in Copenhagen, the National Hospital, Queen Square, London, and the Cornell Medical Center, New York. Consultant neurologist at Gentofte Hospital 1985-1993, Glostrup Hospital 1993- . He is the founder Danish Headache Center 2001-Previous Associate Editor of Cephalalgia and Pain. He was Editorial board member of several journals and President of several Organisations, such as the Danish Headache Society, Scandinavian Migraine Society, International Headache Society, Danish Stroke Association, Year of the Brain 1997 campaign, European Federation of Neurological Societies (EFNS) and European Brain Council (EBC). Honorary member Australian, German, Austrian and International headache societies and of the Austrian, French, British, German and Polish Neurological Societies and of European Federation of Neurological Associations (EFNA) and EAN (as former EFNS President). He received the Great Nordic Research Prize of the Lundbeck Foundation and many other national and international prizes. Citations: Google Scholar 50673 H-Factor: Google Scholar 113, i/10-index: Google Scholar 539. 525 articles in refereed journals, 235 book chapters, 33 books. Has supervised 16 doctoral and 25 Ph.D. dissertations.
Case-based Workshop 4:
Difficult decisions in treatment of myasthenia gravis

Chairperson:
Jan J.G.M. Verschuuren (Leiden, The Netherlands)

- Refractory MG treatment
  Nils Erik Gilhus (Bergen, Norway)

- Thymectomy in MG
  Jan J.G.M. Verschuuren (Leiden, The Netherlands)

- Treatment in pregnancy
  Jacqueline A. Palace (Oxford, UK)

Educational content:
In this case-based workshop the participants will learn in small working groups how to diagnose and treat myasthenia gravis in different stages of their condition.

Limited to 60 participants.
This course is sold out!

Interactive Session 4:
How to diagnose acute vertigo and acute double vision

Chairperson:
Michael Leo Strupp (Munich, Germany)

- Acute vertigo
  Michael Leo Strupp (Munich, Germany)

- Acute diplopia
  Konrad P. Weber (Zurich, Switzerland)

- Acute vertigo and diplopia
  Caroline Tilikete (Lyon, France)

Educational content:
- Acute vertigo. The first question to be answered is whether this is central, i.e., brainstem or cerebellar infarction, or peripheral, i.e., acute unilateral vestibulopathy/vestibular neuritis. This has major diagnostic and therapeutic consequences. By means of a careful patient history and a systematic clinical examination one can make a correct diagnosis with a sensitivity and specificity of more than 90%. Key clinical signs of a central lesion (“the big five”) are: skew deviation/vertical divergence, central fixation nystagmus (versus peripheral vestibular spontaneous nystagmus), gaze-evoked nystagmus, saccadic smooth pursuit and normal head-impulse test. Typical signs and symptoms and their interpretation in terms of a topographic anatomical diagnosis are presented by the cases and discussed with the audience.

- Acute diplopia. The goal of the session is to provide practicing neurologists with a framework for examining patients with acute diplopia. Based on a targeted history, the participants will be introduced to bedside examination skills with objective methods (e.g. cover test) and subjective methods (e.g. Maddox rod). Simple instrument-based methods, such as the Hess screen test, will be demonstrated to document strabismus. The examination skills will be presented in a case-based manner and discussed with the audience.

Please download the app “EAN Congress” to actively participate in this Session and vote.

Special Session 1:
EAN/MDS-ES: European Basal Ganglia Club

Chairperson:
Evzen Růžička (Prague, Czech Republic)

- David Marsden Award Lecture – Functional (psychogenic) Dystonia
  Mark Hallett (Bethesda, USA)

- Video case presentations

Session Content:
Every year the European Basal Ganglia Club features a prominent speaker to present a C. David Marsden Award lecture. In addition, selected video case studies will be featured. Presenters of the video case studies will have been chosen through an application and selection process in collaboration with the International Parkinson and Movement Disorder Society – European Section’s Education Committee.
Sunday 17 June
15.00 – 18.15

Special Session 10: Clinical Grand Rounds

Chairpersons:
José Ferro (Lisbon, Portugal)
Miguel Coelho (Lisbon, Portugal)

• Neuromuscular disorders
Mamede Carvalho (Lisbon, Portugal)

• Movement disorders
Werner Poewe (Innsbruck, Austria)

• (Post) Stroke
Didier Leys (Lille, France)

Patients will be examined during the session.
The clinician will first inform on the patient’s history, focus on neurological examination, work up a plan to confirm the diagnosis and etiology.

Session Content:
The practice of Neurology has been transformed and much improved by the use of a myriad of ancillary procedures, from neuroimaging to antibody and genetic testing. The current technology-based style of patient evaluation raises the question of the role of clinical skills in the diagnostic process. In this session, highly experienced neurologists will interview and examine real patients with difficult or complex neurological conditions. They will discuss the clinical diagnosis, request and review all available diagnostic tests and will end by formulating a final diagnosis.
The session will highlight how clinical reasoning and skills are fundamental in guiding the neurological patient clinical pathway.

Target audience:
residents, practicing neurologists with interest in general neurology, movement disorders, stroke and neuromuscular disorders.

Teaching Course 6: Update on MS treatment - Level 2

Chairperson:
Giancarlo Comi (Milan, Italy)

• Treating relapsing remitting MS: what we have learned and what we still need to know
Per Soelberg Sørensen (Copenhagen, Denmark)

• Is there an option to treat progressive MS?
Giancarlo Comi (Milan, Italy)

• What is new on symptomatic treatment
Alan Thompson (London, UK)

• Strategies to enhance remyelination
Catherine Lubetzki (Paris, France)

Educational content:
This course is designed for neurologists wishing to update their knowledge in the treatment of Multiple Sclerosis. The recent availability of new treatments for relapsing Multiple Sclerosis and the growing evidences of the importance to personalise treatment requires a careful evaluation of the tools that may assist the neurologist in treatment choice and in monitoring the response to the intervention. The first treatment for progressive MS has been recently approved by EMA with some restrictions. In parallel some positive perspectives have also been opened for the treatment of secondary progressive MS - how to implement these new options in clinical practice will be discussed. New perspectives on remyelination have also quite recently appeared through some proof of concept studies. Success and failures in remyelination strategies and the future developments will be extensively explored. Relevant news are also available in symptomatic treatments and rehabilitation which are fundamental aspects in patient management.

Teaching Course 7: Clinical neurophysiology in neurorehabilitation - Level 2

Chairpersons:
Josep Valls-Solé (Barcelona, Spain)
Dafin Muresanu (Cluj Napoca, Romania)

• Evoked potentials as biomarkers of neurologic dysfunction
Peter Fuhr (Basel, Switzerland)

• Non-invasive brain stimulation for the improvement of motor function after stroke
Joseph Classen (Leipzig, Germany)

• From immobility to spasticity. Neural and non-neural components of movement limitation
Josep Valls-Solé (Barcelona, Spain)

• Neurophysiological signals for brain computer interface
Donatella Mattia (Rome, Italy)

Educational content:
Brain lesions involve changes in brain activity, either because of adaptation, compensation, plasticity or loss of function. Neurorehabilitation intends to make beneficial use of such changes by promoting those that are adequate to give better function or quality of life. Neurophysiology is the way to understand how the basic mechanisms of neurorehabilitation can work. In this course, the speakers will deal with several aspects of how neurophysiology contributes to assessment of clinical deficit, helps elucidating pathophysiological mechanisms and provides useful guidance to treatment. The attendants will be able to understand the value of biomarkers of central nervous system function, the bases for non-invasive stimulation treatment, the physiology of changes from immobility to spasticity and the role of remaining neurophysiological signals to assist in the use of computer-driven devices.
Teaching Course 8: Tips and tricks in diagnosing headache disorders – Level 1

Chairperson:
Rigmor Hojland Jensen
(Glostrup, Denmark)

• Taking a proper headache diagnosis
Rigmor Hojland Jensen
(Glostrup, Denmark)

• Introduction into the IHS classification
Gisela Terwindt (Leiden, The Netherlands)

• Neuroimaging in headache: why, when, how?
Gioacchino Tedeschi (Naples, Italy)

• Neurophysiology and laboratory testing in headache
Delphine Magis (Liège, Belgium)

Educational content:
Participants will learn how to diagnose headache disorders according to the IHS classification and how to apply further imaging and other investigations.

Teaching Course 9: New insights in the management of patients with ischaemic stroke or TIA – Level 2

Chairperson:
L. Jaap Kappelle
(Utrecht, The Netherlands)

• Mechanical thrombectomy for acute ischaemic stroke
Jesper Petersson (Malmö, Sweden)

• Secondary prevention after stroke and atrial fibrillation
Valeria Caso (Perugia, Italy)

• Moyamoya syndrome
L. Jaap Kappelle
(Utrecht, The Netherlands)

• TIA and mimics
Maria Tuna (Oxford, UK)

Educational content:
Without any doubt intra-arterial thrombectomy is the most spectacular breakthrough in the treatment of acute ischaemic stroke of the last decade. In this course both recent advances and chances for research with respect of this treatment will be discussed. Atrial fibrillation is one of the most common causes of TIA in elderly patients. New oral anticoagulants have been proven beneficial, but there are still some uncertainties how and when to use these new medications. Moyamoya disease should nowadays be considered as an uncommon cause of TIA or ischaemic stroke in young patients. Clinical features, diagnosis and management of this intracranial vasculopathy will be the topic of the third presentation in this course. Finally, stroke neurologists know that a TIA can be a difficult diagnosis and that one of the most common causes of a TIA that does not respond to proper treatment is a wrong diagnosis. Therefore, mimics of TIA are important to recognise and will be discussed from a clinical point of view.

Teaching Course 10: Current treatments in neurology – Level 1

Chairperson:
Nadine Attal
(Boulogne-Billancourt, France)

• Current treatment possibilities in dementia
Ana Verdelho (Lisbon, Portugal)

• Update on diagnosis and therapy of metabolic myopathies
Pascal Laforêt (Paris, France)

• Current treatment in Guillain-Barré Syndrome and myasthenia gravis
Pieter A van Doorn
(Rotterdam, The Netherlands)

• Pain in neurology: what to treat and how
Nadine Attal
(Boulogne-Billancourt, France)

Educational content:
This Teaching Course on current treatments in various neurological disorders/diseases will give an update of current treatment and management strategies in dementias, muscle disorders, two major autoimmune neuromuscular diseases, i.e. GBS and myasthenia gravis. Furthermore, not only neuropathic pain, but pain associated with different types of neurological diseases will be covered. The lectures will not only refer to current state of the art therapies but also address secondary and tertiary therapies and allow a glimpse into potential future therapeutic options and developments.
15:00 – 18:15
Room Oslo

Teaching course 19: The neurological bedside examination – the art of identifying pathology - Level 1

Chairperson:
Klaus V. Toyka (Würzburg, Germany)

- Cranial nerves
  Jean Schoenen (Liège, Belgium)

- Motor system including functional motor disorders
  Klaus V. Toyka (Würzburg, Germany)

- Reflexes & sensory system
  Claudio Bassetti (Bern, Switzerland)

- Higher cortical functions and coma
  Joseph Classen (Leipzig, Germany)

Educational content:
The TC is in part a repetition of the 2015 TC in Berlin with a largely extended video demonstration of the examination techniques and its contextual interpretation, and the examination of comatose patient. Its content largely reflects the sections of the EAN-e-book co-authored by Profs. Toyka, Classen, Schneider and Saur (see the website of the EAN). The aim of the course is familiarising neurologists in training how to do the various tests at the bedside and in the emergency room and how to interpret findings in the context of other abnormalities ultimately identifying pathology and making a diagnosis. In addition, the course will briefly address the principles of diagnosing pseudo-neurological motor disorders by (1) analysing motor patterns and (2) identifying incongruences of abnormal findings and (3) understanding the role of psychiatric confounders.

In order to have access to the eBook and to download it directly from the website, you have to be an EAN member.

16:45 – 18:15
Room CbW

Case-based Workshop 5: Neurogenetics goes therapy

Chairperson:
Ettore Salsano (Milan, Italy)

- A young female with sudden and recurrent abnormal movements
  Iris Unterberger (Innsbruck, Austria)

- A young man with bilateral abnormalities of the basal ganglia
  Yann Nadjar (Paris, France)

- A strange case of psychotic behaviour and intermittent ataxia
  Ettore Salsano (Milan, Italy)

Educational content:
Main goal of the workshop is to guide clinicians through the clinical reasoning process in diagnosing rare or very rare hereditary diseases (i.e., GLUT1 deficiency syndrome, biotin-responsive encephalopathy, and Hartnup disease) which are effectively treatable. We will stress that the change in the treatment (beyond genetic counselling) is possible also in very recently identified in-herited neurologic diseases (Taraio-Graovac et al., NEJM, 2016), thus justifying the need of deep phenotyping and prompt access to advanced genetic studies to obtain the precise diagnosis. Each case will allow to revise the causes of three uncommon neurologic/neuroimaging syndromes, i.e., paroxysmal dyskinesias, bilateral abnormalities of basal ganglia and thalamus, and episodic ataxias, and two of them will allow to briefly talk about the differential diagnosis (sometimes difficult) of the functional/psychogenic disorders.

Limited to 60 participants. Please register separately – additional fees will apply.

16:45 – 18:45
Room HoC

Hands-on Course 5: Ultrasound in vascular diagnosis - Level 1

Chairpersons:
Elsa Azevedo (Porto, Portugal)
Natan Bornstein (Tel Aviv, Israel)

- Basic principles in evaluation of carotid systems
  Natan Bornstein (Tel Aviv, Israel)

- Evaluation of intracranial arteries by ultrasound
  Elsa Azevedo (Porto, Portugal)

- Assessment of the venous system by ultrasound
  José Valdueza (Bad Segeberg, Germany)

Educational content:
This course will give an overview about the diagnostic abilities of extra and intracranial ultrasound with special emphasis on stroke and emergencies. Investigations with extra- and intracranial ultrasound will be demonstrated on healthy volunteers.

Limited to 60 participants. Please register separately – additional fees will apply.
15.00 – 16.30
Room Lisbon

Cerebrovascular diseases 1

Chairpersons:
Jacques De Reuck (Ghent, Belgium)
Christian Enzinger (Graz, Austria)

15.00 | O204
Effect and safety of Tenecteplase in stroke patients with atrial fibrillation
A.H. Aamodt1, E. Eriksen1, M. Kurz2, L. Alteheld2, A. Fromm3, N. Logallo3, H. Naess3
1Oslo, 2Stavanger, 3Bergen, Norway

15.15 | O202
Idarucizumab in cerebral ischemia or intracranial hemorrhage under Dabigatran therapy in Germany – a nationwide case collection
P. Kermer1, C. Eschenfelder2, H.-C. Diener3, M. Grond4
1Sande, 2Ingelheim, 3Essen, 4Siegen, Germany

15.30 | O205
Characterisation of TRPM4-blocking antibody in ischaemic stroke
K.Y. Loh, R.Z. Lee, C.P. Poore, P. Liao
Singapore, Singapore

15.45 | O206
Mechanical thrombectomy for acute ischaemic stroke in the very old
A.S. Lopes de Sousa, M. Mariano, S. Galega, A. Fior, P. Ferreira, A. Paiva Nunes
Lisbon, Portugal

16.00 | O203
Cerebral thrombi are heterogeneous and their composition correlates with the density of the occluded vessel on CT scan
Milan, Italy

16.15 | O201
Short and long-term risks of stroke after orthodox-definition transient ischaemic attack versus disqualified monosymptomatic events: Oxford vascular study
M.A. Tuna, P.M. Rothwell
Oxford, UK

16.15 | TBASIC04
A novel gene causing primary familial brain calcification: JAM2
L.V. Schottlaender1, R. Abeti1, Z. Jaamukhtane1, M. Soutar1, J. McKinley1, O. Swayne1, C. Bettencourt1, R. Forbes2, P.J. Morrison2, D. Hughes, A. Pittman1, B. Kalmar1, M. de Grandis1, G.V. McDonnell2, S. Brandner1, M. Aurrand Lyons1, P. Giunti1, H. Houlden1
1London, United Kingdom, 2Belfast, United Kingdom, 3Portadown, United Kingdom, 4Marseille, France

16.00 | TBASIC05
Subcortical anatomy of the default mode network: a functional and structural connectivity study
P. Nascimento Alves1, C. Foulon2, L. Cerbon2
1Lisbon, Portugal, 2Paris, France

16.15 | TBASIC06
A passive transfer animal model of CASPR2 antibodies
M.P. Giannoccaro1, D.A. Menassa1, L. Jacobson1, E.P. Coutinho1, B. Lang1, R. Liguori2, A. Vincent1
1Oxford, United Kingdom, 2Bologna, Italy

16.45 – 18.15
Room Lisbon

Epilepsy

Chairpersons:
Tim von Oertzen (Linz, Austria)
Ivan Rektor (Brno, Czech Republic)

16.45 | O207
Will this child have epilepsy? Development and validation of a prediction model to assess the risk of epilepsy after (a) paroxysmal event(s)
E. van Diessen1, H. Lamberink2, W. Otte1, N. Doornebal2, O. Brouwer2, F. Jansen1, K. Braun1
1Utrecht, 2Groningen, Netherlands
17.00 | O212
National surveillance of mortality in children with Epilepsy in the UK and Ireland
O. Abdel-Mannan, A. Sutcliffe
London, UK

17.15 | O211
Laryngeal motor-evoked potentials as an indicator of vagus nerve activation
C. Bouckaert, R. Raedt, S. Gadeyne, E. Carrette, S. Proesmans, F. Deuwele, J. Delbeke, P. Boon, K. Vonck
Ghent, Belgium

17.30 | O209
Properties of epileptiform activity in the human hippocampus and temporal lobe in the intraparously recorded: preliminary results
F. Farias Serratos1, C.V. Farias Serratos1, B.M. Farias Serratos2, K. Kawai3
1León, 2Querétaro, Mexico, 3Tokyo, Japan

17.45 | O210
MiR-134 serum expression in Mesial Temporal Lobe Epilepsy (MTLE) patients
Porto, Portugal

18.00 | O208
Late onset epilepsy of unknown origin and progression to dementia: two faces of beta amyloid pathology
M. Romoli1, P. Eusebi1, L. Farotti1, C. Liguori1, C. Bedetti2, S. Siliquini2, N.B. Mercurii2, L. Parinetti2, P. Calabresi2, C. Costa1
1Perugia, 2Rome, Italy

16.45 – 18.15
Room Copenhagen

Neuro-oncology

Chairpersons:
Wolfgang Grisold (Vienna, Austria)
Anette Storstein (Bergen, Norway)

16.45 | O216
Stroke and „stroke-like” events after brain radiotherapy: a large series with long-term follow-up
G. Berzero1, A.L. Di Stefano2, F. Ducray3, M. Eoli4, A. Pichiecchio1, L.M. Farina1, V. Cuccarini1, M.C. Brunelli2, L. Diamanti1, S. Condette Auliac2, A. Salmaggi1, A. Silvani1, B. Giometto1, F. Bourdain1, A. Pace*, A. Vidi*, S. Bastianello1, M. Ceroni1, E. Marchioni1
1Pavia, Italy, 2Suresnes, 3Lyons, France, 4Milan, 5Treviso, 6Lecco, 7Padua, 8Rome, Italy

17.00 | O213
Increased efficacy of carboplatin after blood-brain barrier opening using low intensity pulsed ultrasound in preclinical models of glioblastoma
Paris, France

17.15 | O214
Clinico- radiological, molecular, therapeutic and prognostic features of medulloblastoma of the adult: results from an institutional series
F. Franchino, F. Roveta, C. Chiavazza, A. Pellerino, F. Bruno, F. Mo, I. Morra, C. Mantovani, R. Rudà
Turin, Italy

17.30 | O215
Associations of anticoagulant use with outcome in newly diagnosed glioblastoma
1Lille, France, 2Brussels, Belgium, 3Chicago, USA, 4Mar- seilles, France, 5Birmingham, 6Los Angeles, 7Boston, USA, 8Heidelberg, Germany, 9Zurich, Switzerland

17.45 | O218
Association between kynurenine metabolism in peripheral blood mononuclear cells and cognition in lung cancer patients undergoing chemotherapy
J. Rybacka-Mossakowska, D. Swiniuch, J. Gazdulska, R. Ramla, W. Kozubski, S. Michalak
Poznan, Poland

18.00 | O217
Long-term follow-up of Optic Pathway Gliomas in children with neurofibromatosis type-1: an oncology hospital experience
M. Valente Fernandes, J. Passos, D. Garcez, M. Mafra, F. Campos, S. Nunes, D. Salgado
Lisbon, Portugal

Sunday 17 June
16.45 – 18.15

16.45 – 18.15
Room Copenhagen
Oral sessions

17.15 – 18.15
Auditorium V

Miscellaneous 1

Chairpersons:
Maxwell Damian (Cambridge, UK)
Gustave Moonen (Charneux-Herve, Belgium)

17.15 | O219
Predicting long-term neurological outcome after cardiac arrest with serum Neurofilament Light chain
M. Moseby Knappe1, N. Mattsson1, N. Nielsen1, H. Zetterberg2, K. Blennow3, J. Dankiewicz4, I. Draganea1, M.P.H. Friberg1, G. Lilja1, P.S. Insel1, C. Rylander5, E. Westhall1, J. Kjaergaard1, M.P. Wise1, C. Hassager1, M.A. Kuiper2, P. Stammet8, M.C. Jaeger Wanscher6, J. Wetterslev6, D. Erlinge1, J. Horn1, T. Pellis5, T. Cronberg1

17.30 | O220
Brain-computer interface technology for upper limb rehabilitation after stroke: a translational effort
F. Pichiorri, E. Colamarino, F. Cincotti, D. Mattia
Rome, Italy

17.45 | O221
Clinical features and risk factors in Metronidazole-induced encephalopathy: a systematic review of 121 patients
C.G. Sørensen, W. Karlsson, F.M. Amin, M. Lindelof
Copenhagen, Denmark

18.00 | O222
Predicting factors for quality of life following Traumatic Brain Injury: CROCFLAME catamnesis
K. Rauen1, L. Reichelt2, P. Probst3, B. Schäpers4, F. Müller5, K. Jahn3, N. Plesnila2
1Zurich/Schlieren, Switzerland, 2Munich, Germany, 3Bad Aibling, Germany

17.15 – 18.15
Auditorium V
EFAS Annual Meeting 2018
in conjunction with ICNMD2018

The European Federation of Autonomic Societies warmly welcomes you to the EFAS Meeting 2018

On behalf of the Scientific Committee, I am very pleased to invite you to our Annual Meeting 2018, to be held in conjunction with the 15th International Congress on Neuromuscular Diseases (ICNMD2018) in Vienna, Austria.

Our Annual Meeting will bring together autonomic scientists throughout Europe and the world to foster scientific research and knowledge exchange.

On Friday, July 6, 2018, the EFAS School trains autonomic skills on clinical evaluation and testing.

On Saturday, July 7, 2018 the EFAS Annual Meeting presents clinically relevant topics in autonomic nervous system research, such as peripheral autonomic neuropathies, neurodegeneration, cardiovascular autonomic failure, epilepsy, syncope, and fatigue in autonomic disorders. The meeting will provide clinical guides through autonomic conditions.

The meeting will offer plenty of networking opportunities with leading scientists and researchers, friends and colleagues.

Join us in Vienna on July 6 – 7, 2018!

Prof. Dr. Walter Struhal
EFAS 2018 Meeting President

JOIN US!
July 6 – 7, 2018
Vienna, Austria

The most authoritative voice in clinical neurological research

The Lancet Neurology is the trusted resource you need to stay informed of the important advances in your field. Our comprehensive coverage includes:

- **Articles**: original research that advocates change in neurological clinical practice
- **Reviews**: comprehensive overviews that are clinically focused and up-to-date on major neurological topics
- **Personal Views and Policy Views**: expert interpretation of recent evidence and its translation for decision makers
- **Commentary**: informative opinion on important recent advances in neurological practice and clinical research
- **In Context**: profiles, reviews of books and other media, lifelines, features on topical issues, and news on research advances

Discover more at www.thelancet.com/neurology
Monday
18 June 2018
08:00 – 09:30
Room CbW

**Case-based Workshop 6: Antibodies causing epilepsy**

**Chairperson:**
Maarten J. Titulaer  
(Rotterdam, The Netherlands)

- Faciobrachial dystonic seizures and other autoimmune seizure types  
  Sarosh Irani (Oxford, UK)
- What is the relevance of GAD65 antibodies in epilepsy?  
  Helena Ariño (Barcelona, Spain)
- Antibodies in status epilepticus  
  Maarten J. Titulaer  
  (Rotterdam, The Netherlands)

**Educational content:**
There is an increasing of studies that link antibodies to epilepsy. However, it is currently unclear when to consider this cause for patients with epilepsy, and what pitfalls can be expected. Three neurologists with expertise in both antibodies and epilepsy will guide the attendants to this evolving new field of clinical neurology. The speakers will discuss the literature within this workshop using different cases. The antibodies most frequently related to epilepsy are LGI1, GAD and GABAbR, and these will be all discussed from different perspectives, and common issues of debate during diagnosis and treatment will be covered within these case presentations.

Limited to 60 participants. Please register separately – additional fees will apply.

---

08:00 – 09:30
Room HoC

**Hands-on Course 6: Interpreting MRI in practice – Level 2**

**Chairperson:**
Maria Assunta Rocca (Milan, Italy)

- White matter lesions  
  Maria Assunta Rocca (Milan, Italy)
- Grey matter lesions  
  Menno Schoonheim  
  (Amsterdam, The Netherlands)
- Brain atrophy  
  Gioacchino Tedeschi (Naples, Italy)

**Educational content:**
This 90-minute hands-on-course on MRI, one of the key elements of diagnosis and differential diagnosis in many neurological disease, is directed to specialist trainees and practitioners who already have a basic knowledge of neuroimaging. The course will have three stations with experts in the various aspects of imaging and the participants will rotate, to increase their possibility to actively discuss practical issues. The attendants will learn how to interpret imaging features of white matter (WM) lesions in the main WM diseases and will be trained in the recognition of imaging red flags, useful for the differential diagnosis of these conditions. They will become familiar with imaging strategies to identify lesions of the grey matter (GM) and will directly apply guidelines for the assessment of these lesions. Finally, they will have the chance to participate to a session of practical quantification of atrophy in healthy subjects and patients with different neurological conditions and will be guided in the interpretation of physiological and disease-related variations of brain atrophy measures.

Limited to 60 participants. This course is soldout.

---

08:00 – 09:30
Auditorium VI

**Interactive Session 5: Diagnostic pitfalls in neuromuscular disease**

**Chairperson:**
Jochen Schäfer (Dresden, Germany)

- Bilateral finger extension weakness – is it treatable?  
  Jochen Schäfer (Dresden, Germany)
- A typical phenotype of proximal muscle weakness with an unusual genetic result  
  Kristl Claeyls (Leuven, Belgium)
- A diagnostic conundrum – various clinical manifestations, same genetic defect  
  Gabriele Siciliano (Pisa, Italy)

**Educational content:**
In this interactive Session, differential diagnostic problems in neuromuscular medicine will be discussed with the audience using four cases to illustrate the diagnostic pathway and potential pitfalls in reaching a diagnosis. The cases will cover major fields of neuromuscular medicine: channelopathies, muscular dystrophies, metabolic myopathies, inflammatory myopathies. After presentation of the cases the audience will be invited to offer diagnostic options by means of a smartphone voting app; furthermore, questions will be asked and discussed regarding investigations and management of the patient. Emphasis will be laid upon demonstrating ways how to approach a neuromuscular patient with seemingly puzzling physical findings and how to consider and evaluate the neuromuscular differential diagnoses.

Please download the app “EAN Congress” to actively participate in this Session and vote.
Focused Workshop 11: CGRP inhibition for migraine prevention – hype or hope?

Chairperson: Michel Ferrari (Leiden, The Netherlands)

- Rationale of blocking CGRP
  Messoud Ashina (Copenhagen, Denmark)

- Clinical results
  Uwe Reuter (Berlin, Germany)

- Clinical interpretation
  Michel Ferrari (Leiden, The Netherlands)

Scientific content:
Phase-2 trials have shown great promise of CGRP (Calcitonin gene-related peptide) and CGRP receptor antibodies and small molecule antagonist in the prevention and acute treatment of migraine and cluster headache attacks. By 2018 most phase-3 trials will have been completed. Efficacy and safety data will be presented and critically compared with those of existing migraine and cluster headache prophylactic (e.g. topiramate, propranolol, verapamil) and acute (e.g. triptans) treatments.

Target audience:
All clinical neurologists; basic science researcher with respect to pharmacology

Focused Workshop 12: Neurogenetic avenues and new directions on risk factors in dementia?

Chairperson: Ana Isabel Verdelho (Lisbon, Portugal)

- The penetrance continuum of genetic variants in common causal and risk genes in neurodegenerative dementia
  Christine Van Broeckhoven (Antwerp, Belgium)

- Large data bases, big science?
  Pieter Jelle Visser (Maastricht, The Netherlands)

- To exercise prevention
  Ana Isabel Verdelho (Lisbon, Portugal)

Scientific content:
The objective of this session is to approach recent advances on the field of dementia and to make a critical appraisal of the real contribute of those advances in clinical practice.

Target audience:
All clinical neurologists; basic science researcher with respect to pharmacology

Focused Workshop 13: Autoimmune encephalitis in the Intensive Care Unit (ICU)

Chairperson: Harald Prüss (Berlin, Germany)

- New concepts in etiology and disease mechanisms in autoimmune encephalitis
  Harald Prüss (Berlin, Germany)

- “Established” and experimental treatments of refractory autoimmune encephalitis
  Stephan Riegg (Basel, Switzerland)

- Epileptic seizures and status in autoimmune encephalitis
  Sophie Demeret (Paris, France)

Scientific content:
In this Focused Workshop we will give lectures about the issue of severe autoimmune encephalitis, requiring neurointensive care. New concepts of etiology and pathophysiology as well as special aspects of treatment, also alternative methods in refractory cases will be discussed. Prompt recognition of epileptic seizures or status epilepticus and adequate treatment are essential as this can prevent permanent neurological damage.
Focused Workshop 14: EAN/MDS-ES: Evidence-based medicine and beyond in neuropsychiatric complications of Parkinson’s diseases

Chairperson: David John Burn (Newcastle upon Tyne, UK)

- Treatments of depression in Parkinson’s disease
  Olivier Rascol (Toulouse, France)

- Therapeutic approaches of cognitive decline and dementia
  David John Burn (Newcastle upon Tyne, UK)

- Therapeutic approaches of hallucinations and psychosis
  Murat Emre (Istanbul, Turkey)

- Prevention, detection and therapeutic approaches of impulsivity disorders
  Angelo Antonini (Padua, Italy)

Scientific content:
This focused workshop will address several key non-motor symptoms that frequently complicate the course of Parkinson’s or may even predate the motor features. In part, these symptoms may be precipitated or exacerbated by drugs used to treat motor impairments. But undoubtedly the genesis of depression, cognitive impairment, psychosis and impulse control disorder relates to underlying neuropathological and neurochemical changes in strategic brain areas. Treatments used to manage these challenging symptoms are generally inadequate, despite their de facto logical focus on neurotransmitter placement and/or receptor stimulation. Furthermore, despite the availability of several agents in class, such as antidepressants, the evidence basis to guide treatment of many of these symptoms is poor. Neuropsychiatric symptoms associated with Parkinson’s are therefore an area of major unmet need. This session will review current treatments for depression, cognitive impairment, psychosis and impulse control disorder and will also consider future possible therapeutic approaches.

Focused Workshop 15: Guillain-Barré Syndrome: new developments in immunology, electrophysiology and treatment

Chairperson: Peter Van den Bergh (Brussels, Belgium)

- Understanding the auto-immune attack
  Hugh J. Willison (Glasgow, UK)

- Unravelling the electrophysiological diagnostic challenges
  Peter Van den Bergh (Brussels, Belgium)

- Novel treatment methods
  Pieter A. van Doorn (Rotterdam, The Netherlands)

Scientific content:
This focused workshop aims at presenting recent advances in the understanding of the pathophysiology of Guillain-Barré syndrome. New insights in the immunopathology and electrophysiological abnormalities will be discussed. They are leading to novel treatment algorithms and to more specific treatments.

Focused Workshop 16: Precision medicine in stroke

Chairperson: José M Ferro (Lisbon, Portugal)

- Do we need precision medicine in stroke?
  Daniel Bereczki (Budapest, Hungary)

- Do we already have precision medicine in stroke?
  Catarina Fonseca (Lisbon, Portugal)

- What to expect in the future?
  Joan Montaner (Barcelona, Spain)

Scientific content:
Precision medicine means a tailored approach to the diagnosis and management of the individual patient. Its ultimate goal is to provide individualised treatment for each patient, avoiding the incertitude and side-effects of current treatment strategies. Personalised medicine is already a reality in current practice in oncology, both for establishing individual prognosis, and more importantly to select chemotherapy and immunotherapy for each patient, based on a number of genetic and biochemical biomarkers. For other fields of medicine the applications of precision medicine in daily practice, although promising, are still in its infancy. That is the case of stroke, whose current management only occasionally needs genetic information. However, this scenario is likely to be modified soon, due to developments in biology, imaging, and informatics. Prof. Bereczki will introduce the topic and will scrutinise if we need precision medicine beyond the clinical, biochemical and imaging parameters that we currently use to decide on treatments and to provide prognostic information. Dr. Fonseca will review recent progresses on the application of precision medicine to stroke, including a glimpse of ongoing studies. The last speaker, Prof Montaner, will address the road to success of future developments in the field, including expected advances in genomics, serological biomarkers, novel biological data, imaging information and on the issues...
raised by the analysis of large data collection of stroke patients both from clinical trials, registries and administrative sets.

08:00 – 09:30
Room Lisbon

Special Session 8: History of Neurology: Lessons from Portuguese clinical neurosciences

Chairperson:
Victor Oliveira (Lisbon, Portugal)

• Functional neurosurgery: leucotomy revisited
  Alim Benabid (Grenoble, France)

• Would whole-exome sequencing change the history of Machado Joseph disease?
  Patricia Maciel (Braga, Portugal)

• From pioneers to interventional angiography
  Victor Oliveira (Lisbon, Portugal)

Scientific Content:
The field of Neurosciences deals nowadays with some challenges where one can track the connection with the early landmarks of Neurology. Some new discoveries or therapeutic applications revisit old attempts and, in some sense, pursue them. Surgical interventions in the brain were desperate attempts to help mental ill patients in the absence of any efficacious medication and without any foreseen way to entertain hope for a barely normal life. Deep brain stimulation for different therapeutic targets pursues the idea of surgical intervention in the brain to achieve therapeutic benefits. Well identified genetic diseases with precise abnormalities, allow us to entertain the hope of some sort of highly selective interventions to restore the normal sequence of amino-acids helping people to benefit from them. The broad use of angiography as it is performed at these early decades of the XXI century only hardly could be anticipated by Egas Moniz when he performed the first angiograms trying to identify intracranial tumours or even when, a few years later, he understood that the vessels, themselves, presented abnormalities that could be of clinical significance. The bridging from diagnostic to therapeutic interventions was made in the last decades of the XX Century with the first devices able to perform intravascular interventions. Emergency intravascular procedures for clot removal, was the next step. These are only a few examples how human creativity can surpass imagination.

08:00 – 09:30
Room Copenhagen

Special Session 9: EAN/EBC/EFNA: The Value of Treatment (VoT) of brain disorders

Chairpersons:
Wolfgang Oertel (Marburg, Germany)
David Vodušek (Ljubljana, Slovenia)
Maura Pugliatti (Ferrara, Italy)

• Brain disorders in Europe: unmet needs
  Wolfgang Oertel (Marburg, Germany)

• The value of early diagnosis and treatment. A patient journey
  Joke Jaarsma (Amsterdam, The Netherlands)

• The Value of Treatment: Using economic modelling to assess costs and outcomes associated with health care interventions.
  Michela Tinelli (London, UK)

• The value of health: improving outcomes and care pathways
  Richard Dodel (Marburg, Germany)

• The value of early treatment
  Maura Pugliatti (Ferrara, Italy)

Session Content:
Brain disorders (mental and neurological disorders) represent an enormous burden on both individuals and societies. The broad impact of brain disorders (BD) is threatening the quality of life of millions of European citizens with important implications on economic growth. Most of the current healthcare systems do not adequately respond to the need of patients with brain disorders. They mainly respond when a person is sick and have many deficiencies in the management of patients with brain disorders who need long-term care and treatment.

We present the results from the Value of Treatment (VoT) Project providing evidence on the socio-economic impact of coordinated and patient-centered clinical interventions which has been launched within the European Brain Council. EAN was responsible for the neurological diseases and the scope of this project will be presented. EFNA will face the issue from the person with BD perspective through the description of a ‘patient journey’ from diagnosis to treatment, with special focus on patient reported outcomes, highlight on the main needs of people with BD, and ultimately providing elements for improving care pathways of people with BD.
Plenary Symposium 3: Molecular and genetic therapies for neurogenetic disorders

Chairpersons:
Jorge Sequeiros (Porto, Portugal)
Jean-Marc Burgunder (Bern, Switzerland)

• Molecular and genetic therapies for Friedreich ataxia
  Massimo Pandolfo (Brussels, Belgium)

• Antisense oligonucleotide and gene replacement therapy in spinal muscular atrophy: a new therapeutic era for motor neuron diseases
  Kevin Talbot (Oxford, UK)

• Anti-amyloid and gene therapy in the treatment of familial amyloid polyneuropathy
  Maria Joao Saraiva (Porto, Portugal)

• Gene-based therapy in neurological disorders: what is in the pipeline?
  Jean-Marc Burgunder (Bern, Switzerland)

Scientific Content:
In recent years, novel therapeutical strategies and new approaches to old ones brought fresh hope for treatment of hereditary neurological diseases. We have been seeing the emergence of a variety of therapies, either aimed at a faulty (missing or toxic) protein function, targeted at RNA expression (gene silencing) or at DNA itself (gene therapy). Increased knowledge on disease progression, biomarkers and measurable outcomes, as well as on pathogenic pathways and networks, enabled more and better functional and preclinical studies (in cell and animal models). As a consequence, abundant clinical trials have been conducted or are now under way. New pharmaceutical molecules and novel genetic therapies have been developed for systemic or intrathecal delivery. Some, like (1) antisense oligonucleotides and (2) RNA interference compounds, interfere with messenger RNA, to reduce its expression, while (3) small molecules are designed to alter RNA splicing or for epigenetic reactivation of endogenous genes. Others, as (4) zinc-finger transcriptional repressors and (5) CRISPR/Cas9 constructs (“gene editing”), interact directly with DNA. Fine examples of these therapeutic strategies, in recessive (spinal muscular atrophy and Friedreich ataxia) and dominant neurological diseases (familial amyloid neuropathy and Huntington disease), are being presented in this session.

Symposium 5: The spectrum of dementias

Chairpersons:
Jonathan Schott (London, UK)
Reinhold Schmidt (Graz, Austria)

Evelien Lemstra (Leiden, The Netherlands)

• Alzheimer’s disease
  Reinhold Schmidt (Graz, Austria)

• Vascular dementia
  José Ferro (Lisbon, Portugal)

• Frontal lobe dementias
  Jonathan Schott (London, UK)

• Lewy body dementia
  Evelien Lemstra (Leiden, The Netherlands)

Scientific Content:
The dementias are at the heart of neurology: brain disorders with a significant impact on society and a huge challenge for neurologists in terms of diagnosis, treatment and care. Knowledge of the full spectrum of dementias is needed for each neurologist because of the high prevalence. The symposium covers all major diseases causing dementia and highlights all aspects of the diseases, given by the best specialists within the EU Neurology community.

Symposium 6: Coma: neuromodulation, imaging and neurobiology

Chairpersons:
Steven Laureys (Liège, Belgium)
Karin Diserens (Lausanne, Switzerland)

• Mechanisms of impaired consciousness
  Daniel Kondziella (Copenhagen, Denmark)

• Where structural changes predict outcome
  Louis Puybasset (Paris, France)

• Cognitive-motor dissociation: caveat
  Karin Diserens (Lausanne, Switzerland)

• Neuromodulation: outlook into the future
  Steven Laureys (Liège, Belgium)

Scientific Content:
Clinical and paraclinical evaluation of patients in coma and with chronic disorders of consciousness after brain injury has experienced an important development in these last years. This symposium aims at providing the audience with updated information on several domains, which will cover current understanding of mechanisms subtending disorders of consciousness, practice in post-cardiac arrest prognostication, newer neuroimaging data, an updated version of evaluation of chronic patients and an outlook into neurostimulation.

Target Audience:
Neurologists, neurointensivists, nurses in ICU, clinical neurophysiologists.
Monday 18 June
15.00 – 16.30

Case-based Workshop 7:
Rare headache syndromes: idiopathic or symptomatic?

Chairperson:
Peter Sandor (Baden, Switzerland)

- Exercise and sexual headache types
  Stefan Evers (Münster, Germany)
- Thunderclap headache types
  Raquel Gil-Gouveia (Lisbon, Portugal)
- Chronic daily persistent headache
  Peter Sandor (Baden, Switzerland)

Educational content:
In this workshop, participants can learn to identify rare other idiopathic headache disorders (group 4 of IHS classification) and to differentiate from similar symptomatic headache disorders

Limited to 60 participants. Please register separately – additional fees will apply.

Controversy 1:
Steroids in neuroinfections & Seizures and epileptiform discharges

Chairpersons:
Israel Steiner (Petach Tikvah, Israel)
Iris Unterberger (Innsbruck, Austria)

- Steroids in Acute and chronic Bacterial Meningitis - PRO
  Diederik van de Beek (Amsterdam, The Netherlands)
- Steroids in Acute and chronic Bacterial Meningitis - CON
  Erich Schmutzhard (Innsbruck, Austria)

- Seizures and epileptiform discharges worsen clinical outcome and should be aggressively treated
  Nicolas Gaspard (Brussels, Belgium)
- Seizures and epileptiform discharges do not impact clinical outcome and should not be aggressively treated
  Vincent Alvarez (Lausanne, Switzerland)

Educational content:
Part 1:
Steroid therapy in neurological infections and seizures impact and management in comatose patients are a controversial topic. The debate will focus on its use in bacterial and viral infections of the nervous system

Part 2:
To know the consequences of seizures on brain and clinical outcome of acutely ill patients and to know how to approach subclinical seizures in the ICU and to understand the pros and cons of aggressive anti-seizures treatment

Limited to 60 participants. Please register separately – additional fees will apply.

Hands-on Course 7:
Neuro-otology - Level 2

Chairperson:
Eleftherios Papathanasiou (Nicosia, Cyprus)

- Benign paroxysmal positional vertigo: provocation and liberation manoeuvres
  Michael Strupp (Munich, Germany)
  Thomas Brandt (Munich, Germany)
- Vestibular evoked myogenic potentials
  Eleftherios Papathanasiou (Nicosia, Cyprus)
  Dominik Straumann (Zurich, Switzerland)
- Video impulse test
  Konrad P. Weber (Zurich, Switzerland)
- Neuro-otological bedside tests
  Adolfo Bronstein (London, UK)
  Marianne Dieterich (Munich, Germany)

Educational content:
This course encompasses the major bedside and auxiliary tests for evaluating patients with vestibular signs and symptoms. A room rotating scheme has been designed with four stations, spending twenty minutes at each, with practical demonstrations. The benign paroxysmal positional vertigo (BPPV) and neuro-otological bedside test stations will involve the neuro-otological clinical examination and the treatment of BPPV with the different manoeuvres for each separate canal BPPV. The vestibular evoked myogenic potential station will use a common evoked potential system available in all neurophysiological laboratories. The head impulse station will demonstrate head mounted video systems commercially available for eye movement documentation.

Limited to 60 participants. Please register separately – additional fees will apply.
Interactive Session 6: Not every twitch or movement is a seizure in the neurological ICU

Chairperson:
Raimund Helbok (Innsbruck, Austria)

- Not every twitch is a seizure - the view of an epileptologist
Andrea Rossetti (Lausanne, Switzerland)

- Movement disorders associated with hypoxic encephalopathy and brain death
Raimund Helbok (Innsbruck, Austria)

- Encephalitis and movement disorders
Pille Taba (Tartu, Estonia)

Educational content:
Seizures are commonly observed in the setting of acutely brain injured patients. Differentiation of epileptic seizures from non-epileptic seizures is challenging for the clinician and may be facilitated by the use of continuous EEG monitoring. Moreover, especially in patients with autoimmune encephalitis, hypoxic brain injury and brain death, typical and sometimes bizarre movement disorders are observed. Clinical cases will be presented with videos of patients and supported by additional monitoring tools (i.e. EEG). Each section will include a brief discussion of the underlying disease.

Please download the app “EAN Congress” to actively participate in this Session and vote.

Teaching Course 11: EAN/MDS-ES: Evidence-based medicine in the treatment disabling motor and non-motor trouble in Parkinson’s disease - Level 2

Chairperson:
Maria Stamelou (Athens, Greece)

- Falls and gait disorders
Evžen Růžička (Prague, Czech Republic)

- Bladder disturbances and sexual disorders
Maria Stamelou (Athens, Greece)

- Hypotension and dysautonomia
Gregor K. Wenning (Innsbruck, Austria)

- Nocturnal and sleep problems in PD
Claudia Trenkwalder (Kassel, Germany)

Educational content:
Parkinson’s disease is heterogeneous in clinical presentation and evolution of motor and non-motor symptoms. The pharmacological and non-pharmacological treatment of the individual patient is challenging in particular in advanced stages of the disease. This teaching course aims to provide the basis for independently and individually apply current evidence based treatments for disabling motor and non-motor features in patients with Parkinson’s disease, in clinical practice. More specifically, the first talk will focus on evidence-based pharmacological and rehabilitation approaches to deal with, probably the most important determinants of quality of life and prognosis in terms of motor symptoms, e.g., the falls and gait-disorders. The following talks will focus on evidence based treatments of important non-motor symptoms of PD, specifically urinary and sexual problems, as well as autonomic dysfunction, as expressed among other with orthostatic or post-prandial hypotension. Lastly, sleep related issues that may be prevalent in Parkinson’s disease and may influence the quality of sleep, and thus, quality of life in PD patients, will be discussed, along with evidence on how best to approach treatment. After successfully completing this course the participants should be able to:
1) identify and approach clinically important motor and non-motor determinants of quality of life in a patient with PD from early to advanced disease
2) understand evidence-based treatments to approach gait problems and falls, as well as autonomic dysfunction and sleep problems in a patient with PD
3) make clinical decisions that take into account the scientific evidence and patient preferences on an individualised level.
**Teaching Course 12:**
EAN/ILAE-CEA: How to approach EEG and avoid overreading in epilepsy - Level 1

**Chairperson:**
Soheyl Noachtar (Munich, Germany)

- Systematic approach to EEG abnormalities
  Soheyl Noachtar (Munich, Germany)

- How to localise EEG potentials
  Sándor Beniczky (Dianalund, Denmark)

- What are epileptiform discharges & what do they mean clinically?
  Francisco Sales (Coimbra, Portugal)

- What is spiky but not epileptiform discharges?
  Matthew C. Walker (London, UK)

**Educational content:**
EEG is a strong tool in the diagnosis of epilepsy. Yet, it is a subjective method with inherent short comings, when it is not approached systematically. This course will first give a systematic approach to reading the EEG and typical pitfalls. Then, the localisation of EEG discharges will be discussed with its use for differential diagnosis and typical pitfalls, when localisation is not done adequately. The last two lectures will give an overview of what constitutes an IED, how well EEG finds IEDs, what they mean clinically and lastly, which discharge differential diagnoses exist and how to identify them.

---

**Teaching Course 13:**
New concepts in critical care of stroke patients - Level 3

**Chairperson:**
Stefan Schwab (Erlangen, Germany)

- Ischemic stroke: periinterventional management for acute neurointerventions
  Bart van der Worp (Utrecht, The Netherlands)

- Intracerebral hemorrhage (ICH) in patients with anticoagulation: New therapeutic options?
  Stefan Schwab (Erlangen, Germany)

- Subarachnoid hemorrhage (SAH): How do we treat delayed ischemic neurological deficit (DIND)
  Erich Schmutzhard (Innsbruck, Austria)

- Spontaneous intracerebral hemorrhage (ICH): The issue of perihemorrhagic edema
  Dimitre Staykov (Eisenstadt, Austria)

**Educational content:**
Discussion of new therapeutic concepts in the management of patients with acute cerebrovascular disease treated on the NCCU. Especially the peri-interventional management of patients undergoing thrombectomy in ischemic stroke is debated and clear guidelines are missing. Another topic will be laid on the management of patients with intracerebral haemorrhage and brain oedema therapy as well as special therapy of ICH under anticoagulation. Patients with subarachnoid haemorrhage often develop further complications after aneurysm repair. However, neurocritical care therapy is often complicated by vasospasm which can cause further ischemic events, possible treatment interventions will be discussed.
Hands-on Course 4: Basic EMG - needle EMG and transcranial magnetic stimulation as an electrodiagnostic tool - Level 2

Chairperson:
Letizia Leocani (Milan, Italy)

- Transcranial magnetic stimulation as an electrodiagnostic tool
  Letizia Leocani (Milan, Italy)

- Needle EMG
  Christian Krarup
  (Copenhagen, Denmark)

Educational content:
Dysfunctions of the pyramidal tract may require assessment of central conduction time and other central motor functions to complete the diagnostic workout. This is accomplished nowadays thanks to the use of transcranial magnetic stimulation (TMS). Apart from the most common evaluation of central conduction time, TMS allows for the study of sensorimotor integration, cortical maps of representation of muscles, excitability threshold, intracortical inhibition and many other features of the motor system. The course is intended to familiarize the attendants with the magnetic stimulators and practice in themselves the evaluation of central motor functions.

Needle electromyography (EMG) is an essential part of electro-diagnosis. Several different criteria are recorded to diagnose neurogenic disorders or myopathy. These include recording of denervation potentials and other spontaneous activity at rest, motor unit potentials (MUP) at weak effort, and the recruitment pattern at maximal voluntary effort. The examiner should be trained and skilful enough to combine sound and vision for the identification of subtle abnormalities. In this Hands-on-Course, the speaker will demonstrate how to perform a needle EMG exam, including positioning of the needle and searching for relevant information. There will also be demonstration of techniques to quantify the shape, duration and amplitude of MUPs, which are useful in the assessment of degenerative neuromuscular disorders. The attendants will actively participate in discussing the exams and interpretation in volunteers.

This course is supported by NATUS Medical Inc. and MagVentures.

Limited to 60 participants. Please register separately – additional fees will apply.
Oral sessions

15.00 – 16.15
Room Copenhagen

Ageing and dementia

Chairpersons:
Patrik Cras (Edegem, Belgium)
Bruno Dubois (Paris, France)

15.00 | O304
Added value of multimodal structural MRI to the clinical diagnosis of primary progressive aphasia variants
E. Canu1, F. Agosta1, F. Imperiale1, F. Caso1, A. Fontana1, G. Magnani1, A. Falini1, G. Comi1, M. Filippi1
1Milan, 2San Giovanni Rotondo, Italy

15.15 | O305
Enrichment of clinical trials in prodromal AD using ventricular volume to identify individuals at increased risk of rapid disease progression
M. Marizzoni1, C. Ferrari1, L. Cavaliere1, M. Didic2, G.L. Forloni2, J. Jovicich2, J.L. Molinuevo Guit2, F. Nobili3, L. Parnetti4, P. Payoux5, F. Ribaldi5, P.M. Rossini5, P. Schonknecht6, A. Soricelli6, M. Tsaliki7, P.J. Visser8, P. Wiltfang8, R. Bordet9, O. Blin9, G. Frisoni9
1Brescia, Italy, 2Marseille, France, 3Milan, Italy, 4Trent, Italy, 5Barcelona, Spain, 6Genoa, Italy, 7Stockholm, Sweden, 8Stockholm, Sweden

15.30 | O302
ABBV-8E12, a humanised anti-Tau monoclonal antibody for the treatment of Early Alzheimer’s disease and PSP: multiple dose, randomised, double-blind, placebo-controlled Phase-2 studies
1Ludwigsafen, Germany, 2North Chicago, USA, 3Saint Louis, USA

15.45 | O303
EEG microstates - association with cognitive impairment and Alzheimer’s disease CSF biomarkers
1Stockholm, Sweden, 2Berne, Switzerland

16.00 | O306
Metabolic correlates of reserve and resilience in MCI due to Alzheimer’s Disease (AD)
M. Bauckneht1, A. Chincarini1, R. Piva1, D. Arnaldi1, N. Girtler1, F. Massa1, M. Pardini1, H. Efeturk1, M. Pagani1, G. Sambucetti1, F. Nobili1, S.D. Morbeli1
1Genoa, 2Rome, Italy

15.00 – 16.30
Room Oslo

Tournament Clinical

Chairpersons:
Klaus V. Toyka (Würzburg, Germany)
Patricia Canhao (Lisbon, Portugal)
Hanna Cock (London, UK)

15.00 | TCLI01
Assessment of diabetic medication in ~8.000 dementia patients with diabetes mellitus. A study from the Swedish Dementia Registry
1Stockholm, Sweden, 2Stockholm, Sweden

15.15 | TCLI02
Cerebrovascular events after surgery versus conservative therapy for moyamoya disease: a meta-analysis
J. Smet, A. Wouters, R. Lemmens
Leuven, Belgium

15.30 | TCLI03
Pediatric and adults: a longitudinal multimodal MRI study to explore the substrates of the different clinical courses
E. de Meo1, M.A. Rocca1, A. Meani1, L. Moiola1, B. Colombo1, M. Rodegheri1, A. Ghezzi2, G. Comi3, A. Falini4, M. Filippi5
1Milan, Italy, 2Gallarate, Italy

15.45 | TCLI04
Safety and efficacy of percutaneous pulsed radiofrequency at the C1-C2 level in chronic cluster headache: a retrospective analysis of 21 cases
T. Kelderman, G. Vanschoenbeek, E. Crombez, K. Paemeleire
Ghent, Belgium
Has deep brain stimulation changed the natural history of Parkinson’s disease? A case control longitudinal study


1Innsbruck, Austria, 2Buenos Aires, Argentina

Neuromyelitis optica spectrum disorder and rituximab: a multi-center analysis


1Genoa, Italy, 2Orbassano, Italy, 3Rome, Italy, 4Gallarate (VA), Italy, 5Pozzilli, Italy, 6Milan, Italy, 7Treviso, Italy, 8CAGLIARI, Italy, 9Cagliari, Italy, 10Orbassano (TO), Italy

Validity and reliability of the Transthyretin Amyloidosis Neuropathy Score (TTR-ANS): a new outcome measure designed specifically for Familial Amyloid Polyneuropathy (TTR-FAP)

C. Monteiro, C. Rodrigues, J. Fernandez, M. Cardoso, C. Alves, A. Martins Da Silva, T. Coelho

1La Jolla, USA, 2Porto, Portugal

Mutations in MME cause autosomal recessive late-onset CMT type-2 disease


1Valencia, 2Santander, 3Santiago de Compostela, 4Torrelavega, 5Albacete, Spain

Peripheral neuropathy in the context of systemic vasculitis and other autoimmune diseases: the importance of etiologic characterisation


1Feira, 2Porto, Portugal

Statins and cryptogenic axonal polyneuropathy: a literature review and case-control study

J. Warendorf, A. Vrancken, N. Visser, N.C. Notermans

1Utrecht, 2Huizen, Netherlands

Direct oral anticoagulants versus Vitamin K antagonists after a recent ischaemic stroke: a pooled individual patient data analysis


1Basel, Switzerland, 2Perugia, Italy, 3London, UK, 4Osaka, Japan, 5Erlangen, Germany, 6Verona, Italy, 7Athens, Greece, 8Perugia, Italy

Cerebrovascular lesions during normal aging: a neuropathological study with 7.0-tesla magnetic resonance imaging

J.L. de Reuck, F. Auger, N. Durieux, V. Deramecourt, C. Cordonnier, C. Maurage, F. Pasquier, D. Leys, R. Borodet

Lille, France

Correlates of pontine small vessel disease: a post-mortem study

R. Geraldes, M. Esiri, J. Palace, G. Deluca

Oxford, UK

Integrity of the circle of Willis as an important predictor of early catastrophic outcome after endovascular thrombectomy in middle cerebral artery occlusion stroke


Salzburg, Austria
17.45 | O311
Predicting intracerebral hemorrhage expansion with non-contrast CT: the BAT Score
A. Morotti1, D. Dowlatshahi2, G. Boulouis3, F. Al-Ajlan2, A. Demchuk4, R. Aviv5, L. Yu6, K. Schwab7, J. Romero8, E. Gurü9, A. Viswanathan9, C. Anderson9, Y. Chang9, S. Greenberg9, A. Qureshi9, J. Rosand9, J. Goldstein9
1Pavia, Italy, 2Ottawa, Canada, 3Lille, France, 4Calgary, Canada, 5Toronto, Canada, 6Boston, USA, 7Minneapolis, USA

18.00 | O315
Atrial fibrillation in cryptogenic stroke: the Nordic Atrial Fibrillation and Stroke Study (NOR-FIB)
1Fredrikstad, 2Oslo, 3Bergen, 4Tønsberg, 5Bærum, 6Bodø, Norway, 7Molde, 8Stavanger, 9Lillehammer, Norway, 10Hunnингe, France

17.15 | O317
AVXS-101 Phase-1 gene replacement therapy clinical trial in SMA type-1: continued event free survival and achievement of developmental milestones
S. Al-Zaidy1, R. Shell1, W. Arnold1, L. Rodino-Klapac1, T. Prior1, L. Louwes1, L. Alfano1, K. Berry1, K. Church1, J. Kissel1, S. Nagendra1, J. L’italien1, D. Sproule1, C. Wells1, A. Burghes1, K. Foust1, K. Meyer1, S. Likhite1, B. Kaspar2, J.R. Mendell1
1Columbus, 2Bannockburn, USA

17.30 | O319
RNA-sequencing and motif analysis of Human Motor Neurons implicates selective role of SMN/SYNCRIP complex and Motif 7 in Spinal Muscular Atrophy
I. Faravelli1, M. Nizzardo1, F. Rizzo1, M. Taiana1, U. Pozzoli2, R. Del Bo1, N. Bresolin1, G.P. Comi1, S. Corti1
1Milan, 2Bosisio Parini, Italy

17.45 | O318
Integrated miRNAs analysis of ALS iPSCs and iPSCs-derived motor neurons towards the development of a molecular therapy for ALS
D. Gagliardi, M. Rizzuti, M. Nizzardo, V. Melzi, G. Filosa, L. Dionio, L. Calandriello, N. Bresolin, G.P. Comi, S. Barabino, S. Corti
Milan, Italy

18.00 | O320
Structural connectivity alterations in Amyotrophic Lateral Sclerosis are modulated by the topology of the anatomical brain connectome
E.G. Spinelli1, F. Agosta1, S. Basaia1, N. Riva1, Y. Falzone1, A. Chiò1, A. Falini1, G. Comi1, M. Filippi1
1Milan, 2Turin, Italy
**16.45 – 18.15  
Room Amsterdam**

**Cognitive neurology/neuropsychology**

**Chairperson:**  
Walter Paulus (Göttingen, Germany)

16.45 | O326  
**Assessment of auditory localisation in patients with disorders of consciousness**  
M. Carrière, H. Cassol, S. Wannez, A. Thibaut, C. Chatelle, G. Martens, S. Laureys, O. Gosseries  
Liege, Belgium

17.00 | O325  
**Transcranial Direct Current Stimulation (tDCS) over lateral parietal cortex facilitates object-location and face-word associative memory**  
J. Bjekčić, M. Čolić, M. Živanović, S. Milanović, S. Filipović  
Belgrade, Serbia

17.15 | O324  
**Association between neuropsychiatric symptoms, cognitive functioning and structural brain changes in Clinically Isolated Syndrome (CIS)**  
E. Hynčicová, M. Vyhnašek, A. Kalina, T. Nikolai, L. Martinovic, J. Lisy, J. Hort, E. Mehlzinová, J. Laczó  
Prague, Czech Republic

17.30 | O322  
**Locus coeruleus atrophy assessed with 3T MRI in typical and atypical Alzheimer’s disease and correlations to neuropsychological data**  
P. Olivieri, J. Lagarde, R. Valabrègue, M. Bottlaender, S. Lehericy, M. Sarazin  
Paris, Orsay, France

17.45 | O323  
**Reduced dynamism of functional connectivity is associated with cognitive impairment in Multiple Sclerosis patients: a dynamic functional connectivity study in a multi-center setting**  
Milan, Naples, Sienna, Italy, Barcelona, Spain, Amsterdam, Netherlands, London, UK, Graz, Austria

18.00 | O327  
**Persistent allocentric navigation deficits indicate hippocampal damage in Transient Global Amnesia**  
Munich, Germany, Senftenberg, Germany

**16.45 – 18.15  
Room Oslo**

**MS and related disorders 2**

**Chairpersons:**  
Ludwig Kappos (Basel, Switzerland)  
Antonella Macerollo (London, UK)

16.45 | O329  
**Multiple Sclerosis Impact Scale and brain volume are independent predictors of cognitive impairment in Secondary Progressive Multiple Sclerosis**  
London, Manchester, UK, Milan, Italy, Leeds, Edinburgh, Coventry, Keele, Sheffield, UK, Amsterdam, Netherlands

17.00 | O331  
**Phase-2 multicenter study results of Ublituximab, a novel glycoengineered AntiCD20 monoclonal Antibody (mAb), in patients with Relapsing Multiple Sclerosis (RMS)**  
E.J. Fox, A. Lovett-Racke, M. Inglese, R. Shubin, C. Twyman, J. Eubanks, K. Mok, W. Su  
Round Rock, Columbus, New York, Pasadena, Lexington, USA

17.15 | O328  
**Efficacy of Ozanimod versus Interferon beta-1a by DMT treatment experience and EDSS categorisation from a multicenter, randomised, double-blind, phase-3 study of relapsing Multiple Sclerosis**  
Düsseldorf, Germany, Cleveland, USA, Milan, Italy, Philadelphia, USA, Lodz, Poland, Montreal, Canada, Stanford, USA, Toronto, Canada, Prague, Czech Republic, San Diego, USA, San Francisco, USA, Basel, Switzerland
Oral sessions

16.45 – 18.15
Room Copenhagen

Sleep disorders

Chairperson:
Ulf Kallweit (Hagen, Germany)

16.45 | O337
Actigraphy ultradian and circadian rhythmicity in disorders of consciousness
A. Camargo, S. Blandiaux, A. Piarulli, O. Gosseries, S. Laureys
Liege, Belgium

17.00 | O334
Sleep microstructure in Parkinson’s disease: Cycling Alternating Pattern (CAP) as a sensitive marker of early NREM sleep instability.
R. Cremascoli, L. Priano, M. Bigoni, G. Albani, L. Sellitti, E. Giacomotti, R. Picconi, A. Mauro
Pavia, Turin, Verbania, Piancavallo, Piancavallo di Oggibbo, Italy

17.15 | O338
Autoreactive T-cells in narcolepsy patients target multiple antigens of hypocretin-producing neurons
Bellinzona, Switzerland, Hagen, Germany, Berne, Barisal, Lugano, Lausanne, Switzerland

17.30 | O339
Differential diagnosis in excessive daytime sleepiness based on sleep- and vigilance tests: a preliminary analysis of the Bern sleep database
J. Mathis, A. Mathis, D. Andres, W. Schmitt, C. Bassetti, D. Schreier
Berne, Switzerland

18.00 | O336
Effects of acute exposure to high altitude on RLS symptoms and PLMS: a bilateral study
A. Stefani, H. Hackner, T. Wildt, N. Seelose, E. Holzknecht, H. Gatterer, M. Faulhaber, M. Burtscher, J. Ulberg, B. Högl
Innsbruck, Austria, Hameplan, Örebro, Sweden

17.30 | O333
A neurometabolic profile of SPMS: the relationship between brain metabolites and clinical disability
London, UK, Pavia, Italy, Leeds, Edinburgh, Coventry, Keele, Sheffield, UK

17.45 | O330
Siponimod affects disability progression in SPMS patients independent of relapse activity: results from the phase III EXPAND study
B. Cree, R. Fox, G. Giovannoni, P. Vermersch, A. Bar-Or, R. Gold, D. Tomic, B. Magnusson, N. Rouyrre, D. Piani Meier, G. Karlsson, F. Dahlke, L. Kappos
San Francisco, Cleveland, USA, London, UK, Lille, France, PA, USA, Bochum, Germany, Basel, Switzerland

18.00 | O332
Measuring disease activity in Multiple Sclerosis: do we need spinal cord MRI?
S. Ruggieri, A. Logoteta, E. Tinelli, L. de Giglio, L. Prosperini, C. Gasperini, C. Pozzilli
Rome, Italy

16.45 – 18.15
Room Copenhagen

17.45 | O331
Reliability of a standardised test to document cataplexy to identify hypocretin deficiency
E. Pizza, S. Vandi, E. Antelmi, G. Plazzi
Bologna, Italy

18.00 | O336
Effects of acute exposure to high altitude on RLS symptoms and PLMS: a bilateral study
A. Stefani, H. Hackner, T. Wildt, N. Seelose, E. Holzknecht, H. Gatterer, M. Faulhaber, M. Burtscher, J. Ulberg, B. Högl
Innsbruck, Austria, Hameplan, Örebro, Sweden
24th Meeting of the European Society of Neurosonology and Cerebral Hemodynamics

Joint Meeting with Neurosonology Research Group

History Meets Future
Linz, Austria
5-7 April, 2019
www.esnch.org

SAVE THE DATE!
We invite you to the 23rd annual congress of the World Muscle Society, the premier congress on neuromuscular disorders, attended by established and young physicians, researchers, therapists, and neuropathologists from all over the world.

wms2018.com

26th Annual Meeting of the European Charcot Foundation

The role of long-term clinical studies in defining DMTs' profile

15 - 17 November 2018

Grand Hotel Dino, Baveno, Italy

Attend the 26th Annual Meeting and...

- get up-to-date about the latest developments in the field of MS research and clinical practice
- actively participate in scientific debates
- get engaged in qualitative discussions with researchers, clinical practitioners and young investigators

To join the live stream or watch the live stream recordings of the 26th Annual Meeting, subscribe to ECF eLearning.

Early Bird Registration deadline: 31 July 2018

To register or for more information about the 26th Annual Meeting: www.charcot-annual-meeting.org/26thannualmeeting
Tuesday
19 June 2018
Symposium 7: A new look in neuropathogenesis of Multiple Sclerosis

Chairpersons:
Ralf Gold (Bochum, Germany)
Maria Troiano (Bari, Italy)

- Role of environmental factors for MS
  Ralf Gold (Bochum, Germany)

- Role of B-cells in different types of MS
  Xavier Montalban (Barcelona, Spain)

- Challenges for modern MS therapy on back-ground of pathogenesis
  Luca Massacesi (Florence, Italy)

- The contribution of MRI for better understanding of MS
  Declan Chard (London, UK)

Scientific content:
Progress in understanding the pathogenesis of MS includes epidemiological studies, influences of lifestyle and nutrition, development of novel MRI techniques and approval of new MS treatments. This is critically needed in view of the growing number of autoimmune diseases of the central nervous system in industrialised countries.

Our proposed symposium aims at giving an integrated view of all these aspects. There is now solid scientific data on the influence of salt intake, dietary fatty acids and obesity, smoking, and UV light-exposure and their impact on the immune system. Novel immune players have entered the scenario: especially the function of B lymphocytes in relapsing and progressive MS, and in turn the therapeutic effects associated with B-cell depletion by monoclonal antibodies shed new light on this immune cell population. In view of the growing armamentarium of MS therapies we are better prepared to offer individualised treatment in relapsing MS. The point is whether we start early enough to avoid chronification of the immune response and still can recognise key factors. In addition, novel risks of highly active immunotherapies must be recognized. All this necessitates non-invasive monitoring of treatment success, and new MRI approaches to detect cortical lesions, damage to myelin sheath and axonal integrity. Also, the contribution of high-Tesla field imaging to differentiation of MS lesions will be covered.

Symposium 8: Advances in molecular characterisation and personalised therapies in brain tumors

Chairpersons:
Riccardo Soffietti (Torino, Italy)
Stefan Oberndorfer (St. Pölten, Austria)

- Targeting the immune cells or the glial cells in glioblastoma: the new question
  Michael Weller (Zurich, Switzerland)

- Subependymal giant cell astrocytoma (SEGA): a model of targeting tumor growth and seizures
  François Ducray (Lyon, France)

- Specific inhibitors of molecular pathways in brain metastases: from improved response to improved survival
  Riccardo Soffietti (Turin, Italy)

- New molecular subtypes of medulloblastomas and ependymomas: different outcome and treatment options
  Stefan Pfister (Heidelberg, Germany)

Scientific content:
The Symposium will provide an overview and update about the recent advances in molecular biology of different types of brain tumors, that have led to innovative treatments either in clinical trials or daily clinical practice.

M. Weller will present the new avenues of research in terms of immunotherapies and molecular treatments in glioblastoma.

F. Ducray will discuss the possibility to target both seizures and tumor growth in SEGAs.

R. Soffietti will report the improvement of prognosis following targeted therapies in molecular subgroups of brain metastases from melanoma, breast and non-small cell lung cancer.

S. Pfister will describe the new molecular classifications of medulloblastomas and ependymomas, and the molecular pathways that are now druggable.

Interactive Session 8: Is it a vasculitis or not?

Chairperson:
Peter Berlit (Essen, Germany)

- CNS- and PNS-manifestations of possible angiitis (case presentations)
  Peter Berlit (Essen, Germany)

Educational content:
The clinical presentations include polyneuropathy, spinal cord disease, brain tumour, epilepsy and stroke. The necessary investigations (e.g. imaging, neurophysiology, CSF, biopsy), possible differential diagnoses and management will be discussed. In a step-to-step approach during each case presentation, several single best answer questions with up to 5 possible answers will be presented and answered by the audience. At the end of the session, attendees should know about the best approach to the diagnosis of vasculitis, important differential diagnoses, and the management of systemic vasculitides and primary CNS-angiitis.

Please download the app “EAN Congress” to actively participate in this Session and vote.
Case-based Workshop 9: Imaging selection of stroke patients for specific treatment interventions

**Chairperson:**
Christian Enzinger (Graz, Austria)

- **Concept:** how to identify “salvageable” brain tissue
  Jean-Claude Baron (Cambridge, UK / Paris, France)

- **Morphologic criteria and perfusion**
  Christian Enzinger (Graz, Austria)

- **Vessel occlusion and collaterals**
  Marc Ribo (Barcelona, Spain)

**Educational content:**
Following the format of this interactive workshop, individual cases presented by experts will be used to demonstrate evidence-based approaches to select stroke patients faced in everyday care for specific treatment interventions, with a particular focus on imaging criteria. This workshop should allow attendants to appreciate the increasing knowledge-based concerning an extension of the time-window for interventions of selected patients fulfilling stringent criteria resting on information derived from neuroimaging, while also emphasizing to remain vigilant to deliver “standard” approaches to patients with stroke within accepted windows of treatment.

Limited to 60 participants. Please register separately – additional fees will apply.

Career development Session 3: Drug development and clinical trials in neurology

**Chairperson:**
Marie Trad (Paris, France)

- **Introduction to drug development:**
  Early stage development
  Isabelle Clavier (Paris, France)

- **Implementing pivotal clinical trials in Neurology**
  Marie Trad (Paris, France)

- **Interpreting clinical trials results**
  Kerry Gordon (Reading, UK)

**Educational content:**
This session will focus on the process of drug development in Neurology. Its objectives are: education for young neurologists’ career development, train young clinical trial investigators on factors contributing to successful implementation and execution of clinical trials in neurology, as well as understanding study designs and clinical trials results interpretation.

Special Session 11: Population, migration and neurological disorders

**Chairperson:**
Antonio Federico (Siena, Italy)

- **Migration as a reality of today**
  Antonio Federico (Siena, Italy)

- **Changing risk factor profile and migration. Health indicators - who cares?**
  Serefnur Öztürk (Konya, Turkey)

- **Neurologic infections in immigrants**
  Mostafa El Alaoui Faris (Rabat, Morocco)

**Session content:**
To increase awareness for effects of migration on neuroepidemiology, generalisation of regional special neurological diseases, negative effects on health care systems, specially effected groups (women, children, elderly)
10:30 – 12:30
Auditorium I

Plenary Symposium: Highlights and Breaking News

Chairpersons:
Joaquim Ferreira (Lisbon, Portugal)
Günter Deuschl (Kiel, Germany)
Paul Boon (Ghent, Belgium)

• Neuromuscular and neurophysiology
  Mamede de Carvalho

• Stroke
  Patricia Canhao

• Headache
  Isabel Pavao Martins

• Multiple Sclerosis
  João Cerqueira

• Dementia and cognition
  Alexandre Mendonça

• Movement disorders
  Miguel Coelho

Breaking News from Lancet Neurology

• Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled trial
  Albert Ludolph (Ulm, Germany)

• Cognitive behavioural therapy with optional graded exercise therapy in severely fatigued patients with myotonic dystrophy type 1: a single-blind randomised trial
  Baziel van Engelen (Nijmegen, The Netherlands)

After the presentation of the Congress Highlights, the winners of the Tournament for neurologists in training will be announced and receive their certificates.

Good-bye words & Presentation EAN 2019
Oslo

13:00 – 14:30
Room CbW

Case-based Workshop 8: Challenging cases of infections of the nervous system

Chairperson:
Israel Steiner (Petach Tikvah, Israel)

• Chronic meningitis
  Diederik van de Beek (Amsterdam, The Netherlands)

• Chronic encephalitis
  Israel Steiner (Petach Tikvah, Israel)

• Space taking focal infection
  Bettina Pfauister (Innsbruck, Austria)

Educational content:
Chronic meningoencephalitis is defined as an inflammation of the brain parenchyma and meninges of subacute onset and persisting evidence for an inflammatory process lasting more than one month. Chronic meningitis and encephalitis can be due to infectious and inflammatory causes. Diagnosis of the cause of this condition is of paramount importance in order to provide effective therapy that in many cases can lead to full recovery. The wide range of different etiologies renders the approach to patients with chronic encephalitis particularly difficult. Taking an in-depth history combined with a complete physical examination is mandatory in every patient. This should be followed by thorough analysis of the CSF, a systemic workup and in difficult and challenging cases also brain biopsy. This course aims to present the current knowledge on etiology, neurological course of disease, diagnostic and therapeutic management steps of patients presenting with clinical signs and symptoms of chronic meningoencephalitis.

Limited to 60 participants. Please register separately – additional fees will apply.

13:00 – 14:30
Auditorium VIII

Controversy 2: Controversies in the diagnosis of Alzheimer’s disease & in the treatment of Multiple Sclerosis

Chairpersons:
Giancarlo Comi (Milan, Italy)
Jonathan M. Schott (London, UK)

• Induction is the key strategy in MS treatment
  Eva Havrdova (Prague, Czech Republic)

• Induction is not the key strategy in MS treatment
  Aksel Siva (Istanbul, Turkey)

• This house believes that all patients diagnosed with young onset dementia should be offered genetic testing – PRO
  James Rowe (Cambridge, UK)

• This house believes that all patients diagnosed with young onset dementia should be offered genetic testing – AGAINST
  Massimo Musicco (Milan, Italy)

Educational content:
Part 1:
The main objective of the topic for controversies in MS is how to decide which treatment should be started in naïve MS patients. The two opposing views on induction will be discussed by each speaker and the rationale for the initiation of more effective treatments.

Part 2:
Advances in genetics mean that it is now easy to screen for multiple mutations that can cause dementia. There is however marked variability in the uptake of genetic testing across different centres and between different countries, and opinion is divided as to when and to whom these tests should be offered. A robust debate will ensure that attendees are aware of the relevant issues including: which genetic tests are available, how genetic testing should be undertaken, the likelihood of...
finding a genetic cause, and the potential benefits of establishing a definite diagnosis; as well as the potential disadvantages including the burden of knowledge on individuals and family members who may find themselves at risk, the costs, and the ethics of testing for conditions for which there are currently no disease modifying treatments.

Interactive Session 7: EAN/MDS-ES: Mixed movement disorders: what do we see and how do we approach

Chairperson: Marina de Koning-Tijssen (Groningen, The Netherlands)

- Hypokinetic movement disorders; mixed movement disorders plus parkinsonism
  Dan Healy (Dublin, Ireland)

- Mixed Hyperkinetic movement disorders: dystonia plus chorea, dystonia plus paroxysmal disorders, dystonia plus myoclonus
  Mark Edwards (London, UK)

- Movement disorders plus ataxia
  Marina de Koning-Tijssen (Groningen, The Netherlands)

Educational content:
This interactive session is focused on mixed movement disorders and how we approach them in clinical practice. For clinicians encountering a patient with a movement disorder there are three main practical questions: what do we see (phenotype), what is the cause (etiology) and what is the optimal treatment? Assessing the phenotype is a crucial first step. Many disorders have a ‘core’ movement disorder such as parkinsonism, chorea, dystonia or ataxia. However, many patients in addition to their ‘core’ movement disorder also reveal pronounced comorbid features, such as other concurrent movement disorders, spasticity, myopathy, neuropathy, epilepsy, cognitive or behavioral impairment. The often-complex heterogeneity of disease presentations and etiologies require clinical tools to recognise and categorise the disorder to subsequently focus on diagnostic and treatment strategies.

Three experts in the field will present cases with mixed movement disorders and discuss these patients interactively with the audience by using a digital (wireless) voting app. The first part will be focused on hypokinetic movement disorders; mixed movement disorders plus parkinsonism and presented by Dan Healy, from Dublin, Ireland. The second part focusses on mixed hyperkinetic movement disorders with a focus on dystonia: it will include cases with dystonia plus chorea, plus paroxysmal disorders, and plus myoclonus. The hyperkinetic cases will be discussed by Mark Edwards, London, UK. The final part is on movement disorders plus ataxia and cases will be presented by Marina de Koning-Tijssen, Groningen, the Netherlands. The focus of the sessions is on phenotyping and to improve clinical diagnosis and management in mixed movement disorders patients.

Please download the app “EAN Congress” to actively participate in this Session and vote.

Tuesday 19 June
13.00 – 16.30
Auditorium VI

Teaching Course 15: The “difficult to treat” headache patient – Level 3

Chairperson: Stefan Evers (Münster, Germany)

- Migraine treatment beyond guidelines
  Stefan Evers (Münster, Germany)

- Neuromodulation in clinical practice
  Jan Hoffmann (Hamburg, Germany)

- Unconventional treatments of cluster headache
  Peter J. Goadsby (London, UK)

- Refractory trigeminal neuralgia
  Giorgio Cruccu (Rome, Italy)

Educational content:
Participants will be learning how to treat patients not responding to treatment according to guidelines; including the use of unconventional treatments and not approved evidence-based treatment.
Teaching Course 16: Autoantibodies in neurological disorders - Level 2

Chairperson: Romana Höftberger (Vienna, Austria)

- What the neurologist needs to know in choosing the right assay for autoantibody testing
  Romana Höftberger (Vienna, Austria)

- Demyelination: what is new in neuromyelitis spectrum disorder (NMOSD) and the value of myelin oligodendrocyte glycoprotein (MOG) antibodies
  Jacqueline Palace (Oxford, UK)

- Autoimmune encephalitis
  Maarten J. Titulaer (Rotterdam, The Netherlands)

- What’s new in myasthenia gravis?
  Amelia Evoli (Rome, Italy)

Educational content:
In this TC, the speakers will prove practical relevant knowledge on autoantibody testing in neurological disorders. They will discuss the clinical phenotypes, suggested treatments and discuss the newest developments in this rapidly advancing field of neurology. They will provide tricks to recognise these diseases and share pitfalls to avoid misdiagnosis. In addition, the attendant will learn how these diseases can be relevant to other disciplines within clinical neurology and basic neurosciences.

Teaching Course 17: Advanced Neurosonology - Level 3

Chairperson: Fabienne Perren (Geneva, Switzerland)

- Transcranial Doppler versus transesophagal echocardiography for the detection of patent foramen ovale
  Georgios Tsiougoulis (Athens, Greece)

- Application and benefits of transorbital sonography in neurological disorders
  Christos Krogias (Bochum, Germany)

- High frequency versus low frequency transcranial ultrasound for sonothrombolysis
  Fabienne Perren (Geneva, Switzerland)

- Brain parenchymal sonography in movement disorder: a practical clinical tool or theoretical research
  João Sargento Freitas (Coimbra, Portugal)

Educational content:
Low cost, avoidance of irradiation, and high temporal resolution are inherent advantages of ultrasound imaging that translate into multiple clinical uses in many domains of neurology. This teaching course will aim to highlight clinical uses of ultrasound examination in cerebrovascular, neurodegenerative, and neuro-orbital diseases. In particular, modern treatment and prevention of ischemic stroke rely on prompt diagnosis. Ultrasonography has found a place as a noninvasive screening test and bedside technique that provides estimates of the degree of patent foramen ovale. Improvement in image quality permits novel uses of ultrasonography in neurodegenerative and transorbital system disorders, providing clinically important information that is complementary to the clinical examination and neuroimaging. Transcranial parenchymal sonography may assist in the differential diagnosis of movement disorders, while transorbital sonography ultrasound may provide structural information regarding the underlying etiology of optic nerve and transorbital diseases. In conclusion, the proposed teaching course will highlight the rapidly expanding indications of neurosonology that increase its applicability on a wide spectrum of neurological disorders. This course is organised on behalf of the ESNCH.

Teaching Course 18: Basics of sleep medicine - Level 1

Chairperson: Rolf Fronczek (Leiden, The Netherlands)

- Normal sleep mechanisms & why do we sleep?
  Rolf Fronczek (Leiden, The Netherlands)

- Diagnostics & methods - sleep investigations and pitfalls
  Ulf Kallweit (Hagen, Germany)

- Primary sleep disorders - symptoms, diagnosis & treatment
  Poul Jørgen Jennum (Copenhagen, Denmark)

- Sleep in neurological disorders
  Giuseppe Plazzi (Bologna, Italy)

Educational content:
Neurological sleep disorders are common. More than 90% of these are either primary neurological disorders or secondary to other neurological disorders. Hence, pathology of the sleeping brain - sleep medicine - is a vital part of neurology training. This teaching course will cover the basics of sleep medicine and sleep-wake-disorders in neurology.

First, we will take a closer look at the sleep questions from the previous EAN exam.

- Dr. Fronczek will cover the basic mechanisms of physiological sleep with a focus on neuroanatomy and sleep staging, and give an update about our current knowledge about why we need to sleep.
- Dr. Kallweit will give an overview about the methods to diagnose sleep disorders (questionnaires, polysomnography, multiple sleep latency test (MSLT), maintenance of wakefulness test (MWT), actigraphy, vigilance tests and biomarkers). Furthermore, diagnostic pitfalls will be discussed, such as the most common mistakes, false-positive MSLT’s and interpretation of the MWT. The evaluation of excessive daytime sleepiness versus fatigue and decreased vigilance will be covered.

- Dr. Jennum will give a broad overview of the different neurological primary sleep disorders (pathophysiology, clinical symptoms, diagnosis & treatment + video’s), including REM parasomnias (primary REM-sleep behavior disorder, RBD), NREM parasomnias (pavor nocturnus, sleep walking), narcolepsy type 1 + 2, idiopathic hypersomnia, the Kleine Levin Syndrome, obstructive sleep apnea syndrome (OSAS)/central apneas, restless legs syndrome and periodic limb movements disorder.

- To conclude, Dr. Plazzi will discuss sleep and wake problems secondary to other neurological disorders (M. Parkinson, M. Alzheimer, M. Huntington, paraneoplastic disorders, Multiple Sclerosis/neuromyelitis optica and traumatic brain injury).

After this, the sleep questions from the EAN exam will be revisited, to hopefully observe a marked improvement in scores.
Oral sessions

08.30 – 10.00
Room Amsterdam

Headache and pain

Chairpersons:
Raquel Santos Gil Gouveia (Lisbon, Portugal)
Elena Lebedeva (Yekaterinburg, Russia)

08.30 | O405
Phase-3 study (SPARTAN) of Lasmiditan compared to placebo for acute treatment of migraine
L.A. Wietecha, B. Kuca, M.G. Case, K.J. Selzler, S.K. Aurora
Indianapolis, USA

08.45 | O406
Field testing the diagnostic criteria for headache attributed to Transient Ischaemic Attacks
E.R. Lebedeva, N.M. Gurary, J. Olesen
Yekaterinburg, Russian Federation, Copenhagen, Denmark

09.00 | O403
Identifying natural subgroups of migraine-based on profiles of comorbidities and concomitant conditions: results of the Chronic Migraine Epidemiology and Outcomes (CoMEO) study
R. Lipton, K. Fanning, D. Buse, V.T. Martin, M. Reed, A. Manack Adams, P.J. Goadsby
New York, Chapel Hill, Cincinnati, Irvine, USA, London, UK

09.15 | O402
Increased preictal beta-ERD-response of primary sensorimotor cortex during brief hand movements with sensory stimulation in migraine
M.S. Mykland, M.H. Bjork, M. Stjern, T. Sand
Trondheim, Bergen, Norway

09.30 | O401
Cluster Headache is more than the extreme pain attack: a prospective diary study of 500 Cluster Headache attacks
A. Scher, N. Lund, A. Hagedorn, R. Jensen, M. Barloes
Glostrup, Copenhagen, Denmark

09.45 | O404
The long-term efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine in patients with medication overuse: results of the COMPEL study
S. Tepper, M.-C. Wilson, A. Orejuda, A. Manack Adams, A. Blumenfeld
Hanover, Covington, Carlsbad, USA

08.30 – 09.45
Room Oslo

Miscellaneous 2

Chairpersons:
Erich Schmutzhard (Innsbruck, Austria)
Alexandre Bisdorff (Esch-sur-Alzette, Luxembourg)

08.30 | O408
Early hemodynamic profile in tilt-induced vasovagal syncope
M. Gharig, D.P. Saal, F.I. Kerkhof, R.H. Reijntjes, D. Thijs, J.G. van Dijk
Leiden, Rotterdam, Netherlands

08.45 | O407
Reduced pupillary modulation in patients with relapsing-remitting Multiple Sclerosis is associated with longer disease duration and higher disease severity
Erlangen, Nuremberg, Germany

09.00 | O409
‘JUMP’, an innovative trans-pathology transitional care program for young adults with chronic neurological disease
E. McGovern, B. Marine, E. Manzato, P. Mochel, C. Guillonnnet, B. Michel, E. Flammard-Roze, E. Maillart
Paris, France

09.15 | O410
Characterisation of a Listeria monocytogenes meningitis mouse model
M. Koopmans, J. Lee, M. Brouwer, W.K. Man, M. Valls Seron, D. van de Beek
Amsterdam, Netherlands

09.30 | O411
Cerebral lesion localisation in patients with acute pure vestibular and ocular motor strokes: results from the prospective EMVERT trial
Munich, Germany
08.30 – 10.00
Auditorium III

Muscle and neuromuscular junction disease

Chairpersons:
Tiziana Mongini (Turin, Italy)
Theodoros Kyriakides (Nicosia, Cyprus)

08.30 | O412
Molecular mechanisms of mitochondrial DNA disease: pathological and genetic studies in patients with Mendelian disorders of mtDNA maintenance
1Ulm, Germany, 2Newcastle upon Tyne, UK, 3Halle, Germany

08.45 | O414
Quantifying muscle amyloid content in inclusion body myositis using [18f] florbetaliposion emission tomography
J. Lilleker1, R. Hodgson2, M.E. Roberts1, K. Herholz2, J. Howard2, R. Hinz2, H. Chinoy2
1Salford, UK, 2Manchester, UK

09.00 | O415
Cardiorespiratory function in Duchenne Muscular Dystrophy in a UK large tertiary care centre: longitudinal progression and the role of steroid treatment
J. Domingos1, C.G. Tay2, K. Maresh3, D. Ridout1, P. Munot1, A. Sarkozy4, S. Robb5, R. Quinlivan6, M. Riley7, M. Burch8, M. Fenton1, C. Wallis1, E. Chan9, F. Abel10, A. Manzur11, F. Muntoni12
1London, UK, 2Malaya, Malaysia

09.15 | O416
Vacuolated PAS-positive lymphocytes as screening tool and a possible therapeutic biomarker in late-onset Pompe disease (LOPD)
O. Musumeci1, D. Parisi2, S. Mondello3, T. Brizzi4, V. Mosca5, A. Migliorato5, A. Ciranni6, T. Mongini6, C. Rodolico6, G. Vita7, A. Toscano8
1Messina, 2Turin, Italy

09.30 | O413
A phase 1/2 Golodirsen trial developed by the SKIP-NMD consortium to identify potential treatments for Duchenne Muscular Dystrophy: study design and patient characteristics
F. Muntoni1, V. Straub2, D. Frank3, A.M. Seferian4, G. Dickson5, M. Guglieri6, J. Domingos7, L. Servais8, E. Mercuri9, S.-N. Study Group10
1London, 2Newcastle upon Tyne, UK, 3Cambridge, USA, 4Paris, France, 5Surrey, UK, 6Rome, Italy

09.45 | O417
Statin-induced myopathies: beyond immuno-mediated necrotising myopathies
Valencia, Spain

09.30 – 10.00
Room Copenhagen

Movement disorders 2

Chairpersons:
Pille Taba (Tartu, Estonia)
Joaquin Ferreira (Lisbon Portugal)

09.30 | O419
The Nocebo effect in Parkinson’s disease
M. Leal Rato1, G. Duarte1, A. Ferreira1, T. Teodoro2, T. Mestre3, J. Costa4, J. Ferreira5
1Amadora, 2Lisbon, Portugal, 3Ottawa, Canada

09.45 | O424
Evaluation of gait and posture in essential tremor before and after unilateral Gamma Knife Thalamotomy
E. Boutin, J.-P. Azulay, A. Eusebio, R. Carron, J. Regis, T. Witts, M. Vaugoyeau
Marseilles, France

08.30 – 10.00
Auditorium III

Muscle and neuromuscular junction disease

Chairpersons:
Tiziana Mongini (Turin, Italy)
Theodoros Kyriakides (Nicosia, Cyprus)

08.30 | O412
Molecular mechanisms of mitochondrial DNA disease: pathological and genetic studies in patients with Mendelian disorders of mtDNA maintenance
1Ulm, Germany, 2Newcastle upon Tyne, UK, 3Halle, Germany

08.45 | O414
Quantifying muscle amyloid content in inclusion body myositis using [18f] florbetaliposion emission tomography
J. Lilleker1, R. Hodgson2, M.E. Roberts1, K. Herholz2, J. Howard2, R. Hinz2, H. Chinoy2
1Salford, UK, 2Manchester, UK

09.00 | O415
Cardiorespiratory function in Duchenne Muscular Dystrophy in a UK large tertiary care centre: longitudinal progression and the role of steroid treatment
J. Domingos1, C.G. Tay2, K. Maresh3, D. Ridout1, P. Munot1, A. Sarkozy4, S. Robb5, R. Quinlivan6, M. Riley7, M. Burch8, M. Fenton1, C. Wallis1, E. Chan9, F. Abel10, A. Manzur11, F. Muntoni12
1London, UK, 2Malaya, Malaysia

09.15 | O416
Vacuolated PAS-positive lymphocytes as screening tool and a possible therapeutic biomarker in late-onset Pompe disease (LOPD)
O. Musumeci1, D. Parisi2, S. Mondello3, T. Brizzi4, V. Mosca5, A. Migliorato5, A. Ciranni6, T. Mongini6, C. Rodolico6, G. Vita7, A. Toscano8
1Messina, 2Turin, Italy

09.30 | O417
Statin-induced myopathies: beyond immuno-mediated necrotising myopathies
Valencia, Spain

09.30 | O419
The Nocebo effect in Parkinson’s disease
M. Leal Rato1, G. Duarte1, A. Ferreira1, T. Teodoro2, T. Mestre3, J. Costa4, J. Ferreira5
1Amadora, 2Lisbon, Portugal, 3Ottawa, Canada

09.15 | O418
Non-invasive intervention for motor signs of Parkinson’s disease: the effect of vibratory stimuli
1London, 2Cambridge, 3Manchester, UK

09.30 | O422
Evaluation of gait and posture in essential tremor before and after unilateral Gamma Knife Thalamotomy
E. Boutin, J.-P. Azulay, A. Eusebio, R. Carron, J. Regis, T. Witts, M. Vaugoyeau
Marseilles, France

09.45 | O423
Functional brain connectome architecture in a large cohort of Parkinson’s disease patients
S. Basagi1, F. Agosta1, H. Zahedmanesh1, T. Stojski2, V. Markovic2, J. Stankovic2, I. Petrovic3, E. Stefanova4, V.S. Kostic5, M. Filippi6
1Milan, Italy, 2Belgrade, Serbia

08.30 – 10.00
Room Copenhagen

Movement disorders 2

Chairpersons:
Pille Taba (Tartu, Estonia)
Joaquin Ferreira (Lisbon Portugal)

08.30 | O420
Generation and characterisation of iPSC-derived oligodendrocytes of patients with Multiple System Atrophy
E. Abati, G. Monzio Compagnoni, N. Bresolin, G.P. Comi, S. Corti, A. Di Fonzo
Milan, Italy

09.00 | O419
The Nocebo effect in Parkinson’s disease
M. Leal Rato1, G. Duarte1, A. Ferreira1, T. Teodoro2, T. Mestre3, J. Costa4, J. Ferreira5
1Amadora, 2Lisbon, Portugal, 3Ottawa, Canada

09.15 | O418
Non-invasive intervention for motor signs of Parkinson’s disease: the effect of vibratory stimuli
1London, 2Cambridge, 3Manchester, UK

09.30 | O422
Evaluation of gait and posture in essential tremor before and after unilateral Gamma Knife Thalamotomy
E. Boutin, J.-P. Azulay, A. Eusebio, R. Carron, J. Regis, T. Witts, M. Vaugoyeau
Marseilles, France

09.45 | O423
Functional brain connectome architecture in a large cohort of Parkinson’s disease patients
S. Basagi1, F. Agosta1, H. Zahedmanesh1, T. Stojski2, V. Markovic2, J. Stankovic2, I. Petrovic3, E. Stefanova4, V.S. Kostic5, M. Filippi6
1Milan, Italy, 2Belgrade, Serbia

08.30 – 10.00
Room Copenhagen

Movement disorders 2

Chairpersons:
Pille Taba (Tartu, Estonia)
Joaquin Ferreira (Lisbon Portugal)
CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS
2019 Annual Meeting
Seattle, Washington
May 29 - June 1
WWW.MSCARE.ORG

Save the Date

AD/PD™ 2019
The 14th International Conference on Alzheimer’s & Parkinson’s Diseases
March 26-31, 2019 | Lisbon, Portugal

ORGANIZING COMMITTEE
Abraham Fisher, Israel, President
Roger M. Nitsch, Switzerland, Executive Organizer
Manfred Windisch, Austria, Executive Organizer

5 Highlights You Should Not Miss at AD/PD™
- Expert Plenary Speakers
- Junior Faculty Awards
- Forum Discussions
- Nobel Prize Laureates
- Beautiful Lisbon

adpd.kenes.com
ESO
EUROP EAN STROK E ORGANISATION

via the following social media platforms

linkedin  facebook  twitter

...and through our ESO Blog

The Voice of Stroke in Europe

Stay connected through different channels be part of the online community to share information, ideas, personal messages and other content

- Join the discussion
- Receive the latest news
- Stay informed with all news and updates in stroke

www.eso-stroke.org
Journal of Neurology, Neurosurgery & Psychiatry

JNNP is a leader in the field, publishing ground-breaking and cutting-edge neurological sciences research from around the world.

Why read?

• Access multidisciplinary content; as a subscriber to JNNP, you will also have access to Practical Neurology (PN) and the Journal of Neurolnterventional Surgery (JNIS)
• Keep up to speed with cutting-edge international research that has a clinical focus
• Save time and digest information in a way that suits you with our multimedia content, including regular podcasts, blogs and social channels
• Access an immense archive collection
• JNNP has the longest half-life of any journal in clinical neuroscience

Find out more jnnp.bmj.com
Industry Sponsored Programme
Acknowledgements

We wish to express our gratitude to the following companies and organisations who contributed to the success at EAN 2018.

Premium Sponsors

Biogen
Celgene
Merck
Novartis Pharmaceuticals
Roche
Sanofi Genzyme

Major Sponsors

Alnylam
Bial
Teva
Zambon

Sponsors

Abbvie
AKCEA Therapeutics
Biomarin
CSL Behring

Contributors

Actelion
Boston Scientific
Deymed
Natus Neuro
Pfizer
### Exhibitors

<table>
<thead>
<tr>
<th>NAME</th>
<th>Booth Number</th>
<th>NAME</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie, Inc.</td>
<td>A18</td>
<td>European Society of Neurosonology and Cerebral Hemodynamics (ESNCH)</td>
<td>C46</td>
</tr>
<tr>
<td>Actelion Pharmaceuticals Ltd</td>
<td>B25</td>
<td>EVER Pharma</td>
<td>A15</td>
</tr>
<tr>
<td>Aequus Research</td>
<td>B30</td>
<td>F. Hoffmann-La Roche Ltd.</td>
<td>A06, A08</td>
</tr>
<tr>
<td>African Academy of Neurology</td>
<td>B09</td>
<td>Glut1 Deficiency Foundation</td>
<td>B07</td>
</tr>
<tr>
<td>Akcea Therapeutics</td>
<td>B21</td>
<td>ILAE-IBE Epilepsy Congress</td>
<td>B03</td>
</tr>
<tr>
<td>Alexion</td>
<td>B15</td>
<td>Impeto Medical</td>
<td>B24</td>
</tr>
<tr>
<td>Alnylam Pharmaceuticals</td>
<td>A12</td>
<td>International Congress on Luxembourg</td>
<td>C36</td>
</tr>
<tr>
<td>American Academy of Neurology</td>
<td>C10</td>
<td>Movement Disorder Society (MDS)</td>
<td>B08</td>
</tr>
<tr>
<td>Asper Biogene</td>
<td>C24</td>
<td>Journal of Medicine and Life</td>
<td>C07</td>
</tr>
<tr>
<td>Bial</td>
<td>A11</td>
<td>Karger Publishers</td>
<td>C04</td>
</tr>
<tr>
<td>Biogen</td>
<td>A04</td>
<td>Lilly</td>
<td>B20</td>
</tr>
<tr>
<td>BioMarin</td>
<td>B01</td>
<td>MedDay Pharmaceuticals</td>
<td>B16</td>
</tr>
<tr>
<td>Biomax Informatics</td>
<td>C09</td>
<td>Merck</td>
<td>A07</td>
</tr>
<tr>
<td>Boston Scientific</td>
<td>C08</td>
<td>National Neuropathy Society</td>
<td>A16</td>
</tr>
<tr>
<td>British Medical Journal</td>
<td>B23</td>
<td>Neuro-Compass</td>
<td>C32</td>
</tr>
<tr>
<td>Cefaly</td>
<td>B42</td>
<td>Norwegian Neurological Association</td>
<td>A01, A03</td>
</tr>
<tr>
<td>CeGaT GmbH</td>
<td>B14</td>
<td>Novartis Pharma AG</td>
<td>A01, A03</td>
</tr>
<tr>
<td>Cellgene</td>
<td>A05</td>
<td>Pfizer Ltd</td>
<td>B40</td>
</tr>
<tr>
<td>CNS- Campus Neurológico</td>
<td>C40</td>
<td>Pharmnext</td>
<td>B10</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>A14</td>
<td>Quanterix</td>
<td>C20</td>
</tr>
<tr>
<td>DEYMED Diagnostic</td>
<td>B18</td>
<td>Sanofi Genzyme</td>
<td>A02</td>
</tr>
<tr>
<td>Dystonia Europé</td>
<td>C02</td>
<td>Teva Pharmaceuticals Industries Ltd.</td>
<td>A09</td>
</tr>
<tr>
<td>ECTRIMS</td>
<td>B06</td>
<td>Wiley</td>
<td>B26</td>
</tr>
<tr>
<td>EPILOG</td>
<td>C30</td>
<td>Wilson Therapeutics</td>
<td>B11</td>
</tr>
<tr>
<td>European Brain Council</td>
<td>C35</td>
<td>Wisepress Medical Bookshop</td>
<td>C21</td>
</tr>
<tr>
<td>European Charcot Foundation</td>
<td>C01</td>
<td>Wolters Kluwer</td>
<td>C03</td>
</tr>
<tr>
<td>European Federation of Neurological Associations (EFNA)</td>
<td>B12</td>
<td>World Federation of Neurology (WFN)</td>
<td>C06</td>
</tr>
<tr>
<td>European Federation of Neurological Diseases</td>
<td>C36</td>
<td>Zambon SpA</td>
<td>A10</td>
</tr>
<tr>
<td>European Huntington’s Disease Network</td>
<td>C37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>European Medical Group</td>
<td>C34</td>
<td></td>
<td></td>
</tr>
<tr>
<td>European Pain Federation (EFIC)</td>
<td>B04</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Redefining the management of relapsing multiple sclerosis and primary progressive multiple sclerosis

Satellite Symposium at the 4th EAN Congress

Saturday 16 June 2018

13:00–14:30
Auditorium VI, Lisbon Congress Centre

13:00–13:15 Welcome and introduction
   Gavin Giovannoni (Chair)

13:15–13:30 Suppressing disease activity and progression in relapsing multiple sclerosis and primary progressive multiple sclerosis
   Gavin Giovannoni

   Ralf Gold

13:50–14:25 Incorporating ocrelizumab into clinical practice
   Aaron Boster

14:25–14:30 Q&A and close
   All faculty
MERCK EVENTS AT THE 4TH EAN CONGRESS
Lisbon, 16–19 June 2018

SATellite SYmposium
Auditorium VI, Lisboa Congress Centre (CCL), Lisbon, Portugal
Foundation and innovation in MS treatment – avoiding continuous immunosuppression
18:30–20:00 • Sunday, 17 June 2018
Chair: Jiwon Oh
João Cerqueira
Bassem Yamout
Raymond Hupperts

SCIENTIFIC THEATRE FORUM PROGRAMME
Scientific Theatre, Hall 1, Lisboa Congress Centre (CCL), Lisbon, Portugal
Selective Immune Reconstitution Therapy in the MS treatment paradigm
10:15–10:30 • Saturday, 16 June 2018
By Gavin Giovannoni
Cladribine Tablets in clinical practice: switching from platform therapies
09:45–10:00 • Sunday, 17 June 2018
By Klaus Schmierer
Cladribine Tablets in clinical practice: initiating treatment in newly diagnosed patients
09:45–10:00 • Monday, 18 June 2018
By Thomas Müller

Visit us at the Merck booth A07

Printed SPC available at Merck booth A07
These meetings are initiated, funded and organised by Merck KGaA
GBPMLR/CLA/0418/00771 Approval date: May 2018
Novartis: committed to neuroscience for over 70 years

Join us on Sunday 17 June 2018

Novartis has three Satellite Symposia at the 4th EAN congress; join us to hear from prestigious speakers in the fields of multiple sclerosis, tuberous sclerosis complex and migraine.

**Multiple Sclerosis**
Our evolving understanding of the MS disease continuum: a decade of change
Sunday 17 June, 12:15–13:15
Auditorium VI

**Tuberous Sclerosis Complex**
Management of seizures in paediatric patients with TSC
Sunday 17 June, 13:00–14:30
Auditorium V

**Migraine**
It’s time to act on Migraine: how can we manage the unmet needs?
Sunday 17 June, 18:30–20:00
Auditorium I

Novartis looks forward to welcoming you at the booth (A01 and A03).
ROOTED IN INNOVATIVE SCIENCE.

DRIVEN BY THE MANY FACES OF MULTIPLE SCLEROSIS.

Our mission to discover, develop and deliver life-enhancing medicines is focused in areas of unmet need in hematology, oncology, immunology and inflammation.

To learn more, come and visit us at Booth A05.

www.celgene.com

© 2018 Celgene Corporation
All rights reserved. 04/18 INT-OZA180004
Satellite Symposia Programmes

13:00 – 14:30
Auditorium I

**LILLY:**
When migraine is refractory: New approaches to shape the future of patient care

Chairperson:
Messoud Ashina (Copenhagen, Denmark)

- Chairman introduction
  Messoud Ashina (Copenhagen, Denmark)

- The treatment resistant migraine patient
  Uwe Reuter (Berlin, Germany)

- Assessment of patient reported outcomes
  Cristina Tassorelli (Pavia, Italy)

- Panel discussion, questions & answers and closing remarks
  All faculty

13:00 – 14:30
Auditorium VI

**ROCHE:**
Redefining the management of relapsing Multiple Sclerosis & primary progressive Multiple Sclerosis

Chairperson:
Gavin Giovannoni (London, UK)

- Welcome and introduction
  Gavin Giovannoni (London, UK)

- Suppressing disease activity and progression in relapsing Multiple Sclerosis and primary progressive Multiple Sclerosis
  Gavin Giovannoni (London, UK)

- Ocrelizumab safety across relapsing Multiple Sclerosis and primary progressive Multiple Sclerosis
  Ralf Gold (Bochum, Germany)

- Incorporating Ocrelizumab into clinical practice
  Aaron Boster (Ohio, United States)

- Q & A
  All faculty

- Close
  Gavin Giovannoni (London, UK)
Satellite Symposia Programmes

13:00 – 14:30
Auditorium V

ZAMBON: What’s New in the Management of Quality of Life in Parkinson’s Disease?

Chairpersons:
Javier Pagonabarraga Mora (Barcelona, Spain)
Angelo Antonini (Padua, Italy)

- Importance of Quality of Life in Parkinson’s Disease patients and caregivers
  Angelo Antonini (Padua, Italy)

- Role of non-dopaminergic pathways in Parkinson’s Disease
  Javier Pagonabarraga Mora (Barcelona, Spain)

- The impact of non–motor symptoms on Quality of Life of Parkinson’s Disease patients
  Heinz Reichmann (Dresden, Germany)

- Impact of pain and pain subtypes on the Quality of Life of patients with Parkinson’s Disease: Clinical evidences
  Olivier Rascol (Toulouse, France)

- Panel discussion

13:00 – 14:30
Auditorium VIII

BIOMARIN: Turning the tide in misdiagnosis in Myasthenic Syndromes: Increasing the index of suspicion for auto-immune neuromuscular disorders

Chairpersons:
Renato Mantegazza (Milan, Italy)
Luís Negrão (Coimbra, Portugal)

- Welcome and introduction
  Luís Negrão (Coimbra, Portugal)

- Current investigations in neuromuscular disease: Role of electrophysiology
  Jörn Peter Sieb (Stralsund, Germany)

- A new wave in confirmatory diagnosis of Lambert-Eaton Myasthenic Syndrome? Use of a specific immunoassay
  Renato Mantegazza (Milan, Italy)

- Diving deeper: Implications of underdiagnosis of Lambert–Eaton Myasthenic Syndrome – a case series
  Sabrina Sacconi (Nice, France)

- Panel discussion
  All faculty

- Meeting close
  Renato Mantegazza (Milan, Italy)
Satellite Symposium at the 4th EAN Congress

WHEN MIGRAINE IS REFRACTORY: NEW APPROACHES TO SHAPE THE FUTURE OF PATIENT CARE

Saturday, 16 June 2018 | 13:00 to 14:30
Auditorium 1 | Lisboa Congress Centre

SYMPOSIUM OBJECTIVES
- Understand the unmet need in migraine, with a special focus on refractory patients
- Review the burden of untreated patients and approaches to treatment of acute and chronic migraine; patients who are non-responders with initial prevention
- Assessment of patient reported outcomes, disability tools and impact on patient function

SYMPOSIUM CHAIR
Messoud Ashina, MD, PhD (Denmark)

AGENDA
13:00-13:10 Welcome and Introduction
Messoud Ashina, MD, PhD (Denmark)

13.10-13.40 The Treatment Resistant Migraine Patient
Uwe Reuter, MD, MBA (Germany)

13.40-14:10 Assessment of Patient Reported Outcomes
Cristina Tassorelli, MD, PhD (Italy)

14:10-14:30 Panel Discussion, Questions & Answers and Closing Remarks
All
Redefining the management of relapsing multiple sclerosis and primary progressive multiple sclerosis

Satellite Symposium at the 4th EAN Congress

Saturday 16 June 2018
13:00–14:30
Auditorium VI, Lisbon Congress Centre

13:00–13:15  Welcome and introduction
             Gavin Giovannoni (Chair)

13:15–13:30  Suppressing disease activity and progression in relapsing multiple sclerosis and primary progressive multiple sclerosis
             Gavin Giovannoni

             Ralf Gold

13:50–14:25  Incorporating ocrelizumab into clinical practice
             Aaron Boster

14:25–14:30  Q&A and close
             All faculty
Satellite Symposium at the 4th EAN Congress 2018
Lisboa, Portugal, 16-19 June 2018

What’s new in the management of quality of life in Parkinson’s Disease?

Pain and mood

Long term results

Good ON time

Motor functions

Please join the Zambon Satellite Symposium
June 16th 2018, 13.00 - 14.30
Auditorium V

Solve the case of her lifetime

Identifying the link can lead to a crucial diagnosis\(^1^\text{-}^5\)

Hereditary transthyretin-mediated (hATTR) amyloidosis is an inherited, rapidly progressive, life-threatening disease that can cause patients to have cardiomyopathy, sensory-motor neuropathy, and dysautonomia, eventually robbing patients of function—and even their lives.

Being aware of the red-flag symptom clusters will help accurately diagnose patients with this rare disease.

Visit Booth A12 to learn the red-flag symptoms.


© 2018 Alnylam Pharmaceuticals, Inc. All rights reserved. TTR02-Global-00006-032018
**ABBVIE:**
Optimizing care in Advanced Parkinson’s Disease: Why, when, and how

- **Introduction**
  
  K Ray Chaudhuri (London, UK)

- **Burden of Advanced Parkinson’s Disease: Individual, societal, and financial aspects**
  
  Matej Skorvanek (Kosice, Slovakia)

- **Early diagnosis: Why and how we should identify Advanced Parkinson’s Disease**
  
  Angelo Antonini (Padua, Italy)

- **Time to refer: Encouraging multidisciplinary care for patients with Advanced Parkinson’s Disease**
  
  Bastiaan Roelof Bloem (Nijmegen, Netherlands)

- **Q & A**
  
  All

---

**NOVARTIS:**
Our evolving understanding of the Multiple Sclerosis disease continuum: A decade of change

- **Chairperson:**
  
  João Cerqueira (Braga, Portugal)

- **Chair’s opening and welcome**
  
  João Cerqueira (Braga, Portugal)

- **Defining treatment success in Multiple Sclerosis: Developing concepts and new approaches**
  
  Finn Sellebjerg (Copenhagen, Denmark)

- **Expanding the evidence: The impact of long-term and real-world evidence on clinical practice (interactive discussion)**
  
  Tjalf Ziemssen (Dresden, Germany) and Melinda Magyari (Copenhagen, Denmark)

- **Questions & answers and closing remarks**
  
  All faculty
Satellite Symposia Programmes

13:00 – 14:30
Auditorium V

NOVARTIS:
Management of seizures in pediatric patients with Tuberous Sclerosis Complex

Chairperson:
David Neal Franz (Cincinnati, USA)

- Welcome and introduction
  David Neal Franz (Cincinnati, USA)

- Identification of Epilepsy in young children with Tuberous Sclerosis Complex
  David Neal Franz (Cincinnati, USA)

- Considerations for management of Tuberous Sclerosis Complex and Tuberous Sclerosis Complex-related seizures
  Anna Jansen (Brussels, Belgium)

- Neurologic consequences of Tuberous Sclerosis Complex-related seizures and potential implications of treatment
  Petrus de Vries (Cape Town, South Africa)

- Panel Discussion and question & answer session
  Petrus de Vries (Cape Town, South Africa) (moderator) and faculty

13:00 – 14:30
Auditorium VIII

BIOGEN:
Bringing hope for adults with Spinal Muscular Atrophy

Chairpersons:
Claudia Wurster (Ulm, Germany)
Tim Hagenacker (Essen, Germany)

- Welcome and introduction
  Claudia Wurster (Ulm, Germany)

- Understanding Spinal Muscular Atrophy: Not just a paediatric disease
  Claudia Wurster (Ulm, Germany)

- Considerations in management of Spinal Muscular Atrophy in adult patients
  Tim Hagenacker (Essen, Germany)

- Questions from the audience
  Claudia Wurster (Ulm, Germany)
  Tim Hagenacker (Essen, Germany)

- Conclusions and closing remarks
  Tim Hagenacker (Essen, Germany)
Your invitation to a Satellite Symposium at the 4th EAN Congress sponsored by Novartis

Our evolving understanding of the MS disease continuum: a decade of change

Sunday 17 June, 12:15–13:15

Auditorium VI,
Lisbon Congress Centre,
Lisbon, Portugal

Chair’s opening and welcome
João José Cerqueira (Braga, Portugal)

Defining treatment success in MS: developing concepts and new approaches
Finn Sellebjerg (Copenhagen, Denmark)

Expanding the evidence: the impact of long-term and real-world evidence on clinical practice
Tjalf Ziemssen (Dresden, Germany) and Melinda Magyari (Copenhagen, Denmark)

Interactive discussion

Q&A and closing remarks
All faculty
Satellite Symposium at the 4th EAN Congress

Management of Seizures in Paediatric Patients with TSC

17 June 2018 / 13:00 - 14:30
Lisbon Congress Centre / Auditorium V / Lisbon, Portugal

**PROGRAMME AGENDA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:15</td>
<td>Welcome and Introduction</td>
<td>CHAIR: David Neal Franz, MD (US)</td>
</tr>
<tr>
<td>13:15 - 13:35</td>
<td>Identification of epilepsy in young children with TSC</td>
<td>David Neal Franz, MD (US)</td>
</tr>
<tr>
<td>13:35 - 13:50</td>
<td>Considerations for management of TSC and TSC-related seizures</td>
<td>Anna Jansen, MD, PhD (Belgium)</td>
</tr>
<tr>
<td>13:50 - 14:10</td>
<td>Neurological consequences of TSC-related seizures and potential implications of treatment</td>
<td>Petrus de Vries, MBChB, MRCPsych, PhD (South Africa)</td>
</tr>
<tr>
<td>14:10 - 14:30</td>
<td>Panel Discussion and Q &amp; A</td>
<td>Petrus de Vries, MBChB, MRCPsych, PhD (moderator) and Faculty</td>
</tr>
</tbody>
</table>

**PROGRAMME OBJECTIVES**

- Educate on the neurological aspects of tuberous sclerosis complex (TSC) and review the long-term efficacy and safety profiles of therapies used for managing TSC-associated seizures in children and adolescents
- Discuss the growing body of evidence for management of TSC-associated seizures with mammalian target of rapamycin (mTOR) inhibitors and describe clinical approaches to manage adverse events in children and adolescents
- Explore the potential impact of early treatment on long-term neurological sequelae in children and adolescents with TSC

**PROGRAMME OVERVIEW**

This 90-minute symposium will focus on the management of treatment-refractory seizures in paediatric patients with TSC. Presentations will be case-based, and will focus on educating the audience about TSC, TSC-associated seizures, and the long-term impact of these seizures and intervention on neurological sequelae in children and adolescents. Topics to be covered will include the diagnosis of TSC-associated seizures, current management strategies, and the emerging role of mTOR inhibitors for TSC-associated seizures. In addition, the symposium will educate on TSC Associated Neuropsychiatric Disorders (TAND) symptomology and discuss the potential role for early intervention and impact on TAND.

This programme is supported by Novartis.

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This programme and/or material was developed for use outside of the US, is intended for non-US healthcare professionals, and is to be used in accordance with local laws and regulations.
BECAUSE WE'RE COMMITTED TO BRINGING YOU THE HIGHEST QUALITY EXPERIENCE AT EAN THIS YEAR.

Satellite Symposia at the 4th EAN Congress

<table>
<thead>
<tr>
<th>“Bringing hope for adults with Spinal Muscular Atrophy”</th>
<th>Prof. Claudia Wurster and Prof. Tim Hagenacker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Understanding Spinal Muscular Atrophy: not just a paediatric disease</td>
<td>Prof. Claudia Wurster; RKI – Universitäts und Rehabilitationskliniken Ulm, Germany</td>
</tr>
<tr>
<td>Considerations in management of Spinal Muscular Atrophy in adult patients</td>
<td>Prof. Tim Hagenacker; Universitätsklinikum, Essen, Germany</td>
</tr>
<tr>
<td>Sunday June 17th</td>
<td>13:00 – 14:00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>“The new ECTRIMS / EAN MS guidelines. The journey continues...”</th>
<th>Prof. João de Sá; Santa Maria Hospital, Lisbon, Portugal</th>
</tr>
</thead>
<tbody>
<tr>
<td>...to optimise individual treatment decisions How can we use registry data to personalise therapy?</td>
<td>Prof. Stefan Braune; NeuroTransData Network, Neuburg an der Donau, Germany</td>
</tr>
<tr>
<td>...to identify biomarkers of treatment response Is serum neurofilament light chain monitoring ready for clinical practice?</td>
<td>Prof. Jens Kuhle; University Hospital Basel, Basel, Switzerland</td>
</tr>
<tr>
<td>...to better understand treatment risk How is long-term safety experience changing patient management?</td>
<td>Prof. Richard Nicholas; Imperial College London, London, United Kingdom</td>
</tr>
<tr>
<td>Monday June 18th</td>
<td>12:15 – 13:15</td>
</tr>
</tbody>
</table>

Forum Talks at the 4th EAN Congress

<table>
<thead>
<tr>
<th>“Progressive supranuclear palsy – Update on diagnostic criteria and clinical research”</th>
<th>Prof. Günter U. Höglinger; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday June 17th</td>
<td>16:15 – 16:30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>“Alzheimer’s disease – Current developments in diagnosis and clinical research”</th>
<th>Prof. Giovanni B. Frisoni; University Hospital of Geneva and University of Geneva, Geneva, Switzerland</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday June 18th</td>
<td>09:30 – 09:45</td>
</tr>
</tbody>
</table>

These symposia and talks have been organised and funded by Biogen. Biogen products may be discussed - the SPCs will be available at the Biogen stand.

Biogen International GmbH Landis + Gyr-Strasse 3 6300 Zug Switzerland. ©2018 Biogen. All rights reserved. MSP-POR-00010a. Date of preparation: May 2018
For chronic inflammatory demyelinating polyneuropathy (CIDP)

FOLLOW THE PATH

DISCOVER the next step in CIDP treatment

VISIT CSL BEHRING AT BOOTH #A14

“Follow the PATH” to the CSL Behring booth and learn about:

- PATH, the largest CIDP study
- The first and only subcutaneous Ig (SCIG) for CIDP
- CSL Behring: over 100 years of expertise in developing and delivering plasma-derived products
SANOFI GENZYME: Demand more from life with Multiple Sclerosis #WomeninMS

Chairperson: Maria José Sá (Porto, Portugal)

- Welcome and opening
  Maria José Sá (Porto, Portugal)

- Family planning and Multiple Sclerosis: 100 key questions answered
  Celia Oreja-Guevara (Madrid, Spain)

- Teriflunomide #WomeninMS
  How can family planning be managed in a real-life setting?
  A Danish example.
  Melinda Magyari (Copenhagen, Denmark)

- Alemtuzumab #WomeninMS
  How can family planning be managed in a real-life setting?
  A Norwegian example.
  Elisabeth Gulowsen Celius (Oslo, Norway)

- Questions & answers

BIAL: Management of Parkinson’s Disease: From science to clinical wisdom

Chairperson: Werner Poewe (Innsbruck, Austria)

- Chairman’s introduction
  Werner Poewe (Innsbruck, Austria)

- Current treatment of fluctuations
  Fabrizio Stocchi (Rome, Italy)

- Managing motor fluctuations – a case-based perspective
  Wolfgang Jost (Wolfach, Germany)

- Facing the challenges of non-motor symptoms
  Francesca Morgante (Messina, Italy)

- Round table discussion – questions & answers
  All faculty
Satellite Symposia Programmes

**NOVARTIS:**
It’s time to Act on Migraine: How can we manage the unmet needs?

**Chairperson:**
Koen Paemeleire (Ghent, Belgium)

- Welcome and introduction
  Koen Paemeleire (Ghent, Belgium)

- Migraine from a neurologist’s perspective – future advances to raise the profile of the disease
  Martin Ruttledge (Dublin, Ireland)

- Calcitonin gene-related peptide pathway monoclonal antibodies, from clinical evidence to clinical practice
  Anish Bahra (London, United Kingdom)

- Making a meaningful difference for patients with high unmet need
  Uwe Reuter (Berlin, Germany)

- Targeted therapy to improve the safety and tolerability profile of prophylactic migraine treatment
  Andreas Gantenbein (Bad Zurzach, Switzerland)

- Panel discussion and questions & answers
  All faculty

- Closing remarks
  Koen Paemeleire (Ghent, Belgium)

**MERCK:**
Foundation and innovation in Multiple Sclerosis treatment – avoiding continuous immunosuppression

**Chairperson:**
Jiwon Oh (Toronto, Canada)

- The burden of Multiple Sclerosis treatment today
  João Cerqueira (Braga, Portugal)

- Solid foundations: 20 years of interferon β-1a
  Jiwon Oh (Toronto, Canada)

- Innovatively simple: Avoiding chronic immunosuppression with Cladribine tablets
  Bassem Yamout (Beirut, Lebanon)

- Case studies: Exploring treatment approaches
  Raymond Hupperts (Sittard-Geleen, The Netherlands)

- Concluding remarks
  Jiwon Oh (Toronto, Canada)
DEMAND MORE FROM LIFE WITH MS
#WomeninMS

VISIT BOOTH A02 TO LEARN MORE

Please join the Sanofi Genzyme Satellite Symposium at the 4th EAN Congress on:
SUNDAY, JUNE 17, 13:45 - 14:45 (AUD. 1)

Chair: Prof. Maria José Sá, Portugal
Speakers: Prof. Celia Oreja-Guevara, Spain
Dr. Melinda Magyari, Denmark
Prof. Elisabeth Gulowsen Celius, Norway
Management of Parkinson's Disease: From Science to Clinical Wisdom

Sunday 17th June 2018

Auditorium VI
13h45 - 14h45

4th Congress of the European Academy of Neurology, Lisbon 2018

Professor Werner Poewe
Innsbruck, Austria
Chairman's Introduction

Professor Fabrizio Stocchi
Rome, Italy
Current Treatment of Fluctuations

Professor Wolfgang Jost
Wolfach, Germany
Managing Motor Fluctuations: A Case-Based Perspective

Professor Francesca Morgante
London, United Kingdom
Facing the Challenges of Non-Motor Symptoms

Round Table Discussion Questions & Answers

This Symposium is organised and fully sponsored by Bial
It’s time to Act on Migraine: How can we manage the unmet needs?

Sunday 17 June 2018
18:30–20:00
Auditorium I
Lisbon Congress Centre
Lisbon, Portugal

Welcome and introduction
Koen Paemeleire

Migraine from a neurologist’s perspective – future advances to raise the profile of the disease
Martin Rutledge

Calcitonin gene-related peptide pathway monoclonal antibodies, from clinical evidence to clinical practice
Anah Bahra

Making a meaningful difference for patients with high unmet need
Uwe Reuter

Targeted therapy to improve the safety and tolerability profile of prophylactic migraine treatment
Andreas Gantenbein

Panel discussion and Q&A
Moderated by Koen Paemeleire

Closing remarks
Koen Paemeleire
Satellite Symposium
at the 4th Congress of the European Academy of Neurology 2018

FOUNDATION AND INNOVATION IN MS TREATMENT – AVOIDING CONTINUOUS IMMUNOSUPPRESSION

18:30–20:00
Sunday, 17 June 2018
Auditorium VI,
Lisboa Congress Centre (CCL),
Lisbon, Portugal

Chair:
Jiwon Oh, Canada
João Cerqueira, Portugal
Bassem Yamout, Lebanon
Raymond Hupperts,
The Netherlands
Satellite Symposia Programmes

18:30 – 20:00
Auditorium V

ALNYLAM PHARMACEUTICALS:
Connecting the dots – diagnosing and identifying hATTR Amyloidosis

Chairperson:
Teresa Coelho (Porto, Portugal)

• Welcome and Introductions
  Teresa Coelho (Porto, Portugal)

• Clinical presentation of progressive neuropathy
  Teresa Coelho (Porto, Portugal)

• Onset of GI manifestations and neuropathy
  Lucía Galán (Madrid, Spain)

• A case on cardiac manifestations leading to misdiagnosis
  Thibaud Damy (Paris, France)

• Questions & answers
  Teresa Coelho (Porto, Portugal)

18:30 – 20:00
Auditorium III

TAKEDA:
New insights in treatment and prevention of vascular cognitive impairment

Chairperson:
Alla Guekht (Moscow, Russian Federation)

• Risk factors of cognitive impairment
  Ingmar Skoog (Gothenburg, Sweden)

• Questions & answers

• Diabetes mellitus and cognitive impairment
  Boris N. Mankovsky (Kiev, Ukraine)

• Questions & answers

• Post-Stroke cognitive impairment: New insights from ARTEMIDA study
  Alla Guekht (Moscow, Russian Federation)

• Questions & answers and close
AKCEA: Amyloid Transthyretin (ATTR) Amyloidosis: One Disease, Many Symptoms

Chairperson: Teresa Coelho (Porto, Portugal)

- Diagnosis of Amyloid Transthyretin Amyloidosis
  Teresa Coelho (Porto, Portugal)

- Relationship between Genotype and Phenotype
  Laura Obici (Pavia, Italy)

- Cardiac Involvement in Amyloid Transthyretin Amyloidosis
  Arnt Kristen (Heidelberg, Germany)

- Evaluating Neuropathy Progression
  Violaine Planté-Bordeneuve (Créteil, France)

BIOGEN: The new ECTRIMS / EAN Multiple Sclerosis guidelines. The journey continues …

Chairperson: João de Sá (Lisbon, Portugal)

- … to optimize individual treatment decisions.
  How can we use registry data to personalize therapy?
  Stefan Braune (Prien, Germany)

- … to identify biomarkers of treatment response. Is serum neurofilament light chain monitoring ready for clinical practice?
  Jens Kuhle (Basel, Switzerland)

- … to better understand treatment risk. How is long-term safety experience changing patient management?
  Richard Nicholas (London, UK)
To those who say “impossible, impractical, unrealistic,” we say:

CHALLENGE ACCEPTED

We are relentless in our pursuit of new treatments. Because people living with rare diseases shouldn’t have to wait for hope.

alnylam.com
Amyloid Transthyretin (ATTR) Amyloidosis: One Disease, Many Symptoms

Monday, 18 June, 2018 | 12:15–13:15
Auditorium 1 | Lisbon Congress Centre

Chair: Teresa Coelho, MD, Neurologist and Neurophysiologist at Santo António Hospital, Porto, Portugal

Join Dr. Teresa Coelho and our expert faculty panel for this 60-minute symposium exploring key topics in ATTR amyloidosis, with an emphasis on polyneuropathy manifestations.

Dr. Coelho will highlight the common clinical presentation of ATTR amyloidosis and provide an overview of characteristic features and symptom combinations that should raise clinical suspicion. Common misdiagnoses will also be outlined, along with an overview of imaging techniques that can assist diagnosis.

We will review the common genotypes in Europe and the clinical spectrum of varying phenotypes observed. Further patient case studies will look at cardiac involvement and the overlap of polyneuropathy and cardiomyopathy phenotypes. The session will conclude with discussion around neuropathy progression and a review of tests/tools to facilitate recognition of neuropathy progression.

Objectives

- To raise awareness of ATTR amyloidosis and common diagnostic challenges
- To describe the multi-systemic nature of ATTR amyloidosis that extends beyond neuropathy
- To provide recommendations for diagnosing and monitoring progression of ATTR amyloidosis

Stop by the Akcea booth B21 for additional information about this important symposium.
SANOFI GENZYME:
Latest tales of the unexpected: Illuminating the path to earlier diagnosis in muscle diseases

Chairperson:
Tiziana Mongini (Turin, Italy)

• Introduction and welcome
Tiziana Mongini (Turin, Italy)

• Pathophysiology and the role of muscle biopsy in vacuolar myopathies: Hunting for hidden clues
Josef Žamek (Prague, Czech Republic)

• Role and risks of magnetic resonance imaging in muscle diseases: A case of mistaken identity?
Cornelia Kornblum (Bochum, Germany)

• A man with limb girdle weakness and respiratory involvement: A clue to an expected diagnosis?
Isabel Conceição (Lisbon, Portugal)

• Pompe disease and differential diagnosis of muscle diseases: An overview
Tiziana Mongini (Turin, Italy)

• Closing remarks
Tiziana Mongini (Turin, Italy)

TEVA:
The role of Calcitonin Gene-Related Peptide in migraine: The latest clinical evidence and its implications in the new era of biologics

Chairperson:
Dimos-Dimitrios D. Mitsikostas (Athens, Greece)

• Welcome and introduction
Dimos-Dimitrios D. Mitsikostas (Athens, Greece)

• Migraine today: Overview and unmet medical needs
Dimos-Dimitrios D. Mitsikostas (Athens, Greece)

• Current treatment options and management of migraine
Patricia Pozo-Rosich (Barcelona, Spain)

• The role of Calcitonin Gene-Related Peptide in Migraine: The latest evidence
Michel D. Ferrari (Den Haag, The Netherlands)

• Panel questions & answers
Dimos-Dimitrios D. Mitsikostas (Athens, Greece) & faculty
Satellite Symposia Programmes

CELGENE:
The ideal real world in Multiple Sclerosis care – a permanent clinical trial?

Chairperson:
Giancarlo Comi (Milano, Italy)

• Welcome

• A neurologist’s perspective: How do you standardise clinical assessment?
  Giancarlo Comi (Milano, Italy)

• A radiologist’s perspective: How do you standardise imaging techniques?
  Mike P. Wattjes (Hannover, Germany)

• A neuropsychologist’s perspective: How do you standardise cognitive assessments?
  Iris-Katharina Penner (Düsseldorf, Germany)

• Summary and closing

EVERPHARMA:
New evidence for pharmacological treatment in post-stroke recovery

Chairperson:
Andreas Bender (Burgau, Germany)

• Timing, training, and spontaneous recovery after stroke: in animals, in humans
  Steven Zeiler (Baltimore, USA)

• Anticorrelated processes in neurobiology - possible consequences for neuro-rehabilitation strategies
  Dafin F. Muresanu (Cluj-Napoca, Romania)

• New evidence from a recent meta-analysis in acute ischemic stroke
  Natan Bornstein (Tel Aviv, Israel)
LATEST TALES OF THE UNEXPECTED:
ILLUMINATING THE PATH TO EARLIER DIAGNOSIS IN MUSCLE DISEASES

MONDAY 18 JUNE 2018, 13:00–14:30
AUDITORIUM V, LISBOA CONGRESS CENTRE, LISBON

Satellite Symposium at the 4th EAN Congress
Lisbon, June 16–19, 2018
The role of CGRP in migraine: the latest clinical evidence and its implications in the new era of biologics

Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Welcome and introduction</td>
<td>Dimos-Dimitrios D. Mitsikostas</td>
</tr>
<tr>
<td></td>
<td></td>
<td>National &amp; Kapodistrian University of Athens, Greece</td>
</tr>
<tr>
<td>13:10</td>
<td>Migraine today: Overview and unmet medical needs</td>
<td>Dimos-Dimitrios D. Mitsikostas</td>
</tr>
<tr>
<td>13:30</td>
<td>Current treatment options and management of migraine</td>
<td>Patricia Pozo-Rosich</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vall d’Hebron University Hospital, Barcelona, Spain</td>
</tr>
<tr>
<td>13:50</td>
<td>The role of CGRP in migraine: the latest evidence</td>
<td>Michel D. Ferrari</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Leiden University Medical Center, The Netherlands</td>
</tr>
<tr>
<td>14:10</td>
<td>Panel Q&amp;A</td>
<td>Dimos-Dimitrios D. Mitsikostas &amp; panel</td>
</tr>
<tr>
<td>14:30</td>
<td>Close</td>
<td></td>
</tr>
</tbody>
</table>
3-Days Satellite Session

Programme
ROOTED IN INNOVATIVE SCIENCE.

DRIVEN BY THE MANY FACES OF MULTIPLE SCLEROSIS.

Satellite Symposium at the 4th EAN Congress:
The Ideal Real World In MS Care—A Permanent Clinical Trial?

AUDITORIUM I

Monday, 18 June, 13:45-14:45

A neurologist’s perspective: How do you standardise clinical assessment?

A radiologist’s perspective: How do you standardise imaging techniques?

A neuropsychologist’s perspective: How do you standardise cognitive assessments?

3-day Satellite Sessions at the 4th EAN Congress

ROOM 0.01

Saturday, 16 June, 10:00-10:30
The importance of real world evidence generation in MS

Sunday, 17 June, 09:30-10:00
Brain volume loss: From healthy individuals to MS patients

Monday, 18 June, 09:30-10:00
Drug sequencing through platform and oral therapies: What should be done?

www.celgene.com
© 2018 Celgene Corporation
All rights reserved. 04/18 INT-OZA180002
CELGENE

10:00 – 10:30  
Session Room 0.01  
Saturday, 16 June  
• The importance of real world evidence generation in Multiple Sclerosis  
  Tjalf Ziemssen  
  (Dresden, Germany)

09:30 – 10:00  
Session Room 0.01  
Sunday, 17 June  
• Brain volume loss: From healthy individuals to Multiple Sclerosis patients  
  Sven Schippling  
  (Zurich, Switzerland)

09:30 – 10:00  
Session Room 0.01  
Monday, 18 June  
• Drug sequencing through platform and oral therapies: What should be done?  
  Hans-Peter Hartung  
  (Duesseldorf, Germany)
Forum Talk

Programmes
Please join Merck for their scientific theatre forum talks at the 4th EAN Congress

Scientific Theatre, Hall 1
Lisboa Congress Centre (CCL), Lisbon, Portugal

Selective Immune Reconstitution Therapy in the MS treatment paradigm
10:15–10:30
Saturday, 16 June 2018
By Gavin Giovannoni, UK

Cladribine Tablets in clinical practice: switching from platform therapies
09:45–10:00
Sunday, 17 June 2018
By Klaus Schmierer, UK

Cladribine Tablets in clinical practice: initiating treatment in newly diagnosed patients
09:45–10:00
Monday, 18 June 2018
By Thomas Müller, Germany
# Forum Talk Programmes

## Exhibition – Hall 1 – Scientific Theater

Overview of forum talk programmes organised in the scientific theater within the exhibition area. Additional talks reserved after the date of printing will be announced on-site.

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Saturday, June 16</strong></td>
<td>10:15–10:30</td>
<td><strong>MERCK TALK – Multiple Sclerosis</strong></td>
</tr>
<tr>
<td></td>
<td>16:30–16:45</td>
<td><strong>ALNYLAM PHARMACEUTICALS TALK</strong></td>
</tr>
<tr>
<td><strong>Sunday, June 17</strong></td>
<td>09:30–09:45</td>
<td><strong>ALNYLAM PHARMACEUTICALS TALK</strong></td>
</tr>
<tr>
<td></td>
<td>09:45–10:00</td>
<td><strong>MERCK TALK – Multiple Sclerosis</strong></td>
</tr>
<tr>
<td><strong>Monday, June 18</strong></td>
<td>09:30–09:45</td>
<td><strong>BIOGEN TALK</strong></td>
</tr>
<tr>
<td></td>
<td>09:45–10:00</td>
<td><strong>MERCK TALK – Multiple Sclerosis</strong></td>
</tr>
</tbody>
</table>

**Selective Immune Reconstitution Therapy in the Multiple Sclerosis treatment paradigm**

Gavin Giovannoni  
(London, UK)

**Acute Hepatic Porphyrias – Inherited metabolic diseases with porphyric neuropathy**

Case reports:  
Jean-Charles Deybach  
(Paris, France)

**Cladribine Tablets in clinical practice: switching from platform therapies**

Klaus Schmierer  
(London, UK)

**Progressive supranuclear palsy – Update on diagnostic criteria and clinical research**

Günter U. Höglinger  
(Munich, Germany)

**Alzheimer’s disease – Current developments in diagnosis and clinical research**

Giovanni B. Frisoni  
(Les Acacias, Switzerland)

**Cladribine Tablets in clinical practice: initiating treatment in newly diagnosed patients**

Thomas Müller  
(Neu-Isenburg, Germany)
Speaker Index

Final Programme
Speaker Index

A
Aamodt, A.H. .......... 80, 98
Abati, E. ............... 113
Ablink, T.E. .......... 66
Abdel-Manan, O. ...... 81
Abe, F. ................. 113
Abeti, R. ............... 80
Acevedo-Arozena, A. .... 80
Adams, D. ............. 64, 66
Adler, C. ............... 64
Ægidius, K.L. ........... 98
Agosta, F. .......... 60, 96, 98, 113
Aguilar, C. ........... 67
Al-Ajlun, F. .......... 98
Albanean, A. ........... 59
Albani, G. .......... 100
Alberti, D. .............. 67
Alfano, L. ............. 98
Alonso, I. ............. 113
Alsagob, M. .......... 66
Al-Tawil, N. .......... 64
Altehled, L. ........... 80
Alvarez, V. .......... 91
Alvarsson, M. .......... 96
Alves, C. .............. 97
Alves, P.N. .......... 80
Al-Zaydiy, S. .......... 98
Amin, F.M. .......... 82
Anderson, C. .......... 98
Anderson, K. .......... 64
Andersson, T. .......... 96
Andres, D. .......... 100
Angelini, C. .......... 51
Annovazzi, P. .......... 97
Antelmi, E. .......... 100
Antonini, A. .......... 61, 88
Antonio, S. ........... 80
Anzalone, N. .......... 80
Arévalo, M.J. .......... 99
Argov, Z. .......... 61
Ariatti, A. .......... 66
Ariño, H. ............. 86
Armangué, T. .......... 67
Armentani, E. .......... 100
Arnaldi, D. .......... 96
Arnold, D.I. .......... 65, 99
Arnold, W. .......... 98
Aznarte, K. .......... 98
Ashina, M. .......... 87, 126
Assunta Rocca, M. .... 86
Atar, D. .......... 98
Attal, N. .......... 78
Attarian, S. .......... 66
Audoin, B. .......... 67
Auger, F. .......... 97
Aurora, S.K. .......... 112
Aurand Lyons, M. .... 80
Aviv, R. .......... 98
Awada, A. .......... 73
Ayryan, X. .......... 67
Azevedo, E. .......... 79
Azorin, I. .......... 113
Azulay, J.-P. .......... 113

B
Bacigaluppi, M. .......... 80
Bacon, CJ. .......... 66
Bahra, A. .......... 58, 139
Baig, F. .......... 64
Baker, I. .......... 50
Ballabriga, J. .......... 67
Balwani, M. .......... 64
Barbelloni, B. .......... 65
Baror, A. .......... 65, 99, 100
Barabino, S. .......... 98
Baralle, F. .......... 80
Barber, T. .......... 64
Barboni, P. .......... 67
Barbot, C. .......... 113
Barceló, M.I. .......... 67
Barrios, J. .......... 113
Barroso, F. .......... 66
Bartenstein, P. .......... 99
Basannia, S. .......... 98, 113
Bassetti, C. .......... 79, 100
Bassez, G. .......... 59
Bastianello, S. .......... 81
Batemanna, R.J. .......... 96
Battagloglu, E. .......... 66
Bauckneht, M. .......... 96
Baumgartner, C. .......... 71
Bazner, H. .......... 73
Beach, T. .......... 64
Beccaria, K. .......... 81
Bedé, P. .......... 60
Bedetti, C. .......... 81
Bednarik, J. .......... 66
Belden, C. .......... 64
Bellatache, M. .......... 66
Belvisi, D. .......... 80
Ben-Shlomo, Y. .......... 64
Benabdelljill, M. .......... 73
Benabid, A. .......... 89
Bender, A. .......... 149
Benedetti, L. .......... 97
Benedetti, M.D. .......... 67
Beniczky, S. .......... 54, 93
Bennett, D. .......... 59
Benson, M. .......... 66
Berardelli, A. .......... 80
Bereczki, D. .......... 88
Berk, J. .......... 64, 66
Blair, P. .......... 106
Berry, K. .......... 98
Berti, E. .......... 66
Berzona, G. .......... 61
Bettencourt, A. .......... 67, 81
Bettencourt, C. .......... 80
Bhatia, K. .......... 59
Bianchi Marzoli, S. .......... 67
Bianchini, E. .......... 80
Bierhals, T. .......... 66
Bigoni, M. .......... 100
Biotti, D. .......... 67
Bisddorf, A. .......... 112
Bissell, D. .......... 64
Bjekić, J. .......... 99
Bjerkeli, V. ............. 98
Bjork, M.H. .......... 112
Blamire, A. .......... 67
Blanco, Y. .......... 67
Blandiaux, S. .......... 100
Blennow, K. .......... 82
Blin, O. .......... 96
Bloom, B.R. .......... 132
Bloomer, J. .......... 64
Blumenfeld, A. .......... 112
Boirie, Y. .......... 64
Bolino, A. .......... 66
Bombardi, R. .......... 67
Bonello-Palot, N. .......... 66
Bonetti, B. .......... 97
Bonkovsky, H. .......... 64
Bonnet, A. .......... 80
Boon, P. .......... 37, 54, 81, 108
Bordet, R. .......... 96, 97
Borns, N. .......... 79, 149
Boster, A. .......... 126
Bottlaender, M. .......... 99
Bouchoux, G. .......... 81
Bouckaert, C. .......... 81
Boulouis, G. .......... 98
Boumédienne, F. .......... 98
Bourdain, F. .......... 81
Boutin, E. .......... 113
Bouzidi, A. .......... 81
Bovi, P. .......... 97
Boyko, A. .......... 65
Branco, M. .......... 97
Brandão, A.F. .......... 113
Brandner, S. .......... 80
Brandt, T. .......... 91, 99, 112
Brannagan, T. .......... 66
Brás, P. .......... 64
Braune, S. .......... 145
Braun, K. .......... 80
Braunstein, J.B. .......... 96
Breitenfeld, T. .......... 73
Bresolin, N. .......... 98, 113
Bril, V. .......... 66
Brizz, T. .......... 113
Brouwer, M. .......... 112
Speaker Index

Brouwer, O. ...............  80
Brownlee, W. ............  70
Brück, W. ..................  65
Bruna, J. ..................  67
Brunelli, M.C. ..........  81
Bruno, F. ..................  81
Büchner, B. ...............  67
Budur, K. ..................  96
Buratti, E. .................  80
Burch, M. ..................  113
Burghes, A. ...............  98
Burgunder, J.M. .......  66, 90
Burn, D.J. ..................  88
Burscher, A. ..............  98
By, D. ......................  65
Buttari, F. ..................  97

C

Calabresi, P. ...............  81
Calandriello, L. ..........  98
Calvi, A. ....................  65, 99
Camargo, A. ...............  100
Campistol, J. ..............  66
Campos, F. .................  81
Canhao, P. .................  96, 108
Canney, M. ..................  81
Cantalupo, G. .............  67
Canu, E. .....................  96
Capobianco, M. ..........  97
Caporali, L. ..................  67
Cappellari, M. ............  97
Capra, R. ....................  67
Carbonelli, M. .............  67
Cardoso, M. ..................  97
Carelli, V. ..................  67
Carpentier, A. ...........  81
Carreño, M. ...............  77, 108
Cascavilla, M.L. ........  67
Case, M.G. .................. 112
Caseo, F. ....................  96
Caseo, V. ....................  20, 78, 97
Cassol, H. ..................  99
Cavaco, S. ..................  67
Cavaliere, L. ...............  96
Cencini, F. ..................  64
Cerliani, L. .................  80
Ceroni, M. ..................  81
Cerqueira, J. ............... 108, 132, 139
Chan, A. .....................  64
Chan, E. .....................  113
Chan, K.H. ..................  67
Chandler, H. ...............  20
Chandran, S. ............... 65, 99, 100
Chang, Y. ..................  98
Chard, D. .................... 106
Chatway, J. ................. 65, 99, 100
Chatelle, C. .................  99
Chaudhuri, K Ray .......... 132
Chaves, J.M.M. ..........  81
Chelban, V. .................  66
Chen, J. .....................  64
Chiavazza, C. ..............  81
Chincarini, A. .............  96
Chinnery, P. ...............  67
Chinot, O.L. ...............  81
Chinoy, H. ..................  113
Chio, A. .....................  98
Chirita-Emandi, A. .......  66
Chitnis, T. ..................  65
Chumillas, M.J. ..........  97
Church, K. ..................  98
Ciccarelli, O. .............  65, 99
Cincotti, F. ...............  82
Ciranni, A. ................. 113
Ciron, J. .....................  67
Claus, K. ....................  86
Classen, J. .................  77, 79
Clavier, I. .................. 107
Cletheroe, D. ..............  113
Cloughesy, T. .............  81
Cobo-Calvo, A. .........  67
Cocco, E. .....................  97
Cock, H. ..................... 39, 53, 73, 96
Coelho, M. .................  77, 108
Coelho, T. .................  52, 64, 66, 97, 144, 145
Cohen, J.A. .................  65, 99
Colamarino, E. ...........  82
Cole, J. ......................  20
Colic, M. ....................  99
Collins, D.L. ..............  87
Collongues, N. ...........  67
Colombo, B. ...............  65, 96
Colosimo, C. .............  53
Comi, G. ..................... 54, 65, 77, 80, 96, 98, 99, 108, 113, 149
Conceição, I. ..............  52, 66, 148
Condette Auliac, S. .......  81
Connick, P. ...............  65, 99, 100
Cordonnier, C. ...........  97
Correia, M. ..................  75
Corrochano, S. ..........  80
Costa, C. ...................  98, 113
Costa, J. ....................  113
Costa, P. ....................  81
Costa, R. .................... 108
Coutinho, E.P. ............  80
Coutinho, P. ..............  113
Cras, P. .....................  29, 96
Cree, B. .....................  100
Cree, B.A.C. ...............  99
Cremaescoli, R. ..........  100
Crombez, E. ...............  96
Cronberg, T. ..............  82
Cruccu, G. ..................  109
Cuccarini, V. .............  81
Cunha, C. ...................  67

D

Dahlke, F. .................. 100
Daizadeh, N. .............  65
Dalmau, J. ..................  67
Damásio, J. ................. 113
D’ambrosio, A. ..........  99
Damian, M. .................. 61, 82
Damier, P.G. ..............  71
Damy, T. ....................  144
Dankiewicz, J. ...........  82
Dankwa, I. ..................  66
Davis, K. ....................  64
De Angelis, F. ...........  65, 99
De Carvalho, M.A. ......  57
De Giglio, L. ..............  100
De Grandis, M. ..........  80
De Koning-Tijssen, M. ...  109
De Leeuw, F.E. ..........  53
De Marchis, G.M. .......  97
De Meo, E. .................  96
De Negri, A.M. ..........  67
De Reuck, J. ...............  80, 97
De Rojas Leaf, C. .......  112
De Sá, J. ....................  145
De Seze, J. .................  65
De Stefano, N. ............  60, 99
De Visser, M. .............  61
De Vries, J. ...............  67
De Vries, P. ..............  133
Deangelis, F. ............  100
Debette, S. ...............  53
Del Bo, R. ..................  98
Del Sorbo, F. ..........  64
Delattre, J.-Y. ............  81
Delbeke, J. ...............  81
Delogu, R. ..................  67
Deluca, G. ..................  97
Demarin, V. ...............  73
Demchuk, A. ..............  98
Demeret, S. ...............  87
Deramecourt, V. .......  97
Desnick, R. ...............  64
Desnick, R.J. .............  64
Deuschl, G. ...............  37, 75, 108
Dewaele, F. ..............  81
Deybach, J.-C. .......  64, 159
Di Fonzo, A. ..........  113
Di Liberto, G. ..........  20
Di Stefano, A.L. .......  81
Di Vito, L. ...............  67
Diamanti, L. ..............  81
Dias, M. ....................  64
Dickson, G................. 113
Didic, M. ..................... 96
Diener, H.-C................. 80
Dieterich, M.............. 70, 99, 112
Dietz, V...................... 72
Dinh, Q........................ 64
Diodato, D.................. 66
Dion, L ......................... 98
Diserens, K.................. 90
Divisova, S.................. 66
Dodel, R...................... 89
Doglioni, C.................. 80
Dojčáňová, D............... 66
Domingos, J................ 113
Donadio, V................... 64
Donati, M.A................. 67
Doornenbal, N............. 80
Doshi, A....................... 65, 99, 100
Doulatshahi, D............ 98
Drachman, B............... 66
Dragancea, I............... 82
Drapier, S.................. 80
Dréan, A...................... 81
Driver-Dunckley, E......... 64
Duarte, G..................... 113
Dubois, B.................... 96
Ducray, F................... 81, 106
Durand Dubief, F........ 67
Durand, E................... 64
Durieux, N................. 97
Durif, F....................... 64
Durn, B.L................... 66
Duthieil, F.................. 64
Dyck, P...................... 66

F
Fabbrini, A.................. 80
Falini, A...................... 80, 96, 98
Falzone, Y.................. 98
Fanciulli, A................ 58, 70
Fanning, K.................. 112
Fantini, M.L................ 64
Faravelli, I.................. 98
Farias Serratos, B.M.... 81
Farias Serratos, C.V........ 81
Farias Serratos, F.......... 81
Farina, L.M.................. 81
Farotti, L................... 81
Farrugia, M.................. 67
Fastbom, J.................. 96
Faulhaber, M............... 100
Fawzi, N...................... 80
Fazekas, F.................. 70
Federico, A................ 61, 107
Fenton, M................... 113
Fernandes, J.............. 97
Ferrante, M.................. 98
Ferrari, C................... 96
Ferrari, M.................. 87, 148
Ferrari, S................... 67
Ferreira, A................. 113
Ferreira, C.................. 71
Ferreira, J................. 37, 71, 108, 113
Ferreira, P.................. 80
Ferreira, R.................. 81
Ferro, J..................... 53, 73, 77, 88, 90, 97
Fetoni, V.................... 67
Fileccia, E.................. 64
Filipovic, S................ 99
Filippi, M.................. 65, 96, 98, 99, 113
Filosa, G.................... 98
Fior, A....................... 80
Fisher, E.................... 80
Flamand-Roze, E........... 112
Florian, H................... 96
Focke, N..................... 65
Foltynek, T.................. 113
Fonseca, C................... 88
Fontana, A.................. 96
Fontao, L.................... 97
Forbes, R.................... 80
Forloni, G.I................ 96
Foulon, C.................... 80
Foust, K..................... 98
Fox, E.J...................... 99
Fox, R....................... 100
Fradette, C.................. 67
Franchino, F............... 81
Frank, D...................... 113
Franz, D..................... 133
Frasquet Carrera, M....... 97
Fratta, P..................... 80
Frau, J....................... 97
Freitas, J................... 81
Friberg, M.P.H............. 82
Frisoni, G.................. 96
Frisoni, G.B................ 159
Fromm, A.................... 80
Fronczek, R................ 110
Fuhr, P....................... 77
Fukumura, R................ 80

G
Gadeyne, S.................. 81
Gagliardi, D................ 98
Gajofatto, A................ 67
Galán, I..................... 144
Galassi, G................... 66
Galego, S.................... 80
Galitzky, M.................. 65
Gallo, A..................... 99
Gallo, F....................... 97
Gamez, J.................... 66
Gandhi, P.................... 64
Gandini Wheeler-Kingshott,
CA.......................... 65, 99
Gantenbein, A.............. 139
Garcia, D..................... 81
Garcia, A.................... 65
Garcia-Garcia, J........... 97
Garcia-Ptacek, S........... 96
Garcia-Sobrino, T.......... 97
Gäßter, J.................... 65
Gaspard, N................... 91
Gasperini, C................ 100
Gasser, T.................... 72
Gatterer, H.................. 100
Gaudio, E..................... 80
Gazdzinska, J.............. 81
Genbrugge, E.............. 81
Geraldes, R.................. 97
Gertz, M...................... 66
Gharbi, M.................... 112
Ghezzi, A................... 65, 96
Giacomotti, E............... 100
Giannoccaro, M.P........... 80
Gil-Gouveia, R............. 91, 112
Gilhus, N.E.................. 76
Gilo, F....................... 67
Giommetto, B.............. 81
Giovannoni, G............. 51, 65, 99...
........................................ 100, 126, 159
Girtler, N.................... 96
Giunti, P..................... 80
Goadsby, P.J................. 109, 112
Gold, R...................... 100, 106, 126
## Speaker Index

<table>
<thead>
<tr>
<th>A</th>
<th>Aburto, O.</th>
<th>98</th>
</tr>
</thead>
<tbody>
<tr>
<td>B</td>
<td>Bach, K.</td>
<td>67</td>
</tr>
<tr>
<td>C</td>
<td>Cacabelos, R.</td>
<td>80</td>
</tr>
<tr>
<td>D</td>
<td>Dauer, S.</td>
<td>65</td>
</tr>
<tr>
<td>E</td>
<td>Edelstein, M.</td>
<td>107</td>
</tr>
<tr>
<td>F</td>
<td>Fazekas, F.</td>
<td>81</td>
</tr>
<tr>
<td>G</td>
<td>Garcia, J.</td>
<td>112</td>
</tr>
<tr>
<td>H</td>
<td>Hakim, A.</td>
<td>81</td>
</tr>
<tr>
<td>I</td>
<td>Isla, M.</td>
<td>100</td>
</tr>
<tr>
<td>J</td>
<td>Joutel, L.</td>
<td>59</td>
</tr>
<tr>
<td>K</td>
<td>Karamanlis, L.</td>
<td>80</td>
</tr>
<tr>
<td>L</td>
<td>Loutradis, I.</td>
<td>100</td>
</tr>
<tr>
<td>M</td>
<td>Matsumoto, H.</td>
<td>67</td>
</tr>
<tr>
<td>N</td>
<td>Nair, R.</td>
<td>80</td>
</tr>
<tr>
<td>O</td>
<td>Osorio, A.</td>
<td>80</td>
</tr>
<tr>
<td>P</td>
<td>Paganini, M.</td>
<td>99</td>
</tr>
<tr>
<td>Q</td>
<td>Quisaba, J.</td>
<td>66</td>
</tr>
<tr>
<td>R</td>
<td>Rossetti, E.</td>
<td>80</td>
</tr>
<tr>
<td>S</td>
<td>Sandoval, M.</td>
<td>107</td>
</tr>
<tr>
<td>T</td>
<td>Thomsen, B.</td>
<td>80</td>
</tr>
<tr>
<td>U</td>
<td>Uemura, T.</td>
<td>67</td>
</tr>
<tr>
<td>V</td>
<td>Van Gompel, J.</td>
<td>113</td>
</tr>
<tr>
<td>W</td>
<td>Wolters, S.</td>
<td>67</td>
</tr>
<tr>
<td>X</td>
<td>Xu, H.</td>
<td>133</td>
</tr>
</tbody>
</table>

---

### Speaker Index

- E. M. Hamilton
- Mark Hallett
- J. Hall
- T. Hagenacker
- A. Hagedorn
- G. Hagberg
- H. Hackner
- E. Gurol
- N. M. Gurary
- E. Gulowsen
- G. Gullotta
- L. Guedes
- L. Goyal
- O. Gosseries
- G. Gorman
- P. Gorevic
- M. Grond
- W. Grisold
- L. Grond
- J. Guedes
- M. Guekht
- J. Guéhennec
- L. Guedes
- M. Grond
- G. Goral
- H. Gurary
- R. Gurol

---

### Speaker Index

- K. Hynčicová
- R. Hupperts
- J. Humphrey
- R. Huppers
- M. Husein
- E. Hyncicova
- A. Idibaib
- H. Ihle-Hansen
- F. Imperiale
- A. Incensi
- R. Infante
- M. Inglese
- P. Insel
- S. Irani
- S. Irving
- A. Isaacs
- C. Jäämsma
- L. Jacobson
- M. Jaeger Wanscher
- K. Jahn
- F. Jans
- J. Jansen
- A. Jansen
- Z. Jaunmuktane
- V. Jelic
- A. Jenedum
- P. Jensen
- R. Jensen
- F. Jansen
- A. Jansen
- Z. Jost
- J. Jovicich

---

### Speaker Index

- H. Hackner
- H. Hadzhikolev
- G. Hagberg
- D. Hagedorn
- T. Hagenacker
- J. Hall
- M. Hallett
- B. Halvorsen
- E. M. Hamilton
- M. Hanna
- O. Hardiman
- D. Häring
- P. Harper
- P. Hartung
- C. Hassager
- E. Havrdova
- C. Hawkins
- J. Hayflick
- D. Healy
- C. Hecker
- W. Heide
- S. Heitner
- R. Helbok
- K. Herholz
- M. Herrmann
- C. Hidalgo de la Cruz
- L. Hitchcock
- H. Höflinger
- D. Högt
- U. Högl
- J. Höglender
- M. Holtzmann
- E. Holzknecht
- M. Horakova
- J. Horn
- J. Hort
- D. Hornqvist
- K. Hösl
- H. Houde
- D. Housman
- J. Howard
- M. Hu
- V. Huang
- D. Hughes
- H. Hulst
- J. Humphrey
- R. Huppers
- M. Husein
- E. Hyncicova
- I. Karin
- G. Karlsson
- W. Karlsson
- S. Karolis
- P. Kaspar
- L. Kawai
- N. Kaya
- M. Kelderman
- T. Kehoefer
- P. Kermers
- R. Khattam
- C. Killer-Oberpfalzer
- J. Kilner
- J. Kissel
- D. Kjærgaard
- C. Klein
- J. C. Klein
- H. Klingenthal
- L. Klopotesk
- C. Kloth
- L. Klucken
- W. Kmiec
- B. Kobelt
- C. Koenig
- M. Koga
- M. Koini
- L. Kondziella
- Y. Kong
- M. Koopmans
- P. Korlpara
- C. Kornblum
- J. Köyr
- V. Kostic
- L. Kovalova
- W. Kozubski
- C. Krarup
- A. Kristen
- C. Krogias
- S. Krogseth
- S. Kropshof
- J. Kruja
- L. Krupp
- C. Kruse
- C. Kubala Havrdova
- 2018 EAN Congress Lisbon

---

### Program Details

- **Final Programme**
- **Speaker Index**
- **EAN Congress 2018**
# Speaker Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Millesi, K.</td>
<td>97</td>
</tr>
<tr>
<td>Misiego, M.</td>
<td>97</td>
</tr>
<tr>
<td>Mitsikostas, D.-D.</td>
<td>148</td>
</tr>
<tr>
<td>Mo, F.</td>
<td>81</td>
</tr>
<tr>
<td>Mochel, F.</td>
<td>112</td>
</tr>
<tr>
<td>Modugno, N.</td>
<td>64</td>
</tr>
<tr>
<td>Möhwald, K.</td>
<td>112</td>
</tr>
<tr>
<td>Moioli, L.</td>
<td>96</td>
</tr>
<tr>
<td>Mok, K.</td>
<td>99</td>
</tr>
<tr>
<td>Mokhtari, K.</td>
<td>81</td>
</tr>
<tr>
<td>Molinuevo Guix, J.L.</td>
<td>66</td>
</tr>
<tr>
<td>Mollenhauer, B.</td>
<td>65</td>
</tr>
<tr>
<td>Molnar, Judith</td>
<td>97</td>
</tr>
<tr>
<td>Monaco, S.</td>
<td>67</td>
</tr>
<tr>
<td>Mondello, S.</td>
<td>148</td>
</tr>
<tr>
<td>Mongini, T.</td>
<td>113, 148</td>
</tr>
<tr>
<td>Monia, B.</td>
<td>66</td>
</tr>
<tr>
<td>Montalban, X.</td>
<td>65, 99, 106</td>
</tr>
<tr>
<td>Montaner, J.</td>
<td>88</td>
</tr>
<tr>
<td>Montcuquet, A.</td>
<td>67</td>
</tr>
<tr>
<td>Monteiro, C.</td>
<td>97</td>
</tr>
<tr>
<td>Monteverdi, A.</td>
<td>100</td>
</tr>
<tr>
<td>Monzio Compagnoni, G.</td>
<td>113</td>
</tr>
<tr>
<td>Moody, J.</td>
<td>113</td>
</tr>
<tr>
<td>Moonen, G.</td>
<td>82</td>
</tr>
<tr>
<td>Morar, B.</td>
<td>66</td>
</tr>
<tr>
<td>Morbetti, S.D.</td>
<td>96</td>
</tr>
<tr>
<td>Moreira, I.</td>
<td>67</td>
</tr>
<tr>
<td>Morgante, F.</td>
<td>138</td>
</tr>
<tr>
<td>Morotti, A.</td>
<td>98</td>
</tr>
<tr>
<td>Morra, I.</td>
<td>81</td>
</tr>
<tr>
<td>Morrison, P.J.</td>
<td>80</td>
</tr>
<tr>
<td>Mosca, V.</td>
<td>113</td>
</tr>
<tr>
<td>Mosby Knappe, M.</td>
<td>82</td>
</tr>
<tr>
<td>Muelas, M.M.N.</td>
<td>113</td>
</tr>
<tr>
<td>Muhlert, N.</td>
<td>99</td>
</tr>
<tr>
<td>Müller, F.</td>
<td>82</td>
</tr>
<tr>
<td>Müller, T.</td>
<td>159</td>
</tr>
<tr>
<td>Mulliez, A.</td>
<td>64</td>
</tr>
<tr>
<td>Muller, T.</td>
<td>82</td>
</tr>
<tr>
<td>Muntean, M.-L.</td>
<td>65</td>
</tr>
<tr>
<td>Muntoni, F.</td>
<td>113</td>
</tr>
<tr>
<td>Murakami, T.</td>
<td>66</td>
</tr>
<tr>
<td>Muresanu, D.</td>
<td>77, 149</td>
</tr>
<tr>
<td>Musicco, M.</td>
<td>108</td>
</tr>
<tr>
<td>Musumeci, O.</td>
<td>113</td>
</tr>
<tr>
<td>Mutzenbach, J.</td>
<td>97</td>
</tr>
<tr>
<td>Mykland, M.S.</td>
<td>112</td>
</tr>
<tr>
<td>Nabors, L.B.</td>
<td>81</td>
</tr>
<tr>
<td>Nadjar, Y.</td>
<td>79</td>
</tr>
<tr>
<td>Naess, H.</td>
<td>80, 98</td>
</tr>
<tr>
<td>Nagendran, S.</td>
<td>98</td>
</tr>
<tr>
<td>Nandedkar, S.</td>
<td>57</td>
</tr>
<tr>
<td>Nardocci, N.</td>
<td>67</td>
</tr>
<tr>
<td>Negrão, L.</td>
<td>127</td>
</tr>
<tr>
<td>Nesbit, V.</td>
<td>67</td>
</tr>
<tr>
<td>Neumayr, L.</td>
<td>67</td>
</tr>
<tr>
<td>Neuteboom, R.</td>
<td>67</td>
</tr>
<tr>
<td>Neuwirth, C.</td>
<td>57</td>
</tr>
<tr>
<td>Ng, Y.S.</td>
<td>67</td>
</tr>
<tr>
<td>Nichelli, P.</td>
<td>66</td>
</tr>
<tr>
<td>Nicholas, R.</td>
<td>145</td>
</tr>
<tr>
<td>Nicoletti, A.</td>
<td>98</td>
</tr>
<tr>
<td>Nielsen, S.</td>
<td>82</td>
</tr>
<tr>
<td>Nikolai, T.</td>
<td>99</td>
</tr>
<tr>
<td>Nizzardo, M.</td>
<td>98</td>
</tr>
<tr>
<td>Noachtar, S.</td>
<td>93</td>
</tr>
<tr>
<td>Nobile-Orazio, E.</td>
<td>93</td>
</tr>
<tr>
<td>Nobili, F.</td>
<td>96</td>
</tr>
<tr>
<td>Nocker, M.</td>
<td>97</td>
</tr>
<tr>
<td>Notermans, N.C.</td>
<td>97</td>
</tr>
<tr>
<td>Novi, G.</td>
<td>97</td>
</tr>
<tr>
<td>Nunes, S.</td>
<td>81</td>
</tr>
<tr>
<td>O</td>
<td></td>
</tr>
<tr>
<td>Oberndorfer, S.</td>
<td>106</td>
</tr>
<tr>
<td>Obici, L.</td>
<td>52, 64, 145</td>
</tr>
<tr>
<td>Oertel, W.</td>
<td>20, 65, 89</td>
</tr>
<tr>
<td>Oh, Jiwon</td>
<td>139</td>
</tr>
<tr>
<td>Oleaga, L.</td>
<td>67</td>
</tr>
<tr>
<td>Olesen, J.</td>
<td>75, 112</td>
</tr>
<tr>
<td>Oliveira, H.</td>
<td>80</td>
</tr>
<tr>
<td>Oliveira, V.</td>
<td>89</td>
</tr>
<tr>
<td>Oliver, D.</td>
<td>20, 50, 54</td>
</tr>
<tr>
<td>Olivieri, P.</td>
<td>99</td>
</tr>
<tr>
<td>Oreja-Guevara, C.</td>
<td>20, 138</td>
</tr>
<tr>
<td>Orejudos, A.</td>
<td>112</td>
</tr>
<tr>
<td>O’riordan, W.</td>
<td>64</td>
</tr>
<tr>
<td>Otte, W.</td>
<td>80</td>
</tr>
<tr>
<td>Ourselin, S.</td>
<td>65, 99, 100</td>
</tr>
<tr>
<td>Outeiro, Tiago F.</td>
<td>53</td>
</tr>
<tr>
<td>Outeiro, Tiago Fleming</td>
<td>96</td>
</tr>
<tr>
<td>Öztürk, S.</td>
<td>107</td>
</tr>
<tr>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Pace, A.</td>
<td>81</td>
</tr>
<tr>
<td>Paciaroni, M.</td>
<td>97</td>
</tr>
<tr>
<td>Padua, L.</td>
<td>62</td>
</tr>
<tr>
<td>Paemeleire, K.</td>
<td>96, 139</td>
</tr>
<tr>
<td>Pagni, M.</td>
<td>96</td>
</tr>
<tr>
<td>Pagonabarraga Mora, J.</td>
<td>127</td>
</tr>
<tr>
<td>Paiva Nunes, A.</td>
<td>80</td>
</tr>
<tr>
<td>Palace, J.</td>
<td>76, 97, 110</td>
</tr>
<tr>
<td>Pamblanco, Y.</td>
<td>113</td>
</tr>
<tr>
<td>Pandolfo, M.</td>
<td>90</td>
</tr>
<tr>
<td>Panicker, J.</td>
<td>20</td>
</tr>
<tr>
<td>Panni, P.</td>
<td>80</td>
</tr>
<tr>
<td>Papathanasiou, E.</td>
<td>91</td>
</tr>
<tr>
<td>Papp, V.</td>
<td>20, 64</td>
</tr>
<tr>
<td>Pardini, M.</td>
<td>96</td>
</tr>
<tr>
<td>Pardo Fernandez, J.</td>
<td>97</td>
</tr>
<tr>
<td>Pareto, D.</td>
<td>99</td>
</tr>
<tr>
<td>Pareyson, D.</td>
<td>66, 97</td>
</tr>
<tr>
<td>Parisi, D.</td>
<td>113</td>
</tr>
<tr>
<td>Parker, C.</td>
<td>64</td>
</tr>
<tr>
<td>Parker, R.</td>
<td>65, 99, 100</td>
</tr>
<tr>
<td>Parman, Y.</td>
<td>66</td>
</tr>
<tr>
<td>Parmenti, L.</td>
<td>81, 96</td>
</tr>
<tr>
<td>Pascual, J.</td>
<td>58</td>
</tr>
<tr>
<td>Pasquier, F.</td>
<td>97</td>
</tr>
<tr>
<td>Passos, J.</td>
<td>81</td>
</tr>
<tr>
<td>Patti, F.</td>
<td>98</td>
</tr>
<tr>
<td>Paulus, W.</td>
<td>54, 99</td>
</tr>
<tr>
<td>Pauws, E.</td>
<td>80</td>
</tr>
<tr>
<td>Pavao Martins, I.</td>
<td>108</td>
</tr>
<tr>
<td>Pavitt, S.</td>
<td>65, 99, 100</td>
</tr>
<tr>
<td>Pavone, A.</td>
<td>67</td>
</tr>
<tr>
<td>Pavy-Le Traon, A.</td>
<td>65</td>
</tr>
<tr>
<td>Payoux, P.</td>
<td>96</td>
</tr>
<tr>
<td>Pearce, G.L.</td>
<td>65</td>
</tr>
<tr>
<td>Pearl, P.L.</td>
<td>73</td>
</tr>
<tr>
<td>Peball, M.</td>
<td>97</td>
</tr>
<tr>
<td>Pelayo-Negro, A.L.</td>
<td>97</td>
</tr>
<tr>
<td>Pellerino, A.</td>
<td>81</td>
</tr>
<tr>
<td>Pellis, T.</td>
<td>82</td>
</tr>
<tr>
<td>Penner, I.K.</td>
<td>149</td>
</tr>
<tr>
<td>Penz, C.</td>
<td>64</td>
</tr>
<tr>
<td>Peralta, C.</td>
<td>97</td>
</tr>
<tr>
<td>Péran, P.</td>
<td>65</td>
</tr>
<tr>
<td>Perren, F.</td>
<td>110</td>
</tr>
<tr>
<td>Petersson, J.</td>
<td>78</td>
</tr>
<tr>
<td>Petri, S.</td>
<td>60</td>
</tr>
<tr>
<td>Petrović, I.</td>
<td>113</td>
</tr>
<tr>
<td>Pausler, B.</td>
<td>108</td>
</tr>
<tr>
<td>Pfister, S.</td>
<td>106</td>
</tr>
<tr>
<td>Phillips, J.</td>
<td>64</td>
</tr>
<tr>
<td>Piani Meier, D.</td>
<td>100</td>
</tr>
<tr>
<td>Pirulli, A.</td>
<td>100</td>
</tr>
<tr>
<td>Piccioni, R.</td>
<td>100</td>
</tr>
<tr>
<td>Pichiecchio, A.</td>
<td>81</td>
</tr>
<tr>
<td>Pichiorri, F.</td>
<td>82</td>
</tr>
<tr>
<td>Pikiya, S.</td>
<td>97</td>
</tr>
<tr>
<td>Pina, S.</td>
<td>113</td>
</tr>
<tr>
<td>Pisciotta, C.</td>
<td>66</td>
</tr>
<tr>
<td>Piteatly, R.</td>
<td>67</td>
</tr>
<tr>
<td>Pittman, A.</td>
<td>80</td>
</tr>
<tr>
<td>Piva, R.</td>
<td>96</td>
</tr>
<tr>
<td>Plagnol, V.</td>
<td>80</td>
</tr>
<tr>
<td>Planté-Bordeneuve, V.</td>
<td>66, 145</td>
</tr>
<tr>
<td>Pizzini, J.</td>
<td>110</td>
</tr>
<tr>
<td>Plazzi, G.</td>
<td>100, 110</td>
</tr>
<tr>
<td>Plesniala, N.</td>
<td>82</td>
</tr>
<tr>
<td>Podnar, S.</td>
<td>62</td>
</tr>
<tr>
<td>Poewe, W.</td>
<td>77, 97, 138</td>
</tr>
<tr>
<td>Polydefakis, M.</td>
<td>66</td>
</tr>
<tr>
<td>Poore, C.P.</td>
<td>80</td>
</tr>
<tr>
<td>Popkirov, S.</td>
<td>67</td>
</tr>
<tr>
<td>Poulton, J.</td>
<td>67</td>
</tr>
<tr>
<td>Poyatos, J.</td>
<td>113</td>
</tr>
<tr>
<td>Pozzo-Rosich, P.</td>
<td>148</td>
</tr>
<tr>
<td>Pozzato, M.</td>
<td>110</td>
</tr>
<tr>
<td>Pozzilli, C.</td>
<td>65, 100</td>
</tr>
<tr>
<td>Pozzoli, U.</td>
<td>98</td>
</tr>
<tr>
<td>Pradhan, C.</td>
<td>99</td>
</tr>
<tr>
<td>Name</td>
<td>Pages</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Prados, F.</td>
<td>65, 99, 100</td>
</tr>
<tr>
<td>Preux, P.M.</td>
<td>50</td>
</tr>
<tr>
<td>Previtali, S.</td>
<td>66</td>
</tr>
<tr>
<td>Priano, L.</td>
<td>100</td>
</tr>
<tr>
<td>Prior, T.</td>
<td>98</td>
</tr>
<tr>
<td>Probst, P.</td>
<td>82</td>
</tr>
<tr>
<td>Proesmans, S.</td>
<td>81</td>
</tr>
<tr>
<td>Proksisch, H.</td>
<td>66</td>
</tr>
<tr>
<td>Prosperini, L.</td>
<td>100</td>
</tr>
<tr>
<td>Prüss, H.</td>
<td>87</td>
</tr>
<tr>
<td>Pugliatti, M.</td>
<td>20, 50, 89</td>
</tr>
<tr>
<td>Puybasset, L.</td>
<td>90</td>
</tr>
<tr>
<td>Q</td>
<td></td>
</tr>
<tr>
<td>Quatrone, A.</td>
<td>66</td>
</tr>
<tr>
<td>Querbes, W.</td>
<td>64</td>
</tr>
<tr>
<td>Querol Gutierrez, L.A.</td>
<td>51</td>
</tr>
<tr>
<td>Quinlivan, R.</td>
<td>113</td>
</tr>
<tr>
<td>Quintanilha, A.</td>
<td>37</td>
</tr>
<tr>
<td>Qureshi, A.</td>
<td>98</td>
</tr>
<tr>
<td>R</td>
<td></td>
</tr>
<tr>
<td>Raeed, R.</td>
<td>81</td>
</tr>
<tr>
<td>Rafiq, S.</td>
<td>98</td>
</tr>
<tr>
<td>Rajdova, A.</td>
<td>66</td>
</tr>
<tr>
<td>Ramalheira, J.E.D.P.</td>
<td>81</td>
</tr>
<tr>
<td>Ramesmayer, C.</td>
<td>97</td>
</tr>
<tr>
<td>Ramlaú, R.</td>
<td>81</td>
</tr>
<tr>
<td>Raputová, J.</td>
<td>66</td>
</tr>
<tr>
<td>Rascol, O.</td>
<td>65, 88, 127</td>
</tr>
<tr>
<td>Rasconà, C.</td>
<td>98</td>
</tr>
<tr>
<td>Ratajczak-Tretel, B.</td>
<td>98</td>
</tr>
<tr>
<td>Rauen, K.</td>
<td>82</td>
</tr>
<tr>
<td>Reardon, D.A.</td>
<td>81</td>
</tr>
<tr>
<td>Reed, M.</td>
<td>112</td>
</tr>
<tr>
<td>Rees, D.</td>
<td>64</td>
</tr>
<tr>
<td>Regis, J.</td>
<td>113</td>
</tr>
<tr>
<td>Reichelt, L.</td>
<td>82</td>
</tr>
<tr>
<td>Reichmann, H.</td>
<td>57, 71, 127</td>
</tr>
<tr>
<td>Reijntjes, R.H.</td>
<td>112</td>
</tr>
<tr>
<td>Reilly, M.M.</td>
<td>66</td>
</tr>
<tr>
<td>Reimao, S.</td>
<td>80, 108</td>
</tr>
<tr>
<td>Reindl, M.</td>
<td>67</td>
</tr>
<tr>
<td>Reimloft, M.D.</td>
<td>71, 127</td>
</tr>
<tr>
<td>Reinken, M.</td>
<td>80</td>
</tr>
<tr>
<td>Reisen, M.</td>
<td>66</td>
</tr>
<tr>
<td>Religa, D.</td>
<td>96</td>
</tr>
<tr>
<td>Rendenbach-Mueller, B.</td>
<td>96</td>
</tr>
<tr>
<td>Reuter, U.</td>
<td>87, 126, 139</td>
</tr>
<tr>
<td>Ribaldi, F.</td>
<td>96</td>
</tr>
<tr>
<td>Ribo, M.</td>
<td>107</td>
</tr>
<tr>
<td>Ricci, G.</td>
<td>66</td>
</tr>
<tr>
<td>Ricketts, T.</td>
<td>80</td>
</tr>
<tr>
<td>Ridsout, D.</td>
<td>113</td>
</tr>
<tr>
<td>Rieu, J.</td>
<td>64</td>
</tr>
<tr>
<td>Righi, C.</td>
<td>80</td>
</tr>
<tr>
<td>Riley, M.</td>
<td>113</td>
</tr>
<tr>
<td>Riou, A.</td>
<td>80</td>
</tr>
<tr>
<td>Riva, N.</td>
<td>98</td>
</tr>
<tr>
<td>Rizzo, F.</td>
<td>98</td>
</tr>
<tr>
<td>Rizzo, G.</td>
<td>64</td>
</tr>
<tr>
<td>Rizzutti, M.</td>
<td>98</td>
</tr>
<tr>
<td>Robb, S.</td>
<td>113</td>
</tr>
<tr>
<td>Roberts, M.</td>
<td>67</td>
</tr>
<tr>
<td>Roberts, M.E.</td>
<td>113</td>
</tr>
<tr>
<td>Robieson, W.</td>
<td>96</td>
</tr>
<tr>
<td>Rocha, I.</td>
<td>70</td>
</tr>
<tr>
<td>Rocha, M.</td>
<td>113</td>
</tr>
<tr>
<td>Rock, S.</td>
<td>64</td>
</tr>
<tr>
<td>Rodegher, M.</td>
<td>96</td>
</tr>
<tr>
<td>Rodinio-Klapac, L.</td>
<td>98</td>
</tr>
<tr>
<td>Rodolico, C.</td>
<td>113</td>
</tr>
<tr>
<td>Rodrigues, C.</td>
<td>97</td>
</tr>
<tr>
<td>Rodrigues, D.</td>
<td>81</td>
</tr>
<tr>
<td>Rodrigues, R.</td>
<td>97</td>
</tr>
<tr>
<td>Rodriguez, C.</td>
<td>65</td>
</tr>
<tr>
<td>Rolinski, M.</td>
<td>64</td>
</tr>
<tr>
<td>Rollot, F.</td>
<td>67</td>
</tr>
<tr>
<td>Romero, J.</td>
<td>98</td>
</tr>
<tr>
<td>Romoli, M.</td>
<td>81</td>
</tr>
<tr>
<td>Rosa, H.</td>
<td>113</td>
</tr>
<tr>
<td>Rosa, J.</td>
<td>64</td>
</tr>
<tr>
<td>Rosa, M.M.</td>
<td>108</td>
</tr>
<tr>
<td>Rosand, J.</td>
<td>98</td>
</tr>
<tr>
<td>Rossetti, A.</td>
<td>92</td>
</tr>
<tr>
<td>Ross, F.</td>
<td>67</td>
</tr>
<tr>
<td>Rossini, P.M.</td>
<td>51, 96</td>
</tr>
<tr>
<td>Rossi, S.</td>
<td>97</td>
</tr>
<tr>
<td>Rostasy, K.</td>
<td>65</td>
</tr>
<tr>
<td>Rothwell, J.C.</td>
<td>51</td>
</tr>
<tr>
<td>Rothwell, P.M.</td>
<td>80</td>
</tr>
<tr>
<td>Rouyrette, N.</td>
<td>100</td>
</tr>
<tr>
<td>Roveri, L.</td>
<td>80</td>
</tr>
<tr>
<td>Roveta, F.</td>
<td>81</td>
</tr>
<tr>
<td>Rowe, J.</td>
<td>108</td>
</tr>
<tr>
<td>Roy, S.</td>
<td>112</td>
</tr>
<tr>
<td>Ruda, R.</td>
<td>81</td>
</tr>
<tr>
<td>Rüegg, S.</td>
<td>87</td>
</tr>
<tr>
<td>Rufa, A.</td>
<td>67</td>
</tr>
<tr>
<td>Ruffmann, C.</td>
<td>64</td>
</tr>
<tr>
<td>Ruggieri, S.</td>
<td>100</td>
</tr>
<tr>
<td>Ruiz, A.</td>
<td>67</td>
</tr>
<tr>
<td>Russell, D.</td>
<td>98</td>
</tr>
<tr>
<td>Ruttledge, M.</td>
<td>139</td>
</tr>
<tr>
<td>Růžička, E.</td>
<td>64, 71, 76, 92</td>
</tr>
<tr>
<td>Rybacka-Mossakowska, J.</td>
<td>81</td>
</tr>
<tr>
<td>Rylander, C.</td>
<td>82</td>
</tr>
<tr>
<td>Ryvlin, P.</td>
<td>50</td>
</tr>
<tr>
<td>S</td>
<td></td>
</tr>
<tr>
<td>Sá, Maria José</td>
<td>138</td>
</tr>
<tr>
<td>Saal, D.P.</td>
<td>112</td>
</tr>
<tr>
<td>Sabatelli, M.</td>
<td>66</td>
</tr>
<tr>
<td>Sacconi, S.</td>
<td>66, 127</td>
</tr>
<tr>
<td>Sadun, F.</td>
<td>67</td>
</tr>
<tr>
<td>Said Inshani, J.</td>
<td>65</td>
</tr>
<tr>
<td>Saiz, A.</td>
<td>67</td>
</tr>
<tr>
<td>Salazar-Lopez, E.</td>
<td>112</td>
</tr>
<tr>
<td>Sales, F.</td>
<td>93</td>
</tr>
<tr>
<td>Salgado, D.</td>
<td>81</td>
</tr>
<tr>
<td>Salustio, F.</td>
<td>100</td>
</tr>
<tr>
<td>Salmaggi, A.</td>
<td>81</td>
</tr>
<tr>
<td>Saloheimo, P.</td>
<td>20, 52</td>
</tr>
<tr>
<td>Salsano, E.</td>
<td>79</td>
</tr>
<tr>
<td>Sambuceti, G.</td>
<td>96</td>
</tr>
<tr>
<td>Samoř, R.</td>
<td>67</td>
</tr>
<tr>
<td>Sampaio, C.</td>
<td>72</td>
</tr>
<tr>
<td>Sánchez-Monteagudo, A.</td>
<td>97</td>
</tr>
<tr>
<td>Sandor, P.</td>
<td>91</td>
</tr>
<tr>
<td>Sandset, E.C.</td>
<td>98</td>
</tr>
<tr>
<td>Sand, T.</td>
<td>112</td>
</tr>
<tr>
<td>Sanford, R.</td>
<td>80</td>
</tr>
<tr>
<td>Sanson, M.</td>
<td>81</td>
</tr>
<tr>
<td>Santoro, L.</td>
<td>66</td>
</tr>
<tr>
<td>Santos, C.</td>
<td>97</td>
</tr>
<tr>
<td>Santos, E.</td>
<td>57</td>
</tr>
<tr>
<td>Sanvito, F.</td>
<td>80</td>
</tr>
<tr>
<td>Saraiva, M.J.</td>
<td>90</td>
</tr>
<tr>
<td>Sarazin, M.</td>
<td>99</td>
</tr>
<tr>
<td>Sardh, E.</td>
<td>64</td>
</tr>
<tr>
<td>Sardeoira, A.</td>
<td>113</td>
</tr>
<tr>
<td>Sargento Freitas, J.</td>
<td>110</td>
</tr>
<tr>
<td>Sarkozy, A.</td>
<td>113</td>
</tr>
<tr>
<td>Sastre-Garriga, J.</td>
<td>54</td>
</tr>
<tr>
<td>Saul, G.</td>
<td>113</td>
</tr>
<tr>
<td>Scaglione, C.L.</td>
<td>64</td>
</tr>
<tr>
<td>Schaedelin, S.</td>
<td>97</td>
</tr>
<tr>
<td>Schaefer, A.</td>
<td>67</td>
</tr>
<tr>
<td>Schäfer, J.</td>
<td>86</td>
</tr>
<tr>
<td>Schanda, K.</td>
<td>67</td>
</tr>
<tr>
<td>Schäfers, B.</td>
<td>82</td>
</tr>
<tr>
<td>Schapira, A.</td>
<td>52</td>
</tr>
<tr>
<td>Schaumburg, M.</td>
<td>65</td>
</tr>
<tr>
<td>Scheinberg, M.</td>
<td>66</td>
</tr>
<tr>
<td>Scheltens, P.</td>
<td>75</td>
</tr>
<tr>
<td>Schenone, A.</td>
<td>66</td>
</tr>
<tr>
<td>Scherer, S.</td>
<td>66</td>
</tr>
<tr>
<td>Schippings, S.</td>
<td>155</td>
</tr>
<tr>
<td>Schmidt, H.</td>
<td>64, 66</td>
</tr>
<tr>
<td>Schmidt, R.</td>
<td>90</td>
</tr>
<tr>
<td>Schmierer, K.</td>
<td>159</td>
</tr>
<tr>
<td>Schmitt, C.</td>
<td>81</td>
</tr>
<tr>
<td>Schmitt, W.</td>
<td>100</td>
</tr>
<tr>
<td>Schmutzhardt, E.</td>
<td>91, 93, 112</td>
</tr>
<tr>
<td>Schneider, E.</td>
<td>99</td>
</tr>
<tr>
<td>Schöberl, F.</td>
<td>99</td>
</tr>
<tr>
<td>Schoenen, J.</td>
<td>79</td>
</tr>
<tr>
<td>Schonknecht, P.</td>
<td>96</td>
</tr>
<tr>
<td>Schoonenheim, M.</td>
<td>86</td>
</tr>
<tr>
<td>Schordan, E.</td>
<td>98</td>
</tr>
<tr>
<td>Schosser, B.</td>
<td>59</td>
</tr>
<tr>
<td>Schott, J.</td>
<td>90, 108</td>
</tr>
<tr>
<td>Schottlaender, L.V.</td>
<td>80</td>
</tr>
<tr>
<td>Schreier, D.</td>
<td>100</td>
</tr>
<tr>
<td>Schwab, K.</td>
<td>98</td>
</tr>
<tr>
<td>Schwab, S.</td>
<td>93, 97</td>
</tr>
<tr>
<td>Schwertner, E.</td>
<td>96</td>
</tr>
<tr>
<td>Scigliano, H.</td>
<td>97</td>
</tr>
</tbody>
</table>
Van der Worp, B. .......... 93
Van Diessen, E. ............. 80
Van Dijk, G. ............... 70, 112
Van Doorn, P.A. .......... 78, 88
Van Engelen, B. .......... 108
Van Geloven, N. .......... 66
Van Wijmeersch, B. ...... 65
Vandi, S. .................... 100
Vandrovcova, J. ........... 66
Vanschoenbeek, G. ...... 96
Vasta, R. ................... 98
Vaugoyeau, M. .......... 113
Vázquez-Costa, J. ....... 97
Vegas Hernandez, J. ...... 113
Ventura, P. ................ 64
Verdelho, A. ............ 78, 87
Verdijk, R. ................. 67
Vérin, M. ................... 80
Vermersch, P. .......... 65, 100
Vernooij, M.W. ........... 67
Veronese, S. ................ 54
Verreauilt, M. .......... 81
Verschuuren, J.J.G.M. ..... 76
Vichinsky, E. .............. 67
Vidalihet, M. ............. 59, 61
Vidiri, A. .................. 81
Vilchez, J.J. ............... 59, 113
Vilchez, R. ................. 113
Villarejo-Galende, A. .... 67
Villar, N. ..................... 113
Vincent, A. ................. 80
Vincent, A.E. ............... 113
Visser, N. ................... 97
Visser, P. J. ............... 87, 96
Vising, J. .................. 57
Viswanathan, A. .......... 98
Vita, G. ..................... 66, 113
Vivacqua, G. ............... 80
Vickova, E. ................ 66
Vodušek, D. ............... 89
Volanti, P. ................ 98
Voltz, R. .................... 54
Von Oertzen, T. .......... 50, 80
Vonck, K ..................... 81
Vrancken, A. .............. 61, 97
Vukusie, S. ............... 67
Vyhnaček, M. ............... 99
Waddington Cruz, M. .... 66
Wagner, M. ................ 66
Waisfisz, Q. ................ 66
Walker, M.C. ............... 93
Wallis, C. .................. 113
Wang, A. ................... 66
Wang, D. .................... 96
Wang, E. .................... 80
Wang, R. .................... 112
Wannex, S .................. 99
Warendorf, J. .............. 97
Wattjes, Mike P ........... 149
Waubant, E. ............... 65
Weber, K.P. ................. 76
Weber, M ................... 57
Weckhuysen, S. ........... 53
Weir, C.J. .................. 65, 99, 100
Wekerle, H .................. 75
Weller, M. ................. 81, 106
Wells, C. ................... 98
Wenning, G .................. 58
Wenning, G.K. ............. 92, 97
Werkmann, M .............. 97
Werring, D .................. 97
Westhall, E. ............... 82
Wetterslev, J ................ 82
Wheel, R.Kinghott, C. .... 100
Welhan, C .................... 66
Wicke, T ................... 65
Wick, W ...................... 81
Wietecha, L.A. ........... 112
Wildt, T ................... 100
Willeit, P ................... 97
Willis, H. J ................ 88
Wilson, D. .................. 97
Wilson, M-C ................ 112
Wiltfang, J .................. 96
Winblad, B .................. 96
Wise, M.P. ................... 82
Witjas, T .................... 113
Wolf, N ....................... 66
Wolinsky, J .................. 65
Wood, N.W. ................ 66
Wurster, C ................... 133
Yamashita, T ............... 64
Yamout, B .................. 139
Yang, C.-C ................... 64
Yick, L.W ................... 67
Yu, L ......................... 98
Zahedmanesh, H ........... 113
Zámečník, J ............... 148
Zamrini, E .................. 64
Zappia, M ................... 98
Zeller, S ..................... 149
Zephyr, H ................... 67
Zepper, P ................... 50
Zetterberg, H .............. 82
Zhang, H ................... 113
Zhang, N ................... 64
Zhao, F ....................... 67
Ziemssen, T ............... 132, 155
Zier, S ....................... 113
Zimmermann, J ........... 65
Živanović, M ............... 99
Zoccarato, M ............... 67
Zorzi, G ..................... 67
Zuliani, L ................... 67, 97
Zwergal, A .................. 99, 112
The official journal of the European Academy of Neurology

FREE Guidelines
Impact Factor 3.988

Free Online Access for EAN Members

FREE Guidelines  
Reviews  
High Impact Research Articles  
Topical Virtual Issues

Discover how you can read - and write for European Journal of Neurology

Publish Your Next Paper With Us
Visit the EAN or Wiley Congress booths to find out why and how

Discover more at wileyonlinelibrary.com/journal/ene or www.ean.org

WILEY